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The human macula is essential for high acuity vision but its biochemical and cellular 
properties are poorly understood.   
A disease that specifically affects the macula, Macular Telangiectasia (MacTel) type2 was 
investigated by studying postmortem tissue from a single donor. This revealed Müller cell 
loss specifically in the macula, which might be responsible for the vascular changes and 
photoreceptor degeneration typical of this disease. To establish whether the disease has 
subclinical vascular changes outside the macula, the peripheral retina was studied. This 
showed that contrary to previous reports, abnormal looking capillaries are not disease-
specific but a normal ageing phenotype in humans.  
Proteomics and immunohistochemistry was used to characterise maculae in healthy donors. 
Comparative proteomics identified differentially expressed proteins and 
immunohistochemistry confirmed the distribution of selected proteins. This led to the 
discovery of several Müller cell markers, lactate dehydrogenase (LDHB), glial fibrillary acidic 
protein (GFAP),αB crystallin (CRYAB) and αA crystallin (CRYAA), which are expressed at higher 
levels in the macula, demonstrating that Müller cells can take on different differentiation 
phenotypes depending on retinal area. Furthermore, the spatial expression pattern of LDHB, 
GFAP and CRYAB was found to correlate with the size/shape of the area that is affected in 
MacTel type2, providing a possible explanation why the disease affects only the macula.   
Embryonic development of the macula was investigated in eye tissue obtained from 
abortions by using immunohistochemistry and gene expression analysis (qPCR and 
differential gene display). Müller cell markers, CRYAA, CD44 and CRALBP were found to be 
specifically expressed in the presumptive macula, starting at 7 gestation weeks (CS20), prior 
to ganglion cell and photoreceptor differentiation. Genomic comparison between this region 
and peripheral retina revealed further differentially expressed genes and led to the 
identification of a morphogen, Retinoic acid, which might play a role in macula development 
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1. General introduction 
1.1 Visual acuity and retinal specialisation 
The region of high acuity vision is a morphological specialisation found in the central retina. 
Humans, old and new world monkeys all have this region of specialisation, but the nocturnal 
primates, such as the owl monkey (Aotes) do not.1 The region of specialisation is known as 
the macula, and the central most point termed the fovea. This region of the retina is highly 
specialised, it has a high concentration of cone photoreceptors, a low concentration of rod 
photoreceptors and the number of signal transduction neurons is also significantly increased. 
The fovea (like its literal meaning in Latin) is a pit in the retina.  
Peripheral retina has a common structure found among all mammals; it has a laminated 
structure of three nuclear layers and two layers of synapses. Ganglion cell nuclei and 
astrocyte nuclei dominate the ganglion cell layer, while amacrine, horizontal, bipolar and 
Müller cell nuclei are found within the inner nuclear layer. The outer nuclear layer only 
consists of photoreceptor nuclei, rods and cones. The projections of the ganglion cells from 
the top and bipolar/amacrine cells from below form the inner plexiform layer (IPL), while the 
photoreceptor projections generate an outer plexiform layer (OPL) below the inner nuclear 
layer. Müller cells have processes that span the entire depth of the retina so can be found in 
both plexiform layers. The Müller cell processes form tight junctions with the photoreceptor 
inner segments to form the outer limiting membrane, and generate the inner limiting 
membrane at the vitreal face of the retina. Below the neural retina there is the sub retinal 
space (remainder of the optic ventricle in development) and then a monolayer of pigment 
epithelium (retinal pigment epithelium) (Fig. 1.1 A).  
The fovea and macula differ in structure from the peripheral retina. During development 
ganglion cells proliferate at the prospective fovea to form a ‘mound’ in central retina. At 7 
months gestation lateral displacement from the fovea occurs and all cell nuclei within the 
ganglion cell layer and the inner nuclear layers migrate radially forming the foveal pit (Fig. 1.1 
B, C). Photoreceptors do not migrate, but their axons are elongated within the OPL, to 
maintain synaptic contact with their corresponding bipolar cells. Along with the elongated 
photoreceptor axons, outer retinal Müller cell processes elongate and the soma shifts within 
the inner nuclear layer, but end feet forming the outer limiting membrane remain located 
nearer to the fovea; this region of laterally displaced processes form what is called the Henlé 
fibre layer (arrow heads in Fig. 1.1 D and E). The lateral displacement generates a central pit 
(fovea) surrounded by a region of increased retinal thickness, the macula. The laminated 
15 
 
structure of the retina remains parafoveally, however at the fovea only the photoreceptors 
with a small number of ganglion cells remain. The foveal pit also contains a population of 
Müller cells, termed the Müller cell cone, but the function of these Müller cells in unclear. 
The macula now consists of an increased ganglion cell thickness up to a maximum of 8/9 cells 
deep (Fig. 1.1 E), and increased numbers of interneuron's and Müller cells. The Müller cell 
nuclei in peripheral retina are a single layer along the central line of the inner nuclear layer; 
this single layer also doubles up within the macula and is missing at the fovea. The fovea 
contains the highest density of cone photoreceptors, the human retina contains on average 
4.6million cones, with a foveal density of 200,000 cones/mm2.2 The cone density at the 
periphery is one hundredth of that at the fovea. In peripheral retina, rod photoreceptors 
outnumber cones, 20:1, however at the fovea there is a 300µm diameter rod free zone, with 
lower ratios in the parafoveal macula.2 Interestingly there is also a central 100µm S-cone free 
zone, making the fovea dominated by M and L cones.3, 4  
The definition of the macula is currently vague. The macula, original name macula lutea or 
‘yellow spot’, was defined as the name suggests; it was the region of the retina where yellow 
macular pigments accumulate.5 Macular pigment consists of the xanthophyll carotenoids, 
Lutein and Zeathanthin.6 These pigments are taken up through the diet and are the only 
carotenoids to be transported into the retina.7 These pigments can be seen with red free or 
blue light fundus imaging and appear to have a higher concentration 5-6mm in diameter 
surrounding the fovea. The concentration of the pigments decreases with eccentricity from 
the fovea. Zeaxanthin has been shown to be most abundant at the fovea and the 
concentration decreases more rapidly, whereas lutein has a more gradual decrease towards 
the periphery, with a lower maximal concentration at the fovea compared to zeaxanthin 
(macular pigment will be described in more detail in chapter 5). Dietary intake of lutein and 
zeaxanthin has a significant effect on the intensity and spread of macular pigment within 
central retina.8 Therefore the region perceived as the macula differs between people.  
Textbooks refer to the macula as consisting of three concentric regions in central retina, the 
fovea at the centre, surrounded by a parafovea and perifovea (Fig. 1.1 F), first coined by 
Polyak in 1941.9 The regions can be generalised by defining the perifovea as the transition 
zone between the specialised central retina and the periphery, the parafovea as region with 
the highest ganglion cell density, and the fovea as the pit. The perifovea takes on 
characteristics of the periphery; such has the higher vascular density and the high rod:cone 
ratio.3 However, it still has a higher ganglion cell density than the peripheral retina, although 
the ganglion cell nuclei decrease to a single layer2, 10 before the proposed outer limit of the 
perifoveal region by Polyak.9 The fovea does have a defined anatomical boundary; it resides 
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within the limits of maximum ganglion cell depth of the retina. This is the location of maximal 
retinal thickness, central to this the retinal thickness sharply decreases to form an inverted 
cone shaped pit. The foveal slope marks a decrease in ganglion cell, Müller cell and 
interneuron numbers and very few astrocytes are present. The foveal slope also marks the 
transition between rod dominated and cone dominated retina, and vascularised and 
avascular retina. The top of the foveal slope contains the perifoveal capillaries which 
anastomose towards the base of the slope and form a single vascular ring and a central 
foveal avascular zone.11 The parafovea as such has a defined inner boundary, but the division 
between parafovea and perifovea is purely based upon an arbitrary distance from the fovea. 
There is no anatomical or biochemical correlates to this region (Fig. 1.1 G).  
The clinical definition of the macula again differs from that proposed by Polyak9 and from 
macula pigment distribution; the macula is defined as any retina between the temporal 
superior and inferior vascular arcades.12 This definition does at least have an anatomical 
correlate, however there is no justification as to why the retina in between the vascular 
arcades is significantly different from that outside; there is no difference in retinal function or 
specialisation at this boundary point. Also this definition leaves the temporal limit of the 
macula again vague as the arcades do not completely encircle the fovea.  
As such the fovea is the only structure of the macula that has a true definition/boundary. The 
macula remains a term given to central, specialised retina, and yet there is no true definition 
as to its limits. There is a gradual change in cell numbers and type starting at the fovea and 
spreading radially. The Henlé fibre layer is the only significant structural feature that changes 
within this region. The lateral displacement of Müller cell processes and photoreceptor axons 
does define an anatomical boundary point within the retina; the point at which the processes 
cease to run horizontally and take on the vertical orientation, perpendicular to the nuclear 
layers. However, no molecular link has been made to date correlating this retinal landmark 
with differences in retinal function or disease susceptibility of the retina.  
 
1.2 Retinal cell types 
Vision is captured by the neural retina. The retina, being part of the central nervous system 
contains glial cells that act as support cells to ensure neuronal survival and signal 
transduction back to the visual cortex of the brain.  
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1.2.1 Retinal neurons 
The retinal neurons are not just there to signal visual perception back to the brain, a lot of 
vertical and horizontal pre-processing occurs within the retina and an image constructed 
before the signal is relayed to the visual cortex.   
 
1.2.1.1 Photoreceptors 
There are two primary types of photoreceptors in the human eye, the rods and cones. Rods 
are responsible for scotopic, low light vision - motion contrast and brightness, while the 
cones capture the photopic, high acuity, spatial resolution, colour vision.13 There are three 
types of cone photoreceptor, blue (short wavelength, S cone), Green (medium wavelength, 
M cone) and Red (long wavelength, L cone). The trichromatic cones allow a broad spectrum 
of colour vision. The photoreceptors are situated to the posterior aspect of the neural retina 
and consist of a cell body packed full of mitochondria (inner segment) with axonal projection 
that synapses with bipolar cells. They also contain a modified primary cilium that has evolved 
to form the photoreceptive element, the outer segment, that contains stacks of membranous 
disks packed full of photo pigments (opsins) and signalling proteins needed to transduce 
photons of light into neural signals.   
Visual perception begins with the photoreceptors. A captured photon isomerises the 
chromophore conjugated to the photopigment of photoreceptor cell. Photoisomerisation 
converts 11-cis retinal to all-trans retinol, via all-trans retinal. This occurs within the outer 
segment of the photoreceptor. All-trans-retinol exits the cell and transported to the RPE; 
here a series of enzymatic reactions converts it back to 11-cis-retinal. 11-cis-retinal returns to 
the outer segment where it regenerates the photoreceptor opsin and completes the visual 
cycle.14 The excited visual pigment then triggers a signal transduction cascade that amplifies 
the signal, leading to closure of ion channels within the plasma membranes and the cells 
becoming hyperpolarised. Hyperpolarisation leads to a block of glutamate (neurotransmitter) 
release at the photoreceptor synapse.15  
 
1.2.1.2 Processing and signal conduction neurons 
The block in release of glutamate through excitation of the photoreceptor cells leads to the 
induction of a signal within the bipolar cells of the retina. This signal is not directly 
transferred into the ganglion cells to be relayed to the brain, first lateral interactions with 
interneurons, the amacrine and horizontal cells, modify the signal and pre-process the image.  
The bipolar cell nuclei are located within the inner nuclear layer; the interneurons also reside 
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within the inner nuclear layer; the amacrine cells primarily along the border of the inner 
nuclear layer and the OPL, and the horizontal cells along the border with the IPL.  
 
1.2.1.3 Retinal ganglion cells 
Retinal ganglion cells (RGCs) are the last neuron in the chain to relay the image to the brain; 
they receive impulses from the amacrine and bipolar cells. As such they sit in the ganglion 
cell layer, vitreal aspect of the IPL. The cell bodies reside here however they have processes 
that project back through the optic nerve to the visual cortex. The processes that run along 
the retina-vitreal surface form what is termed the nerve fibre layer. The RGC axons are not 
myelinated within the retina, signal conduction is maintained by astrocytes and Müller cell 
end feet that ensheath the axonal projections.  
 
1.2.2 Retinal Glia 
There are three types of glia within the vascularised retina, like that of humans and mice; the 
Müller Cell, Retinal astrocyte and the microglia. Avascular retinae, like that of birds, do not 
contain astrocytes, as explained later.  
1.2.2.1 Müller Cells 
The Müller cells, the principal glia of the retina span the entire depth of the retina, with a cell 
body in the inner nuclear layer. They have projections that span radially to form the inner 
and outer limiting membranes, the inner limiting membrane where they make contact with 
the RGCs projections and the outer limiting membrane where they form tight junctions with 
the inner segments of the photoreceptors. Müller cells also make contact with all retinal 
neurons. Müller cells play a key role in neuronal survival and processing of information.16, 17 
Müller cells are crucial to the stabilisation of the retinal structure. They create a framework 
around which the layered arrangement of neurons is patterned.18  
Retinal extracellular homeostasis is maintained by the Müller cell. The plasma membrane of 
a Müller cell has a high density of K+ channels, especially inwardly rectifying K+ (Kir) 
channels19-22 and tandem-pore (TASK) channels.23 Thus allowing them to clear the 
extracellular K+ released by activated neurons, they transport K+ into Müller cells, where K+ 
levels are increased during light exposure.24 The Müller cell morphology then allows them to 
redistribute these ions into various sinks; the vitreous, the blood supply through direct 
contact with the blood vessels, and to a lesser extent into the subretinal space, 25-27 where 
they will be less damaging. The Müller cells are capable of redistributing the K+ only when 
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they maintain a negative membrane potential (around -80 mV) 28-30 via open Kir channels.24 
Water content and extracellular pH are also maintained by Müller cells. Pathological fluxes in 
extracellular K+ leads to changes in the neuronal cell and glia membrane potentials.31 The 
Müller cell membranes from diseased retinas may adversely affect retinal K+ homeostasis 
and other transport systems of Müller cells. Transretinal water fluxes are osmotically coupled 
to any osmolyte changes, as such wherever K+ moves to; water will follow through selective 
channels, the aquaporins.32  Aquaporins regulate transport of water in response to osmotic 
gradients and differences in hydrostatic pressure. The retina contains two known aquaporins 
(AQP1 and AQP4), in RPE and retinal glia, AQP4 is known to be primarily expressed in the end 
feet of Müller cells.33-35  
Müller cells are also involved in waste metabolism and provision of trophic substances to 
neurons.36 Glucose is metabolised into lactate which is then used in oxidative metabolism in 
the photoreceptors, this process occurs in Müller cells and as such Müller cells are essential 
for neuron survival. Müller cells are also essential in neuronal information processing; they 
provide the precursors of neurotransmitters and also have a fast uptake of any 
neurotransmitters released. Müller cells release glutamine into presynaptic terminals of the 
neurons; they therefore play a crucial in the Glutamate-glutamine cycle of the retina. The 
primary glutamate transporter of the Müller cell is L-glutamate-L-aspartate transporter 
(GLAST).37, 38 Immunoreactivity against GLAST shows a localisation to the cytoplasm and all 
radial processes in a Müller cell.39 Müller cells mop up extracellular glutamate rapidly, thus 
reducing excitoxicity and disturbances to the neuronal processing of information, for 
example the termination of light envoked ganglion cell activity is swiftly carried out by the 
rapid uptake of glutamate by the Müller cells.40 The glutamate is degraded within Müller cells 
by glutamine synthetase, a Müller cell specific enzyme41 that will degrade both ammonia and 
glutamate36 GLAST and GS have both been reported to change in some ocular diseases. 
Decreases in both proteins in Müller cells have been shown in diabetes,42, 43  and in ischemia 
in rat retina.39 
Müller cells and retinal neurons are mutually interdependent; Müller cell processes make 
contact with neurons which in turn determine the formation and characteristics of those 
processes.17 Müller cells respond to signals from distressed cells via the Müller cell p75 
neurotrophin receptor, a pro-apoptotic receptor.44 The receptor is found in Müller cell 




In vitro experiments indicate that Müller cells are implicated in immunoregulation; however 
their role in vivo has not been confirmed. Müller cells have been shown to phagocytose 
apoptotic neuronal cells during development,45 and explanted cultures of Müller cells have 
been shown to phagcytose dying photoreceptor cells.46  Müller cells have also been shown to 
phagocytose melanosomes after melanin implantation in the sub retinal space of albino 
rats,47 although the data for this is speculative, what appear to be melanin granules under 
electron microscopy could also be lipofuscin or other lipid vesicles.  
Müller cells, along with astrocytes (chapter 1.2.2.2) aid in generating the retinal equivalent of 
the blood brain barrier, the blood retinal barrier. A barrier that protects the neuronal retina 
from exposure to ions and small molecules from the blood. A tight restriction on diffusion 
through the endothelial cells of vessels is established through tight junctions between 
endothelial cells, which are induced by the surrounding glial cells.48-51 Müller cells associate 
with all vascular plexus of the retina, however astrocytes are restricted to the primary plexus.  
Müller cells respond to a perturbation of the retinal homeostasis by becoming reactive. This 
includes photopic damage, ischemia, glaucoma, retinal detachment, trauma, retinopathy and 
age-related degenerations, inflammatory disease or excitotoxicity. In each case Müller cells 
undergo reactive gliosis, characterised by proliferation of52 and a biochemical, morphological, 
(due to alterations in intermediate filament formation53) and physiological change of the 
Müller cell.54, 55 Müller cells respond to alterations in retinal homeostasis long before the 
appearance of clinical features. Diabetes stimulates a rearrangement of intra and 
extracellular structures, including the arrangement of Kir and AQP channels of Müller cells56 
prior to initiating a series of gliotic changes.57 Retinal injury stimulates the Müller cells to 
release neurotrophic factors and free radical scavengers and clear excess glutamate which 
protects neurons. Müller cells also have been shown to de-differentiate and take on 
progenitor-like properties with subsequent transdifferentiation towards a neuronal 
phenotype (the transdifferentiation is restricted)58 aiding in tissue regeneration.  They are 
also key players in facilitating neovascularisation, one means of which is to up regulate 
vascular endothelial growth factor (VEGF).55, 59-61 Müller cell gliosis is not always beneficial; 
Müller cells have been implicated in neuronal degeneration, oedema formation and can have 
an adverse effect on vascular survival in diseased retina.32, 43, 55, 59 Diabetic retinopathy is 
exacerbated by reactive gliosis60-62  and Müller cell scars, which hinder the repair and 
transdifferentiation properties of the Müller cells. Müller cell scar formation after destruction 
of RPE due to a retinal detachment, (this can be recreated by sub retinal injection of sodium 




 Immunohistochemical markers of Müller cells 
Cellular retinaldehyde binding protein (CRALBP/RLBP1) is a water soluble vitamin A binding 
protein specifically found in retinal Müller cells and RPE.64 Vitamin A, essential in the visual 
cycle, undergoes repeated shuttling between RPE and photoreceptors as bleaching of 
rhodopsin occurs.65 Vitamin A is contained within the interphotoreceptor matrix (sub retinal 
space), the Müller cells or the RPE, this is to resolve the problems of toxicity and limits 
solubility.66 Vitamin A derivatives have specific carrier proteins within these three 
compartments; CRALBP in the RPE and Müller cells, and interstitial retinol-binding protein 
(IRBP) in the sub retinal space.66  
Glutamine synthetase (GS) and carbonic anhydrase (CA) are both also found in Müller cells.41 
These are normally expressed by astrocytes and oligodendrocytes outside of the retina, 
implying shared function between the different glia.41, 67 GS requires glial-neuron contact to 
remain expressed, in a purified culture of Müller cells GS is downregulated after 8 days.44 
The type III intermediate filaments, vimentin and glial fibrillary acidic protein (GFAP) are both 
found in Müller cells. Vimentin is found throughout the entire Müller cell.68 In the healthy 
retina, GFAP is located in some Müller cell endfeet, whereas the other primary glia, 
astrocytes express GFAP evenly distributed throughout their cell cytoplasm.69 Müller cells 
dramatically upregulate GFAP expression in response to injury.69 Activation markers such as 
GFAP in Müller cells have traditionally been used as a marker of disease progression. After 
laser photocoagulation, GFAP is even upregulated in Müller cells distant from the site of 
injury70, 71 indicating that Müller cell activation may be driven by cell-mediated signals. Both 
vimentin and GFAP are increasingly expressed with age in human retina.72, 73   
CD44 is a transmembrane glycoprotein and a cell surface receptor for hyaluronic acid (HA).74 
CD44 interacts with hyaluronic acid to stimulate Rac1 signalling leading to a cytoskeletal 
effect and cell migration in astrocytes.74 Localisation of CD44 to Müller cell apical microvilli 
has been reported in adult rat retina.75, 76 CD44 has also been reported in the developing 




Retinal astrocytes emerge from the optic nerve and spread radially as a proliferating cell 
population across the inner surface of the retina. They develop from a precursor lineage at 
the optic nerve, these precursor cells are positive for the transcription factor Pax2.78, 79 They 
produce two lineages of astrocytes, those resident in the optic nerve and those that will 
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migrate into the retina. The earliest marker that distinguishes the retinal astrocytes from the 
resident optic nerve astrocytes is platelet derived growth factor alpha (PDGFRα). PDGFRα is 
expressed days before invasion into the retina.80 Platelet derived growth factor A (PDGFRA) is 
the ligand for the PDGFRα and is expressed by RGCs,81 this factor is likely to be responsible 
for triggering the migration of retinal astrocytes into the retina.80 Immature astrocytes have a 
spindle like morphology as they migrate through the retina into the periphery,82 once they 
reach the peripheral retina they proliferate further and join up to form a mesh-like network. 
The network of astrocytes provides a template for the developing retinal vasculature.83, 84 
There is a direct correlation between astrocytes and vasculature within the retina; in animals 
that do not have retinal vasculature, such as the possum, there are no astrocytes.85 However 
the horse, which has a small vascularised region around the optic nerve also has a matching 
region of retinal astrocytes,86 in primates and mice retinal astrocytes and vasculature cover 
the entire surface of the retina.86, 87 The implication from this is that astrocytes and the 
developing vasculature are evolutionarily linked.88 Retinal astrocytes release vascular 
endothelial growth factor (VEGF) in response to regional hypoxia,89, 90 thought to be brought 
about by the developing neuronal cells.91 VEGF is a key stimulus for angiogenesis92 driving the 
vasculature to proliferate into the retina. As the vessel network expands over the astrocytes, 
the astrocytes begin to mature.82 They change morphology from spindle-like to stellate and 
proliferation stops, glial fibrillary acidic protein (GFAP) is upregulated and vimentin and VEGF 
are downregulated.78, 90 
 
Astrocyte function goes beyond development and driving the vascularisation of the retina. 
They have many functions similar to Müller cells.93 Astrocytes also contribute to the blood-
retinal barrier, in the formation of the glia limitans.94 However as mature astrocytes are 
largely restricted to the ganglion cell layer and nerve fibre layer95 they only play a role in the 
functioning of the primary vascular plexus. Also like Müller cells, astrocytes contain glycogen, 
and can provide glucose to neurons. They also regulate ion homeostasis96 and metabolism of 
neurotransmitters like GABA.  
 
1.2.2.3 Microglia 
Microglia, although not technically neuroglia having originated from mesodermal origin, 
appear in the retina prior to the retinal blood vessels. Here they lie dormant in the IPL and 
OPL of the retina until activated. Retinal microglia appear in three forms; parenchymal 
macrophages associated with neurons, paravascular macrophages associated with blood 
vessels and the perivascular macrophages, found within the perivascular space.97, 98 Microglia 
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originate from the bone marrow and the term encompasses both dendritiform cells (resident 
tissue microglia) and macrophages that express luekocyte common antigen (CD45).97, 98, 98 
Both types of microglia can be stimulated into macrophagic function as a result of trauma to 
the retina.  
 
1.2.3 Retinal pigment epithelium 
The retinal pigment epithelium (RPE) is composed of a monolayer of cells, with the apical 
side in contact with the photoreceptors of the neural retina. The RPE cells contain melanin 
granules, necessary to absorb excess light that passes through the retina and thus reduce 
scattering within the globe that would otherwise decrease visual acuity.  Highest levels of 
pigment (melanin) are found in peripheral retina, it decreases towards the posterior pole, 
but then increases again towards the submacula/fovea region.99, 100 The RPE is positioned 
between the Bruch’s membrane basally and the interphotoreceptor matrix apically, thus it is 
essential in forming a selectively permeable blood-retinal barrier between the underlying 
choroidal vasculature and the neural retina above. RPE cells have a cobble stone 
morphology, polygonal in shape, cell-cell contacts contain tight junctions and they have 
apical microvilli.  
The photoreceptors are reliant upon the RPE to maintain healthy function. The apical 
microvilli of RPE surround the outer segments of the photoreceptors; each day when the 
outer segment discs of the rods and cones are shed, they are engulfed by the RPE in which 
they are degraded by phagolysosomes.101 This process occurs in diurnal cycle, with the first 
light of each day inducing the shedding of the outer segment tips.102 RPE also recycle the 
visual pigments for the photoreceptors.103  
 
1.2.4 Retinal oxygen supply  
As I have previously stated, astrocytes enter the retina and lay down the framework over 
which the retinal vasculature grows. In the human retina, blood vessels first start to appear 
around the optic nerve at 14-15 weeks gestation (WG)91, 104, 105 and then spread to the 
periphery, not reaching the retinal margins until 34 WG.106 Oxygen tension of the retina is 
key to regulation of vascular spread and modelling.107, 108 The retinal astrocytes respond to 
hypoxia in the retina and release VEGF.89-91 The retinal vasculature initially spreads through 
the nerve fibre layer and the ganglion cell layer forming the primary plexus. Subsequently 
vessels penetrate down through the retinal layers forming a deeper plexus network with 
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blood vessels running along the vitreal and sclera margins of the inner nuclear layer. The 
photoreceptor layer does not contain any retinal vessels, and are thought to be supplied with 
oxygen by the choroidal vasculature; a network of vessels that lies below the RPE. The 
primary plexus of the human retina develops in a ‘lobular’ arrangement, with four lobes, 
each of which will form the territory of a quadratic artery in the mature retina (Fig. 1.2 A, B). 
As development continues the lobes begin to fuse to form the network. This occurs 
throughout the retina excluding the future fovea (Fig. 1.2 C). Here the lobes remain distinct 
and skirt around the fovea. They meet at the horizontal meridian on the temporal side of the 
fovea at around 25WG.104, 109 (Fig. 1.3 A) The fovea remains avascular into mature retina and 
the foveal depression forms within a pre-defined foveal avascular zone110 (FAZ, Fig. 1.3 B) 
whilst peripheral retina is a continuous network (Fig. 1.3 C). Fitting with the fact that 
astrocytes pattern the developing primary plexus, the incipient fovea also lacks astrocytes 
during development and into adulthood.110 
The retina, like the brain is vascularised via angiogenesis, where proliferating endothelial cells 
form new blood vessels sprouts and the vascular network is formed from pre-existing 
vessels.111 The other methods of vascularisation within the body in vasculogenesis, where 
vascular endothelial precursor cells within the tissue coalesce and form vessel lumens, not 
requiring existing vasculature.111 Authors are unified in the understanding that the deeper 
plexus vessels form through angiogenesis, however the development of the primary plexus 
has the field divided. Some authors propose that this occurs through vasculogenesis,105, 108, 
112-114 however identification of free standing precursor cells distal to the developing vascular 
front have not been identified, human studies have identified ADPase/CD39 and CXCR4 
positive cells distal to the vascular front however these are not conclusive endothelial 
precursor markers,112, 115-117 a definitive marker such as VEGFR2118-120 would need to be 
shown. There is more evidence that supports the theory that the primary plexus develops via 
angiogenesis;82 mouse studies have shown that the cells at the leading edge of the vascular 
front extend numerous filopodia121-123 suggesting that they respond to attractant and 
repellent gradients within the retina and direct vascular growth.124 These sub class of 
endothelial cells are referred to as tip cells and their expression pattern differs to other 
endothelial cells. Endothelial cells have an expression pattern dependent upon position as 
part of a venule, artery or capillary, and location within the vascular plexus. Tip cells have an 
expression pattern that shows that they have the potential to differentiate into various sub 
classes of endothelial cell. They express delta-like 4 (Dll4), PDGFB and apelin,125-127 along with 
netrin receptor Unc5b and VEGFR2.125, 128  
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The retina is highly metabolically active and actually has the highest oxygen consumption of 
any organ.129 The inner segments, OPL and inner portion of the IPL demand the most 
oxygen.129, 130 The retinal vascular unit consists of endothelial cells surrounded by 
pericytes.131 These two cell types lay down an extracellular matrix or basement membrane 
which is high in Collagen IV.132 (Fig. 1.4) This unit is then further surrounded by glial end feet 
processes,133 processes from both astrocytes and Müller cells surround the primary plexus, 
and Müller cells only at the deeper plexus. Retinal capillary endothelial cells are not 
fenestrated134 however, they contain a high number of endocytotic vesicles suggesting that 
they are more permeable than capillaries of the brain.134 Each cell type contributes to the 
barrier properties of the blood retinal barrier.131 Endothelial cells form tight junctions/zonula 
occludens between one another, apparent with electron microscopy as electron dense 
regions at cell-cell contacts.  
    
1.3 Susceptibility to disease 
The macula, the highly specialised region of the retina is particularly susceptible to disease. 
One such disease, Macular Telangiectasia type 2 only affects the macula, in a defined central 
region. Other diseases such as X-linked Retinoschisis and Sjögren Larsson syndrome mimic 
the disease locality, whilst others such as Canthaxanthin retinopathy actually spare a region 
in central retina during disease progression. There are also diseases that initially affect the 
macula, but then spread into peripheral retina with disease progression, such as Age Related 
Macular Degeneration (AMD) and Diabetic retinopathy.   
 
1.3.1 Macular Telangiectasia type 2 
Macular telangiectasia type 2 (MacTel type 2), also known as idiopathic juxtafoveolar 
telangiectasia type 2, is an uncommon retinal disease that can lead to legal blindness, it was 
recently discovered that its prevalence is  higher than previously thought, being 0.1% of the 
participants in the Beaver Dam Eye study,135 which equates to approximately 70,000 people 
having it in the United States.136 Recent studies have been able to more clearly elucidate the 
clinical phenotype of the disease.137-141 110-115 The predominant clinical features include loss of 
macular transparency,142, 143 a reduction in macular pigment (Fig. 1.5 A),137-139 increased 
macular autoflourescence139, 140 and superficial white crystals (white arrow heads Fig 1.5 B), 
compared to control retina (Fig. 1.5 C and D).142, 144 There is also progressive foveal 
atrophy/foveal thinning as a result of disturbances in the photoreceptor layer (asterisks Fig. 
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1.5 E), inner and outer retinal cavitation.142, 145 As the disease name suggests, there is also a 
significant vascular component to the disease; intraretinal vascular abnormalities are seen 
parafoveally, including vascular telangiectasis (tortuous vessels) (arrow Fig. 1.5 F), leakage 
(Fig. 1.5 G), right angled venules, and intraretinal and subretinal neovascularisation with 
disease progression.141, 142, 144  The deterioration in visual function is predominantly caused by 
foveal atrophy, hyperplasia and migration of RPE into neural retina (arrow head Fig. 1.5 F) 
and the development of subretinal and intraretinal neovascularisation.  
The clinical phenotype of MacTel type 2 is restricted to the parafoveal retina. The 
morphologic and functional problems are most pronounced and normally originate just 
temporal to the fovea, spreading around the fovea with disease progression.144, 146-149  
The genetics of the disease have only recently been investigated. Most of the reported cases 
of MacTel type 2 are sporadic, nevertheless affected sibling pairs and affected pairs of 
monozygotic twins have been described in the literature.150, 151 Some relatives of MacTel type 
2 patients also present with subtle signs of MacTel type 2, however they suffer no vision 
problems.152 This led Rando Allikmets and colleagues in New York to believe that MacTel type 
2 has a genetic cause in a significant proportion of cases.153 Vertical transmission is reported 
in families, therefore an autosomal dominant model of Mendelian inheritance with reduced 
penetrance has been assumed by Allikmets’ lab.153 They have so far screened 27 candidate 
genes against a cohort of MacTel type 2 patients and their relatives. Candidate genes 
included those known to be causative in diseases with phenotypic similarities to MacTel type 
2, including familial exudative vitreoretinopathy (FEVR) and Norrie disease,154-158 and also 
genes with a genetic role in retinal vascularisation, macular pigment transport and genes of 
interest based on the lab’s familial linkage study.153 However this approach revealed no 
associated genes with any significance to MacTel type 2.153 Allikmets and colleagues are 
continuing the search for the causative gene in MacTel type 2 by combining a linkage analysis 
and whole genome sequencing approach.  
The cause of MacTel type 2 is not known, and no treatment exists to prevent the progressive 
loss of central vision that is often seen in this disease.  
 
1.3.2 X-linked Retinoschisis 
X-linked Retinoschisis patients present with localised macula problems similar to that seen in 
MacTel type 2; they have central vision loss and parafoveal oedema. A common phenotype is 
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retinal schisis, not found in MacTel type 2, however, this schisis is most often located to 
parafoveal retina, however 50% of patients also present with minimal peripheral schisis.159  
X-linked retinoschisis is a common form of juvenile macular degeneration, primarily affecting 
males.160, 161 It is characterised by splitting (schisis) of the fovea, and often bilateral, and 
oedema formation. The schisis can occur along any level of the retina, however it is more 
common to split along the inner nuclear layer.162 Visual signal transmission is affected in X-
linked retinoschisis shown by a decrease in b-wave (Müller cell/bipolar response) amplitude 
but a preservation of the a-wave (photoreceptor response) amplitude in a scotopic 
electroretinogram (negative ERG).163 The causative gene has been identified responsible for 
X-linked retinoschisis using a positional candidate gene approach as retinoschisin 1 (RS1).164 
The gene encodes 224 amino acids, of which the N-terminal 23 amino acids are a secretory 
signal, and there is also a highly conserved discoidin domain comprising 75% of the 
processed protein. The 24kDa retinoschisin polypeptide is secreted165 and is distributed 
around the surface membranes of bipolar and photoreceptor cells.166, 167 The exact function 
of retinoschisin in maintaining retinal structure is unknown, however potential binding 
partners have been established; there is a direct interaction between retinoschisin and Na/K-
ATPase.168 The Na/K-ATPase enzyme (ATP1A3 and ATP1B2 subunits are highly abundant in 
retina) is essential in generating the Na+ and K+ gradients required for maintenance of cellular 
homeostasis.169 Dysfunction of cellular homeostasis can lead to oedema formation, one of 
the characteristics of retinoschisis, however it doesn’t explain the generalised foveal schisis. 
The ATP1B2 subunit of Na/K-ATPase has been shown to be an adhesion molecule on glial 
cells that mediates glial-neuron interactions,170, 171 it is potentially possible that retinoschisin 
dysfunction alters the adhesion properties of ATP1B2 in the retina, however there is no 
evidence to support this.  
In the retina carbonic anhydrase II is found in Müller cells and red/green cones, while the RPE 
and corneal epithelium contain the membrane bound form of carbonic anhydrase, carbonic 
anhydrase IV.172 Carbonic anhydrase inhibitors have been shown to have beneficial clinical 
effects; they have been shown to modulate membrane bound carbonic anhydrase IV 
receptors in RPE.173 Carbonic anhydrase inhibitors enhance the fluid transporter system 
present within in the RPE and improves retinal adhesiveness, thus is thought that patients 
with diffuse RPE disease respond better to carbonic anhydrase inhibitors in removal of 
cystoids macular oedema.172  
It has been shown that resolving cystic macular oedema can improve visual acuity in 
patients.174, 175 A further study in 2011 treated patients with retinitis pigmentosa and X-linked 
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retinoschisis, which had macular oedema with carbonic anhydrase inhibitors. The treatment 
decreased macular oedema periodically during treatment; however reoccurrence of cysts did 
occur.176 Visual acuity did not improve at a statistically significant level, however returning 
the retinal anatomy to normal might prevent a more rapid decrease in vision loss. 
Again there is no treatment to date for X-linked retinoschisis and the specificity and exact 
mechanisms behind the disease remain unknown.  
 
1.3.3 Sjögren Larsson Syndrome 
In Sjögren Larsson syndrome, retinal crystals are commonly seen, limited to the parafoveal 
retina,  mirroring the crystals seen within MacTel type 2 patients. Sjögren Larsson syndrome 
also results in a reduction of macular pigment, however unlike MacTel type 2 the macular 
pigment loss is pan retina and not limited to central macula. 
Sjögren Larsson syndrome, an autosomal recessive neurocutaneous disease, has the clinical 
features of spastic diplegia or tetraplegia, mental retardation, ichthyosis, and the presence of  
crystalline retinopathy. Sjögren Larsson syndrome patients suffer from photophobia and low 
visual acuity. The crystalline maculopathy develops gradually within childhood, with onset 
within the first decade,177 the crystals, not seen in control patients, are restricted to a 
parafoveal pattern (Fig. 1.6 C) and are found within the inner retinal layers. The fovea itself is 
sparred from crystal deposits. However visual acuity is decreased. Optical coherence 
tomography (OCT) reveals that the fovea is affected by the disease; there is thinned central 
fovea and intrafoveal cystoid spaces.178 OCT also made it possible to locate the inner retinal 
crystals more specifically; focal hyper reflectivity’s, which correspond to clinically visible 
retinal crystals, are located within the ganglion cell layer and IPLs.178 Sjögren Larsson 
syndrome is also characterised by a pan retina reduction in Macular pigment levels, unlike 
MacTel type 2 that has a restricted loss parafoveally.179 (Fig. 1.6 A-D) 
Sjögren Larsson syndrome is caused by defects in the fatty aldehyde dehydrogenase enzyme, 
ALDH3A2,180, 181 and subsequent disruption of lipid metabolism, ALDH3A2 catalyses the 
oxidation of long chain aliphatic aldehydes into fatty acids.182 Resulting in an accumulation of 
fatty alcohols and fatty aldehydes within the tissues of the body.183, 184  
Fuijkschot et al178 have speculated that the crystals located within the GCL and IPL, where the 
dendrites and axons of the ganglion cell and inner retinal neurons reside, suggests a 
participation of the perifoveal ganglion cells in the deposition of lipids in Sjögren Larsson 
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syndrome. The theory does correlate with previous studies that show ganglion cell 
involvement in other lipid storage diseases, such as lysosomal storage disorders. However 
there is no firm conclusions over this; the other possibility is that the crystals reside within 
the Müller cell end feet, the only other cell type found at this level of the retina.  
How the build-up of intraretinal crystals and defect in ALDH3A2 directly cause foveal thinning 
and cystoids spaces is currently unknown, also why there is a parafoveal restriction to the 
crystalline phenotype, yet a pan retina phenotype of macular pigment reduction is unknown.   
 
1.3.4 Canthaxanthin retinopathy 
Interestingly Canthaxanthin retinopathy is characterised by a region in central retina that is 
spared from retinopathy. The region unaffected mirrors the region that is affected in MacTel 
type 2. This is an intriguing finding especially as Canthaxanthin retinopathy results in 
crystalline deposits, like that seen in MacTel type 2, yet the deposits form in adjacent regions 
(Fig. 1.6 E and F).  
Canthaxanthin is a carotenoid pigment commonly given to patients with tumours due to its 
strong anti-oxidant properties.185-187 It has also been popular in the past as a natural skin 
tanning agent in tablet form.188  
Canthaxanthin intake is associated with golden yellow crystal deposits forming within the 
retina. These crystals develop until they reach 10-14µm in size189-191 and they are located in a 
ring around the fovea between 5° and 10°.192 Studies in animals and humans show that even 
small quantities consumed result in crystal deposit accumulation around the macula.192-200 
The crystals are likely to consist of a canthaxanthin-lipoprotein complex.192 The crystal 
deposition has been correlated with vascular abnormalities of the retina,192, 201 however a 
more recent study has demonstrated that patients were asymptomatic with no defect 
directly correlating to the intake of canthaxanthin.202  Although after canthaxanthin intake 
has stopped, the crystals remain within the retina and can take up to 20 years to be removed 
completely.202  
1.3.5 Age related macular degeneration 
Age related macular degeneration (AMD) is the most common macular disease in western 
society. A disease that, like MacTel type 2, initially affects the macula and onset of the 
disease is often in 5-6th decade of life. Unlike MacTel type 2 though it spreads into peripheral 




AMD is a late-onset, progressive degenerative disease, characterised by loss of 
photoreceptors, RPE and small blood vessels from the choroid. It encompasses a wide 
spectrum of pathologies and clinical phenotypes however, the primary affected region is the 
macula and surrounding central retina. The prevalence of AMD increases with age, and 
typically does not manifest before the age of 55 years.203  The clinical phenotype shows 
minimal visual impairment initially, with decreases in high resolution central vision as the 
disease progresses. There have been many classifications of AMD over the years.204 The 
pathology of AMD starts initially with the appearance of drusen; lipid and protein deposits 
between Bruch’s membrane and the RPE. There are three stages of AMD, early AMD can be 
categorised by the presence of small drusen, ≥63μm but <125μm in size and more than 5 
present in central retina. Intermediate AMD is characterised by increased deposit size to 
above 125μm. Larger drusen are often accompanied by pigment changes of the RPE, hypo 
and hyper pigmentation has been noted.  Advanced AMD has more of an impact to the vision 
of the patient; further lesions develop; geographic atrophy (GA), followed by neovascular 
(NV) AMD. These are more commonly referred to as Dry AMD and Wet AMD respectively.  
GA lesions are defined when a region of retina, at least 175μm in diameter with a definable 
border, depigment and choroidal vessels are visible through the lesion, many patients with 
GA are asymptomatic and unaware of the disease, however 10-15%  have a rapid 
deterioration of the retina and suffer severe vision loss. NV AMD is the most severe disease 
phenotype, it accounts for 90% of central vision loss among AMD patients. NV AMD can 
follow GA, it manifests itself as retinal or RPE detachment, sub retinal haemorrhage, 
subretinal fibrous tissue and generalised RPE atrophy, with the presence of 
neavascularisation.205-207  Wet AMD, if untreated can progress to the cicatricial stage, 
referred to as a disciform scar, a 4-8mm fibroitic scar below the macula.  
 
Pathobiology and genetics 
Biochemical analysis of drusen shows that they consist of glycoconjugates and constituents 
of atherosclerotic plaques including, apolipoprotein B and E, vitonectin, alpha crystallin, lipids 
and complement proteins.208-210 Drusen present in two forms, hard (discrete nodules) and 
soft (large deposits with ill-defined boundaries).211, 212 Soft drusen are more associated with 
damage to the retina, RPE and choroid and are indicators of a more severe clinical outcome; 
the development of GA and choroidal neovascularisation (CNV).213 GA is characterised by 
abnormalities of the REP; hypertrophy and hypotrophy, hyper and hypopigmentation, loss of 
photoreceptors, thinning of Bruch’s membrane and degeneration of the choriocapillaris.214 In 
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AMD the RPE is the primary cell type affected, however the photoreceptors are also 
attenuated.215 CNV is the growth of new blood vessels from the choroid, penetrating through 
the Bruch’s membrane,216 these can then breach the RPE and invade the sub retinal space.217 
It is this neavascularisation that often results in the severe phenotypes of AMD, leading to a) 
neaovascular AMD, where lipid rich fluid accumulates under the RPE and/or neural retina; b) 
haemorrhagic AMD, where blood breaks through the RPE into subretinal space; c) disciform 
AMD, where fibrous tissue, blood vessels and RPE proliferation invades and replaces the 
neural retina. AMD ultimately leads to loss of central vision through the death of 
photoreceptors at the macula.218  
In 2005 there was a significant breakthrough in understanding AMD; a strong association 
between disease variants in and around the complement factor H (CFH) gene was identified. 
The initial reports of association were via a candidate gene approach, fine mapping of 
candidate loci and also the first whole-genome association study in humans219-221 and 
replicated the same year.222 This genetic link between CFH and other complement genes, 
including complement 2 (C2), complement factor B (CFB)223 and complement 3224 focused the 
search for the cause of the disease. Complement associated genes are not the only genetic 
contributors to AMD susceptibility, the ARMS2/HRA1 region has also been identified. Three 
potential candidate genes reside in the region of association; however, the specific gene 
affected is still controversial; two reports indicate HTRA1 as a target gene225, 226 whilst other 
studies claim ARMS2 as the stronger candidate.227, 228  
The question still remains why AMD affects the macula and not the peripheral retina. It has 
been proposed that the variations in the topography of Bruch’s membrane might be the 
cause. Morphometric data show that the elastic lamina of the Bruch’s membrane is 3-6 fold 
thinner at the macula and 2-5 fold less dense relative to mid-peripheral retina,229 this might 
render the submacular region more susceptible to ingrowth of blood vessels from the 
choroidal vasculature. Also elastin degradation releases peptides that have been shown to be 
extremely pro-angiogenic and possess macrophage recruiting properties,230 thus initial 
degradation at Bruch’s membrane due to its weakness could then propagate the phenotype.  
The choriocapillaris may also be a cause of the macula specific location of AMD; the 
choriocapillaris decrease in vessel calibre in the submacular area, and the network becomes 
more intricate. It is known that vessel calibre decreases with increasing age231 and the 
macula would therefore undergo a more significant change in perfusion with age compared 
to the periphery. This might lead to hypoxia or other environmental factors that promote 
disease progression.  
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1.3.6 Diabetic retinopathy 
Diabetic retinopathy is characterised by proliferation and/or ischemia of the retinal blood 
vessels. Although MacTel type 2 has a vascular phenotype, it is not similar to that seen in 
diabetic retinopathy. Diabetic retinopathy does affect the macula though, often resulting in 
ischemia and oedema formation.  
Chronic hyperglycaemia in the early stages of diabetes results in blood flow alterations and 
increased vascular permeability. This can be characterised by a decrease in the activity of 
nitric oxide, and other vasodilators, whilst at the same time over activity of vasoconstrictors 
such as angiotensin II and endothelin 1, and release of vascular permeabilising cytokines such 
as VEGF. Programmed cell death is triggered in microvessels and an overproduction of 
extracellular matrix proteins. This leads to progressive vascular occlusion. Hyperglycemia 
decreases endothelial and neuronal cell trophic factors leading to oedema, ischemia, and 
neovascularisation driven by localised hypoxia.232 
In diabetic retinopathy, retinal blood flow is always seen to increase.233 This is believed to be 
due to a loss of autoregulation of the arterioles and venules which are seen to elongate and 
dilate. This leads to an increase in effective intraluminal pressure in the following capillaries. 
Starling’s law then states that this would lead to fluid passage from the vessel into the 
extracellular space surrounding.234 In combination with vasoactive cytokine release (i.e. 
VEGF) breaking down the blood retinal barrier, this can then lead to accumulation of albumin 
outside the capillaries and oedema formation.  
 
Diabetic maculopathy - macular oedema/ischemia 
There are two forms of diabetic maculopathy; ischemic maculopathy – capillary drop out, 
and macular oedema – fluid exudation from retinal or choriocapillaris.  Oedema can be found 
both extracellular and intracellular, histological studies of enucleated eyes reports Müller, 
bipolar, ganglion and photoreceptor cell degeneration235 and extracellular cystic spaces.236 
Cystoid macular oedema is seen to form in only the two plexiform layers of the retina. 237 
Studies show that there is no correlation between the blood flow of the retina and macular 
oedema, thus ischemia does not cause macular oedema. Blood retinal barrier breakdown has 
been linked to retinal thickening.238  
The question again is why the macula is more prone to oedema formation. One hypothesis is 
based on the avascularity of the fovea. In other areas of the retina, oedema can collect but is 
then dissipated from extracellular space in two ways, via the choroidal vasculature- the RPE 
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actively ‘pumps’ the fluid out of the retina, or via the retinal vasculature, where nearby less 
affected vessels transport the extracellular fluid back into the blood flow. However the 
vasculature at the centre of the macula is minimal and fovea is avascular. Therefore 
accumulated fluid can only be removed via the RPE/choroid and this is less efficient. It is also 
known that in diabetes the choroidal blood flow is decreased239 (the opposite effect to the 
retinal blood flow) and that this has a degenerative effect on the basement membrane, so 
any functions of the choroidal vasculature are likely to be decreased.  
 
1.3.7 Conclusions 
Many retinal diseases specifically affect the macula. The cell types and pathways affected in 
AMD and diabetic retinopathy are known, and even the genes are known in AMD, and yet 
the reason as to why the macula is more susceptible in these diseases still remains elusive. 
Furthermore an explanation behind the very localised diseases; MacTel type 2, X-linked 
retinoschisis, canthaxanthin retinopathy and Sjögren Larsson syndrome has not been 
established. There is no known anatomical or biochemical boundary in the retina that 
restricts diseases to this perifoveal region. Understanding why the diseases are 
restricted/excluded to this domain of the retina might better direct therapies towards 
tackling these diseases.  
 
1.4 Why should we study the macula? 
Macular diseases such as AMD is the leading cause of severe and incurable blindness in 
developed countries.205 It accounts for 54% of all causes of blindness in the USA, with 1.75 
million over 40 year olds affected with advanced AMD and a further 7.3 million with 
intermediate AMD.240  Increased age has been linked as a major risk factor to the 
development of AMD241, 242 The incidence of early AMD, large drusen and pigmentary 
changes in intermediate AMD, and choroidal neovascularisation (CNV) and GA in advanced 
AMD increase with advancing age.240 The number of individuals with AMD is expected to 
increase worldwide as the population ages and treatments for preventable blindness (such as 
cataract) become more widely available. Diabetic retinopathy is close behind AMD as the 
most common disease that leads to blindness. With the number of diabetics increasing year 




1.5 Thesis Aims 
Elucidating the molecular signalling pathways that induce regional differences in the human 
retina will lead to a better understanding of the underlying mechanisms of macular disease 
and aid in the design of future treatments.  
This thesis aims to gain further insight into the mature and developing macula, to be able to 




Figure 1.1. Retinal structure and macular morphology.  
A: The retina has a laminated structure, consisting of the ganglion cell layer (GCL), inner 
plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL) and outer nuclear 
layer (ONL). This is then separated from the retinal pigment epithelium (RPE) by the 
subretinal space (SRS), the space into which the photoreceptor outer segments extend. The 
primary cell types of the retina are; ganglion (G), amacrine (A), bipolar (B), horizontal (H), 
Müller (M), astrocytes (AG), microglia (MG) and the photoreceptor cells, cones (C) and rods 
(R). Also there is the retinal vasculature (BV) associated with pericytes (P). (Artists impression 
of the retinal structure, adapted from Reichenbach and Bringmann).243 B-E: Morphology of 
the fovea and macula in a human retina of a 72 year old (adapted from Penfold and 
Provis244), the foveal pit (C) contains only cone nuclei and limited numbers of ganglion cells 
(black arrow), at the foveal pit edge (D) and into parafovea (E), the Henlé fibre layer is 
present within the OPL (white arrow heads). F and G: The region defined as the macula by 
Polyak9 (adapted from Provis245), G highlights the lack of anatomical correlates between the 




Figure 1.2. Primary plexus growth pattern of the human retinal vasculature. 
 The early vessels form four lobes of vasculature stemming from the optic disc (A). Temporal 
lobes skirt around the incipient fovea forming the arcades (B), smaller vessels branch and 
spread towards the fovea (B). Capillaries fuse surrounding the fovea, but leave an avascular 
zone directly above the central foveal pit (C). Primary vessels continue to spread outwards 






Figure 1.3. Human retinal vasculature.  
Anti-collagen IV immunohistochemistry of a retina from a 75 year old donor reveals the 
retinal vasculature. Primary blood vessels arc around the macula/fovea (asterisk) originating 
at the optic disc (OD) (A). Arrow heads indicate temporal inferior and superior vascular 
arcades (A).The foveal pit is avascular (B) whilst the peripheral retina is a continuous network 
of vessels (C). Scale bars are 1mm in A, 0.5mm in B and C. Figure prepared from my own 




Figure 1.4. Retinal vascular unit.  
 Cross section through a retinal capillary seen by transmission electron microscopy. A: The 
endothelial cells (E) form a lumen (L) through which the blood vessels flow. Pericytes (P) 
surround the endothelial cells and both contribute to the formation of the basement 
membrane (B). Glial cells finish the vascular unit as their end feet surround the basement 
membrane (G). B: Highlighting the specific components reveals how the basement 
membrane (yellow) lies between the pericyte (green) and endothelium (purple), and borders 
with the glial cells. Note the lumen (pink) contains an erythrocyte. Scale bar is 1µm. Figure 





Figure 1.5. Clinical phenotype of MacTel type 2.  
MacTel type 2 is characterised by a loss of parafoveal macular pigment (A) with a clearly 
demarcated ring remaining (arrows in A), formation of retinal crystals (arrow heads in B), and 
increased parafoveal reflectivity with confocal blue reflectance imaging; compared to control 
retina macular pigment distribution (C) and hyper reflectivity in the parafoveal retina using 
confocal blue reflectance (D). Optical coherence tomography reveals disruption to the 
photoreceptor layer in MacTel type 2 patients (asterisks in E). Telangiectatic vessels (arrow) 
and retinal pigment epithelium migration into the retina (arrow head) can be seen with 
fundus imaging (F). Late phase fluorescein angiograms reveal leakage from tortuous retinal 
vessels (G). Scale bar in A is 400µm, and is applicable for A, B, F and G. No scale available for 
C, D and E.  Clinical images courtesy of Dr. Catherine Egan, Moorfields Eye Hospital, London, 




Figure 1.6. Clinical presentation of Sjögren Larsson Syndrome and Canthaxanthin 
retinopathy. 
 Retinal imaging shows no crystal deposits in a control retina (A) and macular pigment (dark 
central shadow) present at the fovea/macula (B). The same imaging modalities show inter 
retinal crystals (C) and pan retina loss of macular pigment in a patient with Sjögren Larsson 
Syndrome (D). Canthaxanthin retinopathy is characterised by retinal crystals, present in the 
macula, but excluded from the parafoveal region (E). Red free fundus photography (F) 
highlights the crystals better than normal fundus photography (E). Images adapted from van 
der Veen et al.179 (A-D) and Espaillat et al.247 (E and F).  
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2. Histopathology of Macular Telangiectasia type 2  
The results reported in this chapter have been published in: 
Powner MB, Gillies MC, Tretiach M et al. Perifoveal muller cell depletion in a case of macular 
telangiectasia type 2. Ophthalmology 2010;117(12):2407-2416.248 
Len ACL, Powner MB, Zhu L, Hageman GS, Fruttiger M, Gillies MC. Pilot application of iTRAQ 
coupled with mass spectrometry to the retinal disease Macular Telangiectasia.  (in Press)  
 
2.1 Introduction: 
Macular telangiectasia (MacTel) has been poorly understood and often misdiagnosed until 
recent years. Gass and Blodi143 first proposed a classification of the disease (also known as 
idiopathic juxtafoveal telangiectasis) in 1993, in which they clearly distinguished type 1 from 
type 2. The two types were found to be distinctly different disease phenotypes; Type 1 
usually occurs unilaterally and is largely restricted to males, whereas MacTel type 2 is 
bilateral and has no sex predilection. The clinical appearances also differ, type 1 is 
characterised by pronounced hyperpermeability and cystoid oedema and retinal thickening. 
Whereas loss of retinal transparency and small telangiectatic vessels, (identifiable only by 
fluorescein angiography), represent early signs of MacTel type 2. Intraretinal pigment 
clumping, parafoveal atrophy, and vascular membranes represented a secondary 
phenomenon only in type 2.  
 
Little research was focused on the disease until about 6 years ago when a worldwide 
collaboration was established between clinicians and basic research scientists, to focus 
research efforts in understanding the clinical and pathological aspects of this disease with, of 
course, the end goal of a therapeutic intervention. As mentioned previously, studies on living 
patients have gathered a lot of new information in recent years, with the finding of macular 
pigment depletion from the central macula, new imaging techniques; including confocal blue 
reflectance and OCT allowing the disease to be diagnosed more accurately.  Updated clinical 
criteria for the diagnosis of Macular Telangiectasia type 2 was published by Yannuzzi et al142 
in 2006. Early stage disease was classified as a patient having mild loss of transparency of the 
retina perimacularly, normally originating temporal to the fovea. Also early stage disease is 
characterised by mild leakage of perimacular capillaries in late stage fluorescein angiography, 
however no visible capillary dilation and telangiectasis need be visible. Late stage disease 
sees the progression of the loss of macular transparency to include a full ellipse surrounding 
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the fovea. Visible macular capillary dilation will be noted and more severe leakage seen with 
fluorescein angiography.142  
 
However the existing knowledge about MacTel type 2 pathobiology is restricted in that it is 
based upon the observations from living patients. There is only one published clinico-
pathological study of a confirmed MacTel type 2 case. In this case a 58 year old female with 
no ophthalmic complaints was found to have MacTel type 2 on routine examination before 
undergoing maxillectomy and orbital exenteration for squamous cell carcinoma of her left 
eye.249  Light microscopic examination revealed no telangiectatic vessels, however they did 
observe retinal thickening, (due to marked proliferation of the basement membrane), in the 
inner retinal layers of the macular area. Capillaries were also noted to be present as far down 
as the photoreceptor layer, a region normally avascular in the retina, and this confirmed the 
findings from patients, where right angled venules are seen. Oedematous and cystic changes 
were present in the OPL that extended into the outer nuclear layer (ONL). Ultrastructural 
analysis of blood vessels in the clinically affected perifoveal zone revealed damaged 
capillaries with an almost total lack of pericytes and occasional reduced endothelial cell 
numbers. Furthermore, occasional loss of pericytes and multi-laminar capillary basement 
membrane with lipid inclusions and debris containing vacuoles was observed throughout the 
retina. The authors noted that these features were similar in many respects to those of 
diabetic retinopathy. A second case study of presumed MacTel type 2 has been carried out 
on a postmortem specimen from a 36 year old woman with Down’s syndrome. However, this 
case was not clinically diagnosed as MacTel type 2. The authors described macular oedema 
and telangiectatic vessels with partial degeneration of endothelium and pericytes.250 They 
also noted proliferation of vessels into the subretinal space, with occasional retinochoroidal 
vascular anastomosis and corresponding migration of RPE cells into the neural retina.250 
Neither of the two cases reported so far used immunohistochemistry to identify individual 
cell types in the retina.  Therefore an attempt was made to obtain a further postmortem 
MacTel type 2 specimen by reviewing the records of the Iowa City - Lions Eye Bank, held by 
Gregory Hageman. This revealed one case with a definite diagnosis of MacTel type 2, based 
upon the clinical notes made by a retinal specialist and supported by fluorescein angiography 
photos. This chapter describes the histopathology of MacTel type 2 in greater detail, 
identifying individual cell populations and distribution patterns in comparison to matched 
controls. 
2.2 Aim: 
To gain insight into the retinal histopathological features of MacTel type 2.  
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2.3 Materials and Methods: 
Institutional Review Board (IRB)/Ethics Committee approval for postmortem eye tissue 
collection and storage at the UCL Institute of Ophthalmology, Universities of Sydney and 
University of Iowa Department of Ophthalmology was in place. 
All reagents used were from Sigma, UK, unless otherwise stated.  
Technical acknowledgements: I would like to thank Greg Hageman, University of Iowa, for 
the provision of the clinical images used in this chapter, and also Mark Gillies, University of 
Sydney, for the provision of the pre-sectioned tissue of the MacTel type 2 sample.  
 
2.3.1 Donors and tissue processing   
The MacTel type 2 specimen used in this study had a postmortem time of 4 hours 12 minutes 
before fixation by submersion into 4% (w/v) paraformaldehyde (PFA). The right eye was fixed 
for histological analysis whereas the left eye had been frozen unfixed and has been used for 
biochemical analysis by our collaborators in Australia. Dissection removed the anterior pole 
of the eye after which the posterior was flattened (using four radial incisions) and 
photographed.  
 
Control eyes for the macroscopic appearance and macular pigment distribution were 
provided by an anonymous 67 year old donor (cause of death: lung cancer, no reported 
ophthalmic pathology) and a 75 year old donor with a diagnosis of unilateral Coat’s disease in 
the left eye (based on fluorescein angiogram and the presence of microaneurysms in the left 
macula, not shown). Control eyes for fluorescent immunohistochemistry were obtained from 
the right eye of a 79 year old male donor (cause of death: lung cancer) with no reported 
ophthalmic problems, retrieved and fixed in 2% PFA 13 hours after death. DAB 
immunohistochemistry was performed on the right eye of a 68 year old male donor (cause of 
death: intracranial haemorrhage, no reported ophthalmic problems) retrieved and fixed in 
2% PFA 9 hours after death. A further control eye from a 78 year old type 2 diabetic patient 
without diabetic retinopathy (cause of death: stroke) was fixed 9 hours after death in 2% 
PFA. An additional control eye from a 71 year donor (cause of death: cerebrovascular 
accident) with a history of diabetic retinopathy, laser surgery and intraocular lens 
replacement, was fixed under 12 hours after death in 2% PFA. To test the effects of 
postmortem fixation delay, both eyes from a 63 year old male donor, (cause of death: 
prostate cancer, no reported ophthalmic pathology), were used; the right eye was taken and 
44 
 
fixed 8 hours postmortem, whilst the left eye was kept at room temperature in sterile PBS for 
48 hours before fixation.  
 
A region of the posterior globe that included the optic disc, fovea and a section of nasal 
periphery was dissected and placed into slow running water for 24 hours before paraffin wax 
embedding. The fixed tissue was dehydrated through graded alcohols and xylene before 
embedded in paraffin wax using a LEICA TP1020 automatic tissue processor (Leica, UK). Naso-
temporal sections were cut at 6µm and collected onto Superfrost® plus slides (VWR, UK). 
Sections were deparaffinised using xylene. Sections for fluorescent immunohistochemistry or 
haematoxylin and eosin (H&E) staining were rehydrated through graded alcohols. Sections 
for DAB immunohistochemistry were first incubated in 3% H2O2 in glacial methanol for 30 
minutes (to block endogenous peroxidases) prior to rehydration.  
 
2.3.2 Antigen retrieval  
Long periods in fixative and the wax embedding of the tissue meant that antigen retrieval 
methods were required prior to immunohistochemical analysis. Each antibody required 
slightly different retrieval conditions. Sections where antibodies directed against GS, RLBP1 
and collagen IV were to be used required heating to a minimum of 125°C in 90% glycerol 
(molecular grade, Sigma, UK) and 10% 0.01M sodium citrate buffer pH6.0 for 20 minutes. 
Claudin-5 immunostaining required 129°C for 15 minutes, whereas GFAP, vimentin, ML-opsin 
and rhodopsin immunostaining required heating to a minimum of 120°C for 15 minutes in 
the same buffer. Eno1, Cox2 and LDHB immunostaining required heating to 135°C for 10 
minutes in 90% glycerol (molecular grade, Sigma, UK) and 10% 0.01M sodium citrate buffer 
pH6.0. Iba1 immunostaining however required heating to 128°C for 10 minutes in 10% 0.1M 
Tris EDTA buffer (10mM Tris-Base, 1mM EDTA, 0.05% Tween20) pH9.0 in Glycerol.  
 
2.3.3 Fluorescent labelled immunohistochemistry 
All incubations were carried out in a dark humidified chamber. Following antigen retrieval, 
sections were briefly washed in water, incubated for 1 hour at room temperature in blocking 
buffer (1% BSA, 0.5% triton X-100 in PBS) and then in primary antibody (diluted in blocking 
buffer, Table 2.1) either at room temperature for 1 hour or overnight at 4°C. Sections were 
washed in washing buffer (0.1% tween20 in PBS) and incubated for 1 hour at room 
temperature in secondary antibodies (Invitrogen, UK, diluted 1:200 in blocking buffer). 
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Subsequently sections were washed in washing buffer, treated with Hoechst (10μg/ml in 
washing buffer) for 30 seconds, washed finally in PBS and mounted in Citifluor mounting 
medium (Agar Scientific, UK) or Mowiol. Images were taken using a Leica DM IRB fluorescent 
microscope (Leica, UK) and/or a Zeiss LSM510 UV confocal microscope (Zeiss, UK).  
2.3.4 DAB Immunohistochemistry 
Following endogenous peroxidase blocking and antigen retrieval, sections were briefly 
washed in water, incubated for 1 hour at room temperature in 100% normal serum (species 
dependant on secondary antibody used), then into primary antibody diluted in 100% normal 
serum for 1 hour at room temperature (Table 2.1 for antibody information). Sections were 
washed in PBS. The sections were subsequently stained using VECTASTAIN Elite ABC kits 
(Vector labs, UK); sections were treated as per manufacturer’s guidelines from the secondary 
antibody incubation step. Sections were incubated for 30minutes in biotinylated secondary 
antibody, 1:200 in 1.5% normal serum in PBS. Sections were washed in PBS and then 
incubated in VECTASTAIN® Elite ABC Reagent (Vector Labs, UK) at room temperature for 
30minutes. To develop the stain, slides were washed in PBS and incubated with SIGMAFAST™ 
3,3’-Diaminobenzidine (DAB) tablets dissolved in dH2O for 30-60seconds or until the stain 
darkened sufficiently. They were then mounted in glycerol and imaged. 
 
2.3.5 Nuclei counting 
Haematoxylin and eosin (H&E) stained sections were used to count the number of cell nuclei 
in the inner nuclear layer. Section numbers 140, 143 and 150, through the macula, superior 
to the fovea from the MacTel type 2 specimen were counted. As a control, three macula 
sections from the corresponding superior/perifoveal region from an age matched control 
donor were analysed. The distance between the fovea and optic disc edge was measured and 
split into 20 equal sized segments. The number of nuclei within the inner nuclear layer were 
counted in 15 segments temporal to the fovea and in 15 segments nasal to, and including the 
fovea. The values for each segment were averaged for the MacTel type 2 sections and the 
control sections, and the most nasal segment was used for normalization to 100%. Statistical 






2.4.1 Clinical features 
The 65 year old male donor, who died from a cerebrovascular accident, had a history of type 
2 diabetes, hyperlipidemia and hyperthyroidism. He had a family history of age-related 
macular degeneration, however no features of diabetic retinopathy (DR) or macular 
degeneration were described in the ophthalmologist’s notes, nor were there any features of 
DR evident in the available colour photographs and fluorescein angiograms, or evidence 
upon gross examination. The donor was diagnosed with MacTel type 2 by a retinal specialist 
12 years prior to death. An angiogram available from that time shows typical features of 
MacTel type 2 (Fig. 2.1). Telangiectatic vessels were observed in the temporal perifoveal area 
early in the angiogram with more widespread diffuse staining of the entire perifoveal area in 
later images. Visual acuity was 20/25 OD, 20/40 OS. These readings were unchanged at the 
last recorded clinic visit, 10 years before death. 
 
2.4.2 Macroscopic appearance of the retina 
Photographs of dissected postmortem eyes (unfixed) revealed a loss of macular pigment in 
the MacTel type 2 retina (Fig. 2.2 A, B). Remaining macular pigment (white arrows in Fig. 2 A, 
B) was clearly visible as a ring around the fovea, with a sharp in inner boundary and more 
diffuse towards the periphery. Control retinas from an anonymous donor, with no reported 
ophthalmic pathology, have macular pigment concentrated as a yellow/brownish dot in the 
centre of the macula at the fovea (Fig. 2.2 C, D). A patient with Coat’s disease in the left eye 
had a normal appearance of macular pigment in both eyes (Fig. 2 E, F). Depletion of macular 
pigment (with the most pronounced alterations in the temporal perifoveolar region) has, as 
I’ve previously stated, been described by Helb et al (2008) to be a specific and early clinical 
feature of MacTel type 2.138, 246, 251, 252 The macular pigment depletion seen in this post-
mortem case  further confirms the nature of the changes to macular pigment distribution in 
MacTel type 2, and in combination with the fluorescein angiogram identify the MacTel type 2 
sample as a definite case of MacTel type 2. 
  
2.4.3 Retinal vasculature 
Serial sections from an eye were immunolabelled with Collagen IV to reveal the vascular 
profiles to observe the previously noted abnormal vessels, since these are a notable 
characteristic of MacTel Type 2. Leakage of fluorescein from perifoveal blood vessels 
(arrowheads in Fig. 2.1) indicates presence of the telangiectatic vessels characteristic of the 
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disease. Wax sections serially cut from the right eye were used to study the nature of the 
telangiectatic vessels further. However the location of this region of retina first had to be 
established to ensure the vessels studied correlated to those seen to be permeable to 
fluorescein. To this end some of the sections were stained with an antibody directed against 
collagen IV to reveal vascular profiles (Fig. 2.3 A). The naso-temporal position of all major 
vessels (insets in Fig. 2.3 A) was mapped in the sections (red dots in Fig. 2.3 A) and then 
matched with the angiogram (Fig. 2.3 B). The specific distribution of main vessels in the naso-
temporal axis allowed identification of the approximate position in the superior-inferior axis 
of each wax section on the angiogram (numbered scale in Fig. 2.3 B).  
 
H&E staining of some of the sections revealed blood-filled, abnormally dilated vessels in the 
deeper plexus of the retinal vasculature (sections 140 and 150; Fig. 2.3 C-E). These abnormal 
vessels were limited to the clinically affected, perifoveal region and particularly pronounced 
temporal to the fovea, but were not present in the periphery. Furthermore, they were 
limited to the deeper plexus whilst vessels in the RGC layer were of normal diameter 
throughout the retina. The specimen showed a tendency to splitting in the horizontal plane 
throughout the macular region. Whether this is a tissue processing artefact or due to 
structural changes inherent in the condition is not clear, although this is unlikely as the eye 
was immersion fixed and the more peripheral regions are well preserved. 
 
Collagen IV, marking vascular basement membrane, and claudin-5, marking tight junctions 
between retinal endothelial cells were used to further characterise these telangiectatic 
vessels (Fig. 2.4 A-G). Claudin-5 immunoreactivity was visible in all vessels (arrowheads Fig. 2. 
4 B, D, F), despite uniform, strong autofluorescence in the lumen of many vessels. Claudin-5 
is a protein involved in tight junction formation between endothelial cells, its 
immunoreactivity in both normal and dilated vessels indicates the presence of endothelial 
cells in both (stars in Fig. 2.4 D, F). However, telangiectatic vessels appeared to have reduced 
collagen IV staining in comparison to normal vessels within the same specimen in the 
unaffected peripheral retina (Fig. 2.4 D-G). This reduction in the basal lamina component 
collagen IV was only seen in deeper plexus vessels in the perifovea. However, other 
abnormalities were also noted. Small vacuoles within vascular basal lamina were noted in 
single confocal slices (arrows Fig. 2.4 E, G) in most macular vessels but also to some degree in 




In order to assess whether an inflammatory component may contribute to the vascular 
abnormalities characteristic of the MacTel type 2 retina, we used the microglia marker Iba1 
253 (Fig. 2.5 A-H). In a control retina from a healthy donor Iba1-positive microglia were found 
in the RGC layer, the IPL and the INL (Fig. 2.5 A-D). Microglia were often associated with 
blood vessels, consistent with previous studies.254, 255 The distribution of Iba1-positive 
microglia in the MacTel type 2 retina was similar to the control and no obvious changes in 
microglia number or morphology were noted. Even around abnormal vessels (arrowheads 
Fig. 2.5 G, H) the density and morphology of macrophages appeared normal. 
 
2.4.5 Glia 
An antibody directed against glial fibrillary acidic protein (GFAP) was used to visualize retinal 
astrocytes. In the healthy control eye (Fig. 2.6 A-D) retinal astrocytes were found in their 
expected distribution in the nerve fibre layer, the RGC layer and in the IPL. The strong GFAP 
positive signal visible in the fovea (Fig. 2.6 C) is likely to be a manifestation of the so-called 
Müller cell cone 256 and not retinal astrocytes as they are normally excluded from the fovea.86 
In the nasal retina the IPL exhibited particularly pronounced astrocyte staining with 
prominent perpendicular processes into the retina (Fig. 2.6 D). These processes did not 
appear to be from Müller cells since they only extended to the boundary between the IPL 
and the INL. In the MacTel type 2 retina (Fig. 2.6 E-H) retinal astrocytes seemed to be 
distributed in a similar fashion as in the control specimen. They were associated with nerve 
fibres and blood vessels in the RGC layer and the IPL. There was no Müller cell cone but this 
may have been because the section examined did not contain the fovea.     
Müller cells normally express GFAP only at very low levels and in healthy retina they are 
barely detectable by immunohistochemistry. Nevertheless we found a very faint stain in 
Henlé’s fibre layer (arrow Fig. 2.6 B). However, GFAP is known to be strongly upregulated by 
reactive Müller cells and is therefore a popular marker to detect certain retinal 
pathologies.257, 258 Remarkably, no evidence of reactive Müller cells was found in the MacTel 
type 2 retina (Fig. 2.6 E-H). 
Müller cell distribution was then visualized with an antibody directed against vimentin (Fig. 
2.7 A, B). In the control retina strong consistent staining was visible throughout the macula 
and peripheral retina, consistent with the expected distribution of Müller cells. However, in 
the MacTel type 2 specimen vimentin immunoreactivity was markedly reduced in the macula 
(Fig. 2.7 B). This lack of staining could either be an indication of downregulation of vimentin 
49 
 
or a gross loss of Müller cells. To further elucidate this two other Müller cell markers, 
glutamine synthetase (GS, Fig. 2.7 C) and retinaldehyde binding protein (RLBP1 also known as 
CRALBP, Fig. 2.7 D) were used. A clearly demarcated area in the central macula exhibited 
reduced staining with both antibodies, suggesting Müller cell dropout in a specific macular 
region in this MacTel type 2 eye. 
Postmortem degenerative changes could be argued to be the cause of the loss of Müller cell 
staining at the macula of the MacTel type 2 eye, and therefore the finding could be an 
artifact. Although the MacTel type 2 eye was enucleated and fixed 4 hours after death and 
showed normal Müller cell staining in the periphery it cannot be entirely excluded that the 
macula could be particularly sensitive to postmortem artifacts, especially due to the reported 
higher metabolic demands in this region.259, 260 In order to address this possibility, an 
enucleated postmortem eye was kept in an unfixed state for a further 48 hours at room 
temperature in phosphate buffered saline (PBS) after enucleation, before standard 
processing for immunohistochemistry was carried out. Müller cell staining was not affected 
in the macula of this eye (Fig. 2.7 E). Furthermore, because the MacTel type 2 donor had a 
history of type 2 diabetes, the distribution of the three Müller cell stains was checked in two 
control eyes from type 2 diabetes patients, one with and one without diabetic retinopathy, 
and found normal distribution of Müller cells (data not shown). 
Since it became apparent that there was a clearly defined Müller cell loss from the macula, 
and there was also macular pigment depletion with a clearly defined inner boundary, it was 
logical to attempt to spatially correlate the macular pigment ring with the region of Müller 
cell loss. The colour photograph (from Fig. 2.2 A) was scaled and matched to the angiogram 
using small traces of blood in the macular region (Fig. 2.7 F-H), and then superimposed the 
area of macular pigment depletion onto the angiogram (green patch in Fig. 2.7 H). Since the 
approximate position and scale of each cross-section was already mapped within the 
angiogram, it was possible to show that the lack of Müller cell staining correlated with the 
area of macular pigment loss (Fig. 2.7 H).  
In order to further test whether the disappearance of Müller cell markers represents a lack of 
cells in the macula, H&E stained sections were used to count the number of cell nuclei in the 
inner nuclear layer (Fig. 2.7 I). In a control retina we found a drop in the fovea and a slight 
increase of cell nuclei numbers either side of the fovea in the perifoveolar region. In the 
MacTel type 2 sample numbers were lower throughout the macula relative to the periphery, 
and when scaled to the macular pigment loss and vimentin stain, this region of decreased cell 
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nuclei numbers closely correlates to the region of Müller cell loss, suggesting that cells - most 
likely Müller cells - were missing or reduced in number.   
Our collaborators Prof. Mark Gillies and Dr. Alice Len at the Save Sight Institute, University of 
Sydney, Australia have carried out a biochemical analysis of the fellow eye from this MacTel 
type 2 donor (from which the macula and peripheral samples were fresh frozen at the point 
of enucleation). Their comparative proteomic analysis highlighted numerous proteins from 
the glycolytic pathway as being downregulated in the macula biopsy when compared to the 
expression pattern between macula and peripheral retina seen in healthy control and 
diabetic retinas  (data not shown). This prompted us to further investigate the distribution 
patterns of some of these glycolytic pathway proteins in the fellow MacTel type 2 eye from 
the same patient we were using. Antibody staining against two selected glycolytic enzymes 
(enolase 1; ENO1 and lactate dehydrogenase B; LDHB) in control tissue from a diabetic 
control patient and a normal donor was consistent with Müller cell specific expression, 
displaying strong staining of perpendicular fibres (black arrowheads in Fig. 2.8 D, E, G, H) and 
Henlé fibres (white arrowheads in Fig. 2.8 D, E, G, H).  Furthermore, ENO1 staining was also 
strongly expressed in a cell population in the inner nuclear layer, the layer of Müller cell 
soma are located (arrows in Fig. 2.8 D, G, M, P).  ENO1 and LDHB staining were both 
significantly depleted in the macular region of the MacTel type 2 sample (Fig. 2.8 A, B) but 
peripheral retina staining was persistent in the diseased eye (Fig. 2.8 J, K).  In contrast, 
staining against COX2 (part of the oxidative phosphorylation pathway and a neuronal marker) 
showed no change in the diseased macula (Fig. 2.8 C, L). 
 
2.4.6 Photoreceptors and retinal pigment epithelium (RPE) 
It has been published that MacTel type 2 patients suffer from reduced retinal sensitivity and 
reduced visual acuity, 261-263 as such we studied the photoreceptors in our MacTel type 2 
specimen to establish if any such cause of visual problems could be determined. As expected, 
in the control specimen anti-rhodopsin immunostaining showed rods were excluded from 
the fovea, but clearly visible in the macula and throughout the periphery, whereas cones 
were concentrated in the fovea (Fig. 2.9 A-D). The anti ML-opsin antibody from Chemicon 
used not only labels cone outer segments but also the entire cell, including synaptic bodies 
and axonal connections in the OPL and Henlé fibre layer (Fig. 2.9 C, D). In the MacTel type 2 
eye the distribution of rods and cones was similar to the control eye. The presence of ML-
opsin staining in Henlé fibre layer was reduced but indicated the presence of at least some 
cone axons in the macula (Fig. 2.9 G, H). ML-opsin staining was also strongly present in the 
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fovea (Fig. 2.9 H) but due to poor preservation of photoreceptors in all of our samples it was 
not possible to ascertain whether there was a reduction of cone numbers in the MacTel type 
2 fovea. 
The structural integrity and general appearance of the RPE (not shown) was checked in all 
sections studied from the MacTel type 2 specimen and, as observed in the previous two 
MacTel type 2 case studies 249, 250, no obvious abnormalities were found.     
 
2.5 Discussion: 
The results listed are limited in that they are from a single case of MacTel type 2, however 
they are still crucial in further understanding the disease. With no other histological case 
reports to date that have addressed the cell types involved, and that diagnosis of the 
condition relies on gathering a pattern of patient signs and symptoms that may sometimes 
result in an equivocal diagnosis any information gathered can advance the understanding 
significantly. Furthermore, lack of insight into the cause of the disease impedes the 
development of treatment strategies. Hence our study, though limited to one patient, is 
important in this field. We have extended the findings of the two previous clinicopathological 
reports of MacTel type 2 by performing immunohistochemical analysis on an eye derived 
from a clinically verified MacTel type 2 donor, thereby providing new information about the 
pathogenesis of this obscure condition. The most striking finding was one of depleted 
expression of Müller cell specific markers in the central macula compared to both peripheral 
retina and control samples. Expression of other markers, such as rhodopsin, ML-opsin, COX2, 
GFAP and others was normal in the central macula of the affected eye. This suggests that the 
reduction of Müller cell markers does not represent general tissue degeneration or fixation 
artifacts within the macular region, but instead is a specific indication of Müller cell 
pathology. The glycolytic pathway is known to be dominant in the glial cells of the retina, 
while the neurons produce their ATP primarily via oxidative phosphorylation.264 Glycolysis in 
Müller cells converts glucose (derived from the blood) into lactate,265, 266 which is then 
secreted by the Müller cells and preferentially taken up by photoreceptors to fuel 
mitochondrial oxidative metabolism and the glutamate resynthesis.267 The absence of the 
glycolytic enzymes ENO1 and LDHB within central macula from the affected eye (Fig. 2.8 A, C) 
further supports the Müller cell loss conclusion. The decreased expression of the two 
enzymes is restricted to the central macula and the cell morphology seen in control samples 
indicates Müller cell localisation. Müller cells being the primary source of lactate for 
photoreceptor function and survival serves to link the pathology of the disease to the effects 
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on visual function seen in patients in clinics. Over time, if Müller cell death is occurring, then 
lactate levels for photoreceptors of the macula will decrease in localised regions, therefore 
potentially limiting photoreceptor function for the patient and a decrease in visual acuity.  
Furthermore, we have been careful to compare findings from macular and extra macular 
regions of the MacTel type 2 eye with controls from healthy patients, a patient with type 2 
diabetes and no retinopathy, a patient with diabetic retinopathy and a sample with a very 
long postmortem delay before fixation to try to ensure the specificity of changes to MacTel 
type2. 
 
The apparent Müller cell loss observed in the MacTel type 2 sample is consistent with the 
reduced numbers of cell nuclei counted in the INL, and is also consistent with the retinal 
thinning observed with optical coherence tomography (OCT) in living patients.268 In contrast, 
both previous MacTel type 2 histology case reports reported oedematous thickening of the 
macula 249, 250. Our MacTel type 2 sample was split and abnormally thickened, particularly in 
the macular region. This discrepancy between in vivo and histological observations might be 
explained by fixation or tissue processing artifacts. It is more likely that increases in retinal 
thickness in vivo are masked by the cellular loss in the MacTel type 2 macula.269 
 Müller cells do not comprise a cellular entity that can be visualised upon clinical 
examination, however the consequences of Müller cell loss and/or dysfunction might well be 
detectable in vivo. Since Müller cells are intimately related to the retinal vasculature, it is 
quite possible that their dysfunction would be associated with clinically visible telangiectasis. 
Müller cells also interact very closely with retinal neuronal cells; for example, they recycle the 
toxic neurotransmitter glutamate to glutamine.270 It is therefore also plausible to suggest that 
Müller cell degeneration would be accompanied by loss of neurons in MacTel type 2 as was 
suggested by recent findings in patients examined with OCT.271 This might also be linked to 
the progressive central macular thinning observed clinically in MacTel type 2 patients.268 
Gass drew attention to the “Müller cell cone”, a layer of Müller cells sitting above the Henlé 
fibre layer immediately beneath the inner limiting membrane (ILM) in the base of the foveal 
depression, which he further postulated to be the major location for sequestration of 
macular pigment.256 Disease of the Müller cells in this case may explain the “ILM drape”, or 
cavities within the inner neural retina in this location that are commonly found in eyes with 




Müller cell processes envelope retinal blood vessels in the deeper plexus of retinal 
vasculature and are believed to contribute to induction of blood retina barrier integrity.51, 55 
Blood vessels in the RGC layer are thought to be supported more by retinal astrocytes.273 
Thus, the observed limitation of vascular abnormalities to the deeper plexus of the retinal 
vasculature is consistent with a Müller cell dysfunction, supporting Gass’ suggestion that the 
primary abnormality may reside in the perifoveolar neuronal retina or Müller cells.274 Further 
research studying the effects of Müller cell loss/disruption in animals models will be key to 
understanding the underlying mechanisms involved in this disease. 
 
It is noticeable that the histological findings and the macroscopic appearance of the MacTel 
type 2 specimen correlated well with the angiogram, which was taken 12 years prior to the 
donor’s death. This suggests that the disease was slowly progressive in this patient, who had 
not developed late stage complications of MacTel type 2 such as neovascularisation and 
retinal pigment invasion by the time of death.143 Abnormally dilated vessels in this patient 
were primarily found in the deeper plexus of the retinal vasculature, which is characteristic of 
the early stages of MacTel type 2. The presence of claudin-5 in these abnormal vessel 
segments implies the presence of at least some endothelial cells but should not be 
interpreted to reflect functional blood retina barrier.275 Green et al. noted normal zonula 
occludens in telangiectatic vessels but also occasional endothelial cell drop out,249 which 
could not be excluded in our specimen. Nevertheless, the dramatic reduction of collagen IV 
in telangiectatic vessels clearly indicates some form of vascular pathology which might be 
associated with pericyte dysfunction. Like Green et al., 276 we also found subtle vascular 
changes in the retinal periphery such as small vacuoles in the vascular basement membrane, 





Table 2.1: Primary antibodies 
Antibody  Company Cat. # Dilution 
Glia 
Retinaldehyde binding 




Enolase 1 (ENO1) Abcam, UK ab49343 1:200 





Glutamine synthetase (GS)  Chemicon, UK MAB302 1:200 






Vimentin-Cy3 Sigma, UK C9080 1:200 
Ionised calcium binding 
adaptor molecule 1 (Iba1)  











ML-opsin  Chemicon, UK AB5405 1:200 
Rhodopsin  Chemicon, UK MAB5356 1:200 
Oxidative phosphorylation 











Figure 2.1. MacTel type 2 fluorescein angiograms 
 Angiogram of the right (A, C, E) and left eye (B, D, F) showing fluorescein leakage in the 
perifovea (arrowheads). The leakage is particularly prominent temporal to the fovea, which is 




Figure 2.2. Macular pigment 
 Photographs of dissected eye globes from three different donors before fixation showing the 
distribution of macular pigment. In the MacTel type 2 patient (A, B) macular pigment is 
absent from the centre of the macula (black arrows) but faintly visible as a perifoveolar ring 
(white arrows). In contrast, in the two control donors (C-F) the highest concentration of 
macular pigment is found in the fovea (black arrows). Images A, B, E and F were provided by 






Figure 2.3. Mapping of wax sections onto the angiogram.  
Two sections (110, superior, and 198, inferior to the macula) stained against collagen IV show 
the distribution of vessels (A). Larger vessels were identified (insets in A) and plotted as red 
dots in the naso-temporal axis. The distribution of red dots was used to define the superior-
inferior position of the two sections and to position a scale that gives the approximate 
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position of every section in the angiogram (B). H&E stains of three sections (C, section 130, 
140 and 150) shows that vascular abnormalities (visible at higher magnification in D, E) match 
well to fluorescein leakage visible in the angiogram (yellow arrows in B). Scale bar is 500μm 








Figure 2.4. Vasculature 
Immunohistochemistry with antibodies against collagen IV (green) and claudin-5 (red) labels 
retinal blood vessels (section 133) of MacTel type 2 retina. A non-specific luminal stain is also 
visible in the red channel and is prominent in telangiectatic, deeper plexus vessels. This is 
particularly obvious in the overview micrograph (A) as an orange stain. However, confocal 
microscopy through the entire thickness of the wax section (B, D, F) from selected regions 
shows that claudin-5 staining can be clearly distinguished as a junctional stain (arrowheads in 
B, D, F). Single confocal slices (C, E, G) reveal fine vacuoles (arrows C, E, G) in vascular basal 
lamina throughout the retina.  In telangiectatic vessels collagen IV staining appears diffuse 
and interrupted (white stars in D-G). Temporal is to the left and nasal to the right. Scale bar is 





Figure 2.5. Microglia 
Immunohistochemistry with the Iba1 antibody (red) labelling macrophages in the control (A-
D) and the MacTel type 2 eye (E-H, section 153). Macrophages are distributed in both 
samples throughout the RGC layer, IPL and INL in the periphery (B, F) and the macula (C, D, 
G, H). They tend to be associated with blood vessels (visible as green/yellow 
autofluorescence), telangiectatic vessels indicated with arrowheads in G, H. RGC; retinal 
ganglion cell, IPL; inner plexiform layer, INL; inner nuclear layer, HFL; Henlé fibre layer, OPL; 
outer plexiform layer, ONL; outer nuclear layer. Temporal is to the left and nasal to the right. 




Figure 2.6. Retinal glia 
Immunohistochemistry with an antibody directed against glial fibrillary acidic protein (GFAP) 
(red). GFAP immunostaining labels retinal astrocytes in a control retina (A-D) and the MacTel 
type 2 specimen (E-H, section 134). Strong GFAP labelling in the fovea of the control eye (A, 
C) might indicate the “Müller cell cone”. There is also weak labelling in Henlé fibre layer 
(arrow B). Retinal astrocytes are associated with blood vessels and nerve fibres in both 
samples and appear in similar distribution and density. Blood vessels are visible as 
green/yellow autofluorescence (telangiectatic vessels; arrowheads G). No GFAP labelling is 
visible in Henlé fibre layer of the MacTel eye (arrow G). GCL; ganglion cell layer, IPL; inner 
plexiform layer, INL; inner nuclear layer, HFL; Henlé fibre layer, OPL; outer plexiform layer, 
ONL; outer nuclear layer. Temporal is to the left and nasal to the right. Scale bar is 200μm in 







Figure 2.7. Müller cells 
Immunohistochemistry with antibodies directed against three different Müller cell markers 
(A-E). The distribution of vimentin (A, B) indicates the presence of Müller cells throughout 
the macula and periphery in the control eye (A) but a strong reduction in the macula of the 
MacTel eye (B). Similarly, glutamine synthetase, GS (C) and retinaldehyde binding protein 1, 
RLBP1 (D) are reduced in the MacTel macula. A 48 hour postmortem delay before fixation did 
not affect vimentin staining in the macula of a control eye (E). In order to compare the area 
of macular pigment depletion with the area of Müller cell depletion, blood residues were 
traced in the colour photograph (F, G). The image was scaled to match vessels in the 
angiogram, which locates the approximate position of the area of pigment depletion (green 
area) in the angiogram (H). The vimentin immunostaining (B) was scaled and centred on the 
angiogram (based on the size relationship established in Fig. 3), which demonstrates a rough 
correlation between macular pigment and Müller cell depletion (yellow arrows in H). The 
relative frequency of cell nuclei in the inner nuclear layer (based on H&E stained, perifoveal 
sections) is plotted in I and shows a reduction in the perifoveal region in the MacTel 
specimen (blue) versus control (red). Stars in I indicate statistical significance with a p-value 





Figure 2.8. Glycolytic pathway proteins are down regulated in macular Müller cells in the 
MacTel type 2. 
Immunohistochemistry on wax sections (A-C, J-L), a control eye from a patient with diabetes 
(D-F, M-O) and a normal control eye (G-I, P-R) using antibodies against ENO1 (A, D, G, J, M, 
P) and LDHB (B, E, H, K, N, Q) showed reduced staining of glycolysis markers ENO1 and LDHB 
in the diseased macula (A, B) in comparison to the retinal periphery (J, K) in the MacTel 
patient. In contrast, staining of the oxidative phosphorylation cytochrome unit COX2 and (C, 
F, I, L, O, R) was similar in diseased and control tissue. Müller cell processes are marked with 
black arrowheads in the inner retina and with white arrowheads in Henlé fibre layer. Black 





Figure 2.9. Photoreceptors 
Immunohistochemistry showing the distribution of ML-opsin (red) and rhodopsin (green) in 
the control (A-D) and the MacTel eye (E-H, section 143).In both samples rods (green) are 
reduced and cones (red) are increased in the fovea. In the control Henlé fibre layer is stained 
by the ML-opsin antibody (C) and high magnification of the ML-opsin stain (D) confirms that 
this particular antibody stains the entire cone cell, including cone axons. ML-opsin stain in 
the MacTel Henlé fibre layer (G, H) suggests the presence of cone axons but is weaker in 
comparison to the control (C). Nevertheless, strong ML-opsin stain is visible in the MacTel 
fovea (H). IPL; inner plexiform layer, INL; inner nuclear layer, HFL; Henlé fibre layer, OPL; 
outer plexiform layer, ONL; outer nuclear layer. Photoreceptor structure: P; pedicle, S; soma, 
IS; inner segment, OS; outer segment. Temporal is to the left and nasal to the right. Scale bar 





3. Microvessels of the peripheral retina 
The results reported in this chapter have been published in: 
Powner MB, Scott A, Zhu M et al. Basement membrane changes in capillaries of the ageing 
human retina. Br J Ophthalmol 2011;95(9):1316-1322.277   
 
3.1 Introduction: 
The clinical phenotype of MacTel type 2 is restricted to the central macula and to date no 
disease phenotype has been reported in the periphery. However one of the two previous 
histopathologic case studies249 has addressed the peripheral retina vascular phenotype using 
conventional light microscopy and transmission electron microscopy (TEM). They reported a 
thickening of retinal capillaries, most likely due to the excess production of basement 
membrane in a multi lamellae configuration, and also sporadic narrowing of the lumen 
calibre249. Degeneration of pericytes was noted using retinal trypsin digests, pericyte counts 
and TEM. Occasional areas showed loss of endothelial cells (only noticeable with TEM). 
Similar findings were found in perimacula capillaries as well as the peripheral retina; the 
degree of lamination was reported to be the same pan retina, whereas the number of lipid 
inclusions in the capillary basement membranes were decreased in number but still present, 
in peripheral tissue. Cellular debris from these degenerated endothelial cells and pericytes, 
and multimembranous lamellar lipid were separated by basement membrane layers, lipids 
present within the basement membrane, visualised both at a TEM level and using oil-red O 
and sudan black B staining and light microscopy. However fluorescein angiography of this 
patient revealed no peripheral vascular abnormalities prior to enucleation, be it leakage or 
significant dilation of the vessels.249  
 
The phenotype described by Green et al249, although thorough, was not compared in any 
form to control tissue. They do postulate the findings of vascular phenotype are similar to 
those found in diabetic and prediabetic patients278, 279  yet the patient had no history of 
diabetes and glucose tolerance tests appeared normal. This is potentially misrepresentative 





Histopathological studies of the retinal vasculature in postmortem human tissue are crucial 
in understanding retinal disease mechanisms.  In diabetic retinopathy, for example, 
degenerative changes in the microvasculature such as non-perfused capillaries and the 
formation of microaneurysms are hallmarks of disease that have been characterised 
extensively both in living patients and in postmortem material. Ultrastructural analysis of 
cross sections of retinal capillaries can provide critical insight into the health of the 
microvasculature that is not possible with normal light microscopy.   
 
In diabetic retinopathy microvascular pathologies such as reduced pericyte - endothelial cell 
ratios and thickened capillary basement membranes have both been recognised for 
decades.278, 280-283  There are numerous studies demonstrating in various diabetic animal 
models degenerating pericytes and capillary basement membranes of irregular and increased 
thickness, comprising debris-like inclusions and vacuoles, whereas the healthy control 
animals maintain intact pericytes and the vessels have basement membrane with 
homogenous density and uniform, ‘normal’ thickness.284-287   
 
Studies attempting to quantify these pathological changes in human tissue specimens are 
less conclusive.  Firstly, fixation procedures in humans are usually less than ideal because in 
most cases eye tissue can only be retrieved and fixed several hours after death.  These 
postmortem delays might introduce artifacts.  Secondly, in ‘healthy’ adult humans the 
basement membrane of retinal capillaries is irregular, containing numerous vacuoles and has 
a “Swiss-cheese” appearance.283, 288  Furthermore, evidence of pericyte degeneration is also a 
common finding in non-diabetic retinas,289 similar in many ways to the phenotypes observed 
in diabetes.  Against this background of ‘pseudo pathology’ it is more difficult to measure 
changes in humans in comparison to animal models, which in general maintain pristine 
capillary ultrastructure throughout adult life and can be processed immediately after death.  
It can therefore be challenging to interpret findings in human samples on an ultrastructural 
level, in particular in case studies, in which controls and statistical comparisons are often 
unavailable.   
 
We herefore used postmortem retina samples from anonymous human donors with no 
known ocular complaints and compared the ultrastructural integrity of capillaries in samples 
with different postmortem fixation delays, different fixation methods and different donor 
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ages, and thus created a baseline of capillary phenotype. Peripheral retina from our MacTel 
type 2 sample (along with the necessary diabetic, retinopathy and no retinopathy controls) 
have been studied in order to determine whether there is a peripheral retina microvascular 
phenotype like that described by Green et al.249 
 
3.2 Aim:  
To determine whether previously reported ultrastructural changes in MacTel type 2 are 
disease specific.  
 
3.3 Materials and Methods: 
Technical acknowledgements: I would like to thank Greg Hageman, University of Iowa, for 
the provision of the pre-embdded MacTel type 2 retina sample. I would also like to thank 
Mark Gillies and Meidong Zhu, University of Sydney, for the provision of the fixed control 
tissue used. Further thanks go to Peter Munro, University College London, for the embedding 
and ultra thin sectioning of the tissue reported in this chapter. 
3.3.1 Donors and tissue processing  
Postmortem retinae were obtained from; a rhesus macaque aged 17 years, 20 anonymous 
human donors with no known ocular disease, aged between 1 to 97 years, 4 type 2 diabetic 
donors without and one with diagnosed proliferative diabetic retinopathy and one donor 
with diagnosed MacTel type 2.  All retina samples were taken from the mid- to far-periphery 
of nasal-inferior retina. Table 3.1 contains the donor and tissue fixation details; retina 
samples were fixed immediately in Karnovsky’s fixative (3% (w/v) glutaraldehyde, 1% (w/v) 
paraformaldehyde in 0.08M sodium cacodylate buffered to pH 7.4 with 0.1M HCl) or tannic 
acid/glutaraldehyde mix. Alternatively they were fixed initially in 2% paraformaldehyde (PFA) 
and later transferred into Karnovsky’s fixative.  
 
3.3.2 Electron microscopy and image analysis 
All tissue was osmium tetroxide treated, dehydrated through a series of alcohols and 
embedded in araldite resin.  Ultrathin sections were cut and floated onto 150x hexagonal 
mesh grids.  Microvessels with a diameter of less than 10µm were imaged using a Jeol 1010 
transmission electron microscope (Jeol, UK) fitted with a Gatan OriusTM SC1000B camera 
(Gatan, UK).  Epoxy resin embedded tissue was also serially sectioned and imaged using the 
Gatan 3VIEW serial block face imaging system (Gatan, UK) fitted to a Zeiss Sigma variable 
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pressure field emission electron microscope (Zeiss, UK).  3D-reconstruction and Boissonnat 
surface modelling was performed using Digital Micrograph (Gatan UK, UK)and Reconstruct 
software290 (Boston university, USA).  
The degree of basement membrane vacuolisation was established by assigning a score to 
each capillary cross-section based on the percentage of the total basement membrane area 
that is covered by vacuoles (0=0%, 1=1-20%, 2=21-40%, 3=41-60%, 4=61-80% and 5=81-
100%, Fig. 3.3 A,A’). Endothelial cell numbers were established by counting the number of 
zonula occludens between endothelial cells forming the lumen (Fig. 3.4 A, A’).  Pericyte 
profile coverage was assessed by using the percentage of the circumference of the outer 
surface of the endothelial cell that was covered by a pericyte profiles (Fig. 3.4 B,B’). 
Basement membrane lamination was assessed by scoring the highest number radially of 
separate lamellae per capillary cross-section. (Fig. 3.4 C, C’). Averages were calculated for 
each donor. The images were scored independently by myself and verified by a colleague 
(Andrew Scott, University College London) and the quantification process was blinded. 
Spearman’s rank correlation coefficient was used to determine significance levels. The r value 
and p values were calculated using the software Stata10 Intercooled (StataCorp, USA). 
 
3.4 Results: 
3.4.1 Fixation and postmortem delays 
A problem with human postmortem material is that significant time periods can elapse 
between the death of the donor and the fixation of the tissue.  Since the cellular and 
ultrastructural changes that may occur after death are not well characterised, it could be 
argued that ultrastructural abnormalities in human retinal capillaries may be based on 
postmortem or fixation artifacts.  In order to establish how postmortem delays and fixation 
methods may influence the ultrastructural appearance of retinal capillaries we used a well 
preserved monkey retina as an example to demonstrate “normal looking” capillaries and 
compared this with three differently fixed human samples.  The monkey eye was fixed within 
15 minutes of death in Karnovsky’s fixative (a fixative containing glutaraldehyde and 
paraformaldehyde).  Retinal capillaries displayed normal looking basement membranes, 
endothelial and pericyte profiles (Fig. 3.1 A).  In contrast, a human sample (donor age 80) 
contained large vacuoles in the basement membrane near the glia interface (arrowheads in 
Fig. 3.1 B). However, this sample was fixed 13 hours after death with paraformaldehyde, 
stored for 19 months and then post-fixed in Karnovsky’s.  It is therefore possible that the 
vacuoles may have been caused by the long postmortem delay or by suboptimal fixation; 
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paraformaldehyde penetrates tissue fast, but its ability to cross link proteins is relatively 
slow, (sufficient cross linking to survive dehydration may take over 24hours), whereas 
glutaraldehyde fixation rapidly cross links proteins, however the penetration rate is slower 
due to the larger polymers that form in solution. Therefore a mixture of the two fixatives is 
ideal in electron microscopy, the formaldehyde penetrates and stabilises the tissue, whist the 
glutaraldehyde follows on and cross links the tissue further.   
We therefore analysed a sample (donor age 75) that has been fixed within 4 hours of death 
directly in Karnovsky’s fixative.  Remarkably, the same vacuoles could be found in the 
capillary basement membrane (arrowheads Fig. 3.1 C).   
 
To further exclude postmortem delay as a factor causing the basement membrane vacuoles, 
we used a sample from an enucleated eye (donor age 55) that was fixed in tannic acid and 
glutaraldehyde within less than 30 minutes of enucleation.  Extensive basement membrane 
vacuolisation was also found in all capillaries (Fig. 3.1 D).  The vacuoles in this sample appear 
to consist of more ‘rounded bubbles’ when compared to previous examples, however this 
structure is visible in parts of the 4 hours after death fixation example (Fig. 3.1 C), in parts the 
bubbles however seem to have merged, and in the 16 hour postmortem example (Fig. 3.1 B) 
larger vacuoles are seen, perhaps due to smaller vacuoles merging postmortem. 
Nevertheless, these findings demonstrate that basement membrane vacuolisation is not an 
artefact of postmortem delay but a normal feature present in adult human peripheral retinal 
capillaries.  
 
To obtain more insight into the morphology of the basement membrane vacuoles we serially 
sectioned a portion of a retinal capillary from our best preserved sample (enucleated eye, 
fixed in under 30 minutes) using the Gatan 3VIEW system (Fig. 3.1 E).  The outer surface of 
endothelial cells, pericyte profiles and basement vacuoles were traced in each section and 
then reconstructed and displayed as smoothened Boissonnat surfaces (Fig. 3.1 F).  This 
showed that the vacuoles were isolated or connected patches of varying size and shape, 




3.4.2 Donor age 
Since it has been previously reported that basement membrane vacuoles are virtually absent 
in children,276, 291 we analysed retinas from donors with different ages.  In the retina from a 
14 month old donor (with a 37 hour postmortem delay) we found that the basement 
membranes from most capillaries did not contain any vacuoles (Fig. 3.2 A).  Due to the very 
long postmortem delay in this case, the tissue surrounding the capillaries was not well 
preserved.  But importantly, this had no effects on the integrity of the capillary basement 
membrane, which further demonstrates that basement membrane vacuoles are not a 
postmortem or fixation artefact.  In samples from older donors (19, 47 and 80 years old) 
basement membrane vacuoles could be readily detected (Fig. 3.2 B-D).  In some instances, in 
particular in older donors, the vacuolisation reached dramatic levels where capillaries were 
entirely surrounded by vacuoles (Fig. 3.2 D). 
In order to quantify how basement vacuolisation correlates with donor age we analysed 
capillaries in the retinal periphery from 20 anonymous donors (with no known eye 
pathologies) aged between 1 and 97 years.  29±7 capillaries from each donor were imaged 
and assessed.  Vacuolisation was quantified by creating a severity scale with 0 representing 
no vacuoles at all and 5 complete vacuolisation of the basement membrane in its entire 
circumference (Fig. 3.3 A).  Interestingly, the severity of this ultrastructural abnormality 
correlated clearly and directly with age (Fig. 3.3 B, Spearman’s rank correlation coefficient, r= 
0.7203, p= 0.0003).  
Most of our samples were fixed within 24 hours of death but we also included three samples 
that were fixed 50 hours after death (Table 3.1).  Plotting the amount of basement 
membrane vacuolisation against postmortem fixation delays revealed no obvious correlation.    
To further exclude the possibility of postmortem artefacts we included some controlled 
fixation delays.  To this end we used a pair of eyes from a young donor (34 years old) with 
relatively low vacuolisation.  One eye was fixed immediately (postmortem delay of 8 hours) 
and the other eye was kept in phosphate buffered saline for an additional 48 hours at room 
temperature. This controlled delay did not introduce any major changes in vacuolisation 
score.  The same was repeated with the eyes from an older donor (63 years old) and they too 
scored in the same range irrespective of fixation delays (Fig. 3.3 C).   
 
3.4.3 Endothelial cell numbers in capillaries  
 Only vessels smaller than 10µm in diameter were included in our analysis.  Green et al. 
(1980) proposed an endothelial drop out in MacTel type 2; as such the average number of 
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endothelial cells that contribute to the lumen of a capillary was established by counting the 
number of tight junctions between endothelial cells.  The tight junctions (zonula occludens) 
are easily recognisable as electron dense areas at an EM level (Fig. 3.4 A).  On average the 
number of tight junctions was between 1.5 and 2 (per capillary cross section) confirming the 
size uniformity of our capillary sample populations and there were no significant changes in 
relation to the age of the donors (Spearman’s rank correlation, r = -0.2742, p= 0.2420, Fig. 3.4 
D). 
 
3.4.4 Other ultrastructural abnormalities  
One possible explanation for the occurrence of basement membrane vacuoles could be that 
they are remnants of degenerated pericytes.  In fact, we found in numerous samples (from 
donors of all ages) signs of degenerating pericytes and many examples of capillaries with 
complete absence of any recognisable pericytes.  Pericyte drop out and reduced pericyte 
coverage are well known signs of diabetic retinopathy but were frequently found in our non-
diabetic population.  In order to obtain an indication of pericyte frequency in our samples we 
therefore measured the percentage of vessel surfaces covered by pericytes (Fig.3. 4 B).  
There was no evidence of decreasing pericyte frequency with increasing age in our non-
diabetic donors (Spearman’s rank correlation coefficient, r=-0.0602, p=0.8008, Fig. 3.4 E).  
Furthermore, in many capillaries the basement membrane displayed extensive lamination 
(Fig. 3.4 C).  This ultrastructural abnormality was sporadically found in most samples studied. 
It is conceivable that successive rounds of pericyte degeneration and regeneration could lead 
to the formation of multiple basement membranes, which might explain the basement 
membrane lamination we observed in many of our samples.  We therefore quantified this 
feature by scoring the maximum number of basement membranes in a given capillary (Fig. 
3.4 C).  Although there was a slight increase in basement lamination with increasing age (Fig. 
3.4 F), this was not statistically significant (Spearman’s rank correlation coefficient, r= 0.1469, 
p= 0.5364).  Furthermore, there was no significant correlation between the level of pericyte 
coverage and basement lamination in our samples (Spearman’s rank correlation coefficient, 
r= 0.3004, p= 0.1982).  There was also no significant correlation between these two features 
and postmortem delays (not shown). 
 
3.4.5 Comparison of MacTel type 2 to the established baseline 
Having established a baseline for the occurrence of ultrastructural abnormalities in the 
normal population, we can test how the ultrastructural features seen by Green et al. (1980) 
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in MacTel type 2 compare. Our MacTel type 2 sample, available for comparison, additionally 
had diabetes type 2 and had not been seen in clinics for 10 years prior to death so the 
development of retinopathy could not be ruled out. As such relevant diabetics were first 
investigated to rule out any diabetic effects. In a case with known diabetic retinopathy (71 
year old) we found numerous capillaries that were completely depleted of pericytes and 
endothelial cells, with only the basement membrane remaining (Fig. 3.5 A). Such acellular 
capillaries are a well described characteristic of diabetic retinopathy.  Other capillaries in the 
same sample had severely vacuolated basement membranes and many lacked pericytes (Fig. 
3.5 B).  Not surprisingly, this case with diagnosed diabetic retinopathy scored very low in the 
pericyte coverage measurements (black triangle in Fig. 3.5 G), serving as a positive control 
and confirming the validity of our method to assess pericyte coverage.  However the other 
traits (basement membrane vacuolisation and lamination and endothelial cell numbers) were 
found at equal frequency as in our control population (black triangles in Fig. 3.5 E, F and H).  
Four cases with reported diabetes but no diabetic retinopathy (Fig. 3.5 C) scored very similar 
to our control population in all four measurements (open triangles in Fig. 3.5 E-H). 
Peripheral retina from the MacTel type 2 demonstrated many capillaries that lacked 
pericytes and displayed basement membrane vacuolisation and lamination (Fig. 3.5 D).  
However, quantification of this sample revealed that the extent of ultrastructural 
abnormalities was very similar to our control population (circle in Fig. 3.5 E-H), suggesting 
that peripheral capillaries in our MacTel type 2 case are normal for a person that age.   
 
3.5 Discussion: 
This study has revealed that with increasing age retinal capillaries in adult humans 
accumulate vacuoles in the basement membrane at the glia interface.  We have 
demonstrated that these vacuoles are not postmortem artefacts or caused by suboptimal 
fixation.  Firstly, they were very rare in the retina from a 14 month old donor that was fixed 
37 hours after death (one of the longest postmortem delays in our study).  Secondly, the 
vacuoles were widespread in our two samples that were fixed within 30 minutes and 4 hours 
after enucleation.  Thirdly, even the introduction of artificial postmortem delays had no 
noticeable influence on the morphological abnormalities measured in our study.  And lastly, 
there was a statistically highly significant correlation between the amount of vacuolisation 
and donor age. 
 Interestingly, even grossly abnormal looking capillaries did not seem to be disease specific 
and were common in the elderly.  Obviously, it is difficult to completely exclude any 
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underlying retinal or vascular disease in anonymous donors.  However, the fact that the 
vacuolisation appeared in all of the samples we tested and that it increased with age strongly 
suggests that this is a ‘normal’ ageing process.  Although it was demonstrated in the early 
1960s that basement membranes in adult human retinal capillaries contain vacuoles,291 this 
is not widely reported in the literature.  Therefore it is not well known that retinal capillaries 
in normal adult humans appear to have a phenotype that normally would be considered as 
pathological.  In fact, ‘healthy’ normal looking capillaries are only present in children;291 and 
remarkably, even in mature animals of several species (monkeys, dogs, cats and rats) 
capillaries do not display the ultrastructural abnormalities seen typically in adult humans.292-
294  In keeping with that, the macaque eye used in this study came from an elderly female 
(past its reproductive age, 17 years old) but showed only very minor capillary abnormalities.  
It is therefore possible that basement membrane vacuolisation relates to absolute lifespan or 
alternatively, it might be a phenomenon specific to the human species.   
So far the chemical nature of the basement membrane vacuoles is not clear.  Their 
morphology is reminiscent of age-related lipid inclusions previously described in Bruch’s 
membrane.295 Furthermore, it has been shown that lipids can accumulate in larger retinal 
vessels in diabetic retinopathy.296 Also Green et al.249 stained paraffin embedded retinal 
sections and found a faint positive stain for lipids (using Oil-red O and sudan black B) in the 
walls of the capillaries, however they did not correlate this staining directly to the vacuoles 
observed in the basement membrane. So the molecular composition of vacuoles in capillary 
basement membrane has yet to be established.  It is also not clear by what mechanism the 
basement membrane abnormalities are created.  It is possible that the basement membrane 
vacuoles are remnants of pericytes that have degenerated.  This would imply a significant 
turnover of degenerating and regenerating pericytes throughout the human lifespan.  
Similarly, multiple basement membrane sheaths could be generated by such a process.  
However, so far no studies have tested such a hypothesis specifically and our study did not 
find a correlation between basement membrane lamination and pericyte drop-out.  Neither 
did these two aspects correlate with age.  Long-term stress, such as hypoxia, might be a 
contributing factor to vacuole formation; in particular in the outer retina, which is more 
prone to experience hypoxic stress .297 However, we did not notice any obvious differences 
between the inner and outer vascular plexus. Furthermore, our analysis was limited to the 
retinal periphery where hypoxic stress is likely to be less pronounced than in the macula. 
Green et al249 did compare macular and mid-periphery, and observed that the microvessels 
of equatorial mid peripheral retina had ‘less intense’ lipid deposition (vacuoles) compared to 
the temporal parafoveal area. Whether this relates to hypoxic stress, or whether vacuoles 
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are a feature increased in number by telangiectasis of parafoveal MacTel type 2 vessels it 
cannot be determined without control data from macular vessels.  
Despite the widespread abnormalities in our non-diabetic population we still managed to 
identify our case of diabetic retinopathy as clearly abnormal, based on reduced pericyte 
coverage.  Traditionally, pericyte coverage has been assessed by counting cell nuclei in 
trypsin digests of entire retinas.298  Nevertheless, the electron microscopy based method of 
quantifying pericyte coverage used in this study seems to be suitable to distinguish clearly 
the case of diabetic retinopathy against our non-diabetic population, confirming the validity 
of such an approach.   
Our study suggests that caution should be exercised in the interpretation of ultrastructural 
capillary abnormalities in case studies of retinal vasculature diseases.  For example, in our 
case of MacTel type 2 we found in the peripheral retina strong basement membrane 
vacuolisation and lamination confirming the findings of two previous MacTel type 2 case 
reports.249, 250  However, our quantification showed that these two ultrastructural features 
were within a range of capillary phenotypes typical for a person of that age, suggesting that 
MacTel type 2 does not induce these disease specific changes in peripheral retinal capillaries.   
The question remains how capillaries with such grossly distended basement membranes, as 
we observed in some elderly, normal donors, can remain functional at all.  With the advent of 
novel high resolution in vivo image technology299, 300 it may be possible in the future to 
address these questions of capillary function in the aging retina directly.  But so far it is not 
even known whether these changes are beneficial or detrimental to vascular function.  If the 
latter were the case, such a progressively worsening function of the glia-vascular unit might 
contribute to age related pathologies in the retina.   
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Table 3.1: Donor tissue and fixation information 
Age 
(yrs) 
Cause of death Postmortem 
delay 




Rhesus Macaque (Macaca mulatta)  
17 Euthanasia 15 minutes Karnovsky’s - - 
  Human Normal Controls 
1 Unknown 37 hours 2% PFA 22 months None reported 
10 Unknown 25 hours 2% PFA 18 months None reported 
18 Cardiac  arrest 13 hours 2% PFA 2 months None reported 
19 Motorbike accident 18 hours 2% PFA 2 months None reported 
24 Intracranial haemorrhage 55 hours Karnovsky’s - None reported 
34* Lung cancer 8 hours* 2% PFA 3 weeks None reported 
42 Hanging suicide 20 hours 2% PFA 16 months None reported 
43 Prescription drug overdose 17 hours 2% PFA 19 months None reported 
47 Rectal carcinoma 8 hours 2% PFA 19 months None reported 




- Extra ocular tumour  
63* Prostate cancer  8 hours* 2% PFA 4 months None reported 
71 Throat cancer  11 hours 2% PFA 4 months None reported 












Healthy eye from a 
unilateral  Coats’ 
disease case   
79 Lung cancer 13 hours 2% PFA 19 months None reported 
80 Chronic obstructive 
pulmonary disease type II 
13 hours 2% PFA 19 months None reported 
84 Lung cancer 9 hours 2% PFA 19 months None reported 
96 Unknown 47 hours 2% PFA 3 months None reported 
97 Unknown 48 hours 2% PFA 3 months None reported 
Type 2 Diabetics 
74 Intracranial haemorrhage 7 hours 2% PFA 13 months None reported  
77 Pancreatic cancer 8 hours 2% PFA 3 months None reported 
78 Stroke 9 hours 2% PFA 15 months None reported 
79 Cardiac arrest 9 hours 2% PFA 14 months None reported 
Diabetic Retinopathy 
71 Cerebrovascular accident <12 hours 2% PFA 6 months Diabetic retinopathy, 
laser surgery 
Macular Telangiectasia Type 2 and Diabetes Type 2 
65 Unknown  4 hours Karnovsky’s - MacTel type 2,  
No retinopathy 
Postmortem Degradation Controls 
34* Lung cancer 56 hours* 2% PFA 3 weeks None reported 
63* Prostate cancer  56 hours* 2% PFA 4 months None reported 
 
Table 3.1. Donor tissue and fixation information. ‘Time until Karnovsky’s fixative’ refers to 
the time between initial fixation of the tissue and its transfer into Karnovsky’s fixative (3% 
(w/v) glutaraldehyde, 1% (w/v) paraformaldehyde in 0.08M sodium cacodylate buffered to 
pH 7.4 with 0.1M HCl). 2% PFA, 2% (w/v) paraformaldehyde; * indicates the normal controls 




Figure 3.1.  Vacuolisation of the basement membrane in human retinal microvessels.   
A capillary from a rhesus macaque retina (A) showed intact basement membranes and good 
pericyte coverage.  In contrast, in humans (B-F) numerous vacuoles were present within the 
vascular basement membrane (arrowheads in B-F) irrespective of fixation methods and 
postmortem delays.  The tissue in B was fixed 13 hours after death and stored in 2% 
paraformaldehyde for 19 months before fixation in Karnovsky’s fixative for electron 
microscopy processing, whereas tissue in C was fixed directly in Karnovsky’s 4 hours after 
death, and tissue in D-F was fixed within 30 minutes after surgical enucleation in tannic acid-
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glutaraldehyde solution.  E: Reconstruction of a vessel (from the enucleated eye) using 300 
consecutive sections. F: 3D-reconstruction of the vessel in (E); endothelial cells and lumen 






Figure 3.2. Vacuolisation of peripheral retinal capillary basement membrane is age 
dependant (A: 14 months, B: 19 years, C: 47 years and D: 80 years old). 
 The majority of retinal capillaries of a 14 month old have no vacuoles in the basement 
membrane (A). Vacuoles increase in number and density in older donors (arrow heads in B-





Figure 3.3.  Quantification of basement membrane vacuolisation.  
Vacuolisation was quantified by assessing the proportion between the area of the vacuoles 
(arrowheads in A, white areas in A’) and the total area of the basement membrane (black 
areas in A’).  A score between 0 and 5 was then given to capillaries based on the percentage 
of vacuoles (0 = no vacuoles, 1 = 1-20%, 2 = 21-40%, 3 = 41-60%, 4= 61-80% and 5 = 81%-
100%).  The example in A had a score of 4.  B: The scores for each donor were averaged and 
plotted against the donor’s age. C: Plotting vacuolization scores (from all normal donors,) 
against postmortem delays did not reveal any correlation.  Furthermore, tests with pairs of 
eyes (squares), where one eye was fixed 8 hours after death and the other eye was kept in 
phosphate buffered saline for an additional 48 hours at room temperature, showed no major 
changes regarding vacuolization ( 34 year old donor;  63 year old donor). E, endothelial 







Figure 3.4.  Other structural features.   
A: Endothelial cell numbers were quantified by counting zonula occludens (black arrow in 
inset in A) per capillary profile. Two zonula occludens are marked in black and circled in A’. 
The two endothelial cells are highlighted in different shades of grey. Plotting zonula 
occludens numbers against donor age showed no age-related changes (D). B: Pericyte profile 
coverage was calculated by determining the percentage of endothelial cell basement 
membrane (black line in B’) that was covered by pericyte profiles (marked in grey). The 
example in B shows coverage of 93%. Plotting pericyte profile coverage against donor age 
showed no age-related changes (E). C: Basement membrane lamination (arrowheads in inset 
in C) was quantified by scoring the maximum number of lamellae (black lines in C’) across a 
given capillary radius. In this example the score was 7. E: Plotting averaged lamination scores 
against donor age showed no age-related changes (F). E, endothelial cell; P, pericyte profile; 
Z, zonula occludens; stippled lines in D, E and F are lines of best fit. Scale bar is 1µm in A, B 




Figure 3.5. Retinal capillary phenotypes in cases with known retinal diseases.  
A-B: The retina from a 71 year old donor with diabetic retinopathy showed acellular 
capillaries (A) and capillaries with no discernable pericyte profiles (B). Basement membrane 
vacuolization (arrow heads in B) was also observed. C shows a capillary from a 74 year old 
donor with type 2 diabetes but no diabetic retinopathy. D: Capillaries from a MacTel type 2 
donor also show ultrastructural abnormalities such as extensive lamination (arrow in D) and 
vacuolization of the basement membrane (arrowheads in D) and lack of pericyte profiles. E-H 
shows quantification of individual disease cases compared to the line of best fit previously 
determined for normal healthy donors.  type 2 diabetics;  diabetic retinopathy;  
MacTel type 2; stippled line is line of best fit through normal donors only. Scale bars are 1µm 
in A-D.  
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4. Characterising the macula 
4.1 Introduction:  
4.1.1 Reviewing the clinical phenotype of MacTel type 2 
As I have previously reported, MacTel type 2 has a clinical phenotype that is restricted to the 
macula. Confocal blue reflectance and Red-Free imaging show an elliptical boundary; a 
restricted region of hyper reflectance around the fovea (Fig. 4.1 A), in a study of 62 MacTel 
type 2 eyes, by Charbel Issa and colleagues,  the region of hyper reflectivity was seen in 
94%.137 It is unknown exactly what the blue light reflectance is an indication of, but it is 
suggested that the increased hyper reflectance is due to the loss of macular pigment in the 
central macula,137 it has also been proposed that the hyper reflectivity could be a result of 
crystals or other neuroretinal deposits that are hyper reflective, such as that seen in 
canthaxanthin retinopathy (chapter 1.3.3), however MacTel type 2 also exhibits crystalline 
deposits, which are clearly seen in confocal blue light reflectance as individual bright flecks 
(arrow heads Fig. 4.1 B). 137  This does not rule out hyper reflective deposits, but makes the 
scenario less likely as the concentration would have to be so high that they would be visible 
with OCT imaging,301 which no one has reported. Macular pigments, zeaxanthin, meso-
zeaxanthin and lutein are all yellow carotenoids, which absorb light preferentially in the blue 
spectrum, and therefore a reduction in the absorbance from the retina would lead to 
apparent hyper reflectance compared to a control (Fig. 4.1 B). Macular pigment depletion, 
shown by Charbel Issa and colleagues, is restricted to the parafoveal region, leaving what can 
be described as a halo of macular pigment, again elliptical in shape, with a clearly 
demarcated inner edge, and more diffuse peripherally,139 correlating with this theory of blue 
light reflectance. All vascular telangiectasis is parafoveal (Fig. 4.1 C), dominantly starting in 
the temporal region and progressing to encircle the fovea with disease progression.137-141 
Leakage in late phase fluorescein angiogram also has a consistent pattern; the leakage 
diffuses radially through the retina, but stops abruptly leaving an ellipse of leakage 
parafovealy (Fig. 4.1 D).148 Oedema can be present, found primarily at the fovea itself, 
resulting in a ‘foveal drape’.146 
When the clinical phenotypes are superimposed, macular pigment loss clearly correlates with 
the region of hyper reflectance in blue light and the region of macular pigment depletion 
forms an external ‘boundary’ point. No vascular telangiectasis or oedema has been reported 
outside of the region of macular pigment depletion and the leakage from late phase 
fluorescein  angiogram diffuses up to a point just within this boundary, but is never seen to 
spread further (Fig. 4.1 E-H). Also retinal crystals have only been reported within this region 
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(arrow heads in Fig. 4.1 E). Importantly is has been shown that the size and shape of the area 
affected in the disease remains constant over time, unlike AMD and diabetic retinopathy the 
disease does not  spread into peripheral retina. The region affected also appears to be 
consistent in size, shape and location between patients.   
 
4.1.2 The macula boundaries 
There is no anatomical or biochemical boundary that defines the edges of the macula as 
previously stated in chapter 1.1. It is therefore interesting that the disease phenotype of 
MacTel type 2 has such a defined limit to its spread through the retina. The ganglion cell 
nuclei gradually decrease to a single layer with increased radial distance from the fovea, 
there is a high density of cone photoreceptors decreasing gradually to periphery and an 
increase in rod numbers, however there is no sudden change in pattern at this point.  
 
4.1.3 Biochemical tools to investigate sample differences 
There are two main ways to approach this question; either to study the genes that are 
differentially expressed between macula and peripheral retina (genomics) or to study the 
proteins that are differentially expressed (proteomics). DNA micro arrays can be used to 
study genomic comparisons, and they give you a full coverage of expression levels across the 
genome, however this would require extremely fresh tissue samples to work with.  
RNA is unstable after death and because of the unavoidable delays inherent in human 
postmortem organ donation, difficult to analyse. Postmortem human eye tissue that we have 
available can be retrieved for processing within 6-12 hours and this material is therefore not 
suitable for genomic analysis. However, proteins in human samples are remarkably stable 
postmortem. Several studies have previously been able to acquire meaningful data from 
proteomic screens of human retina with postmortem delays between 4.5 and 17 hours.302-306 
Therefore with the tissue available to us, the most suitable approach was comparative 
proteomics. Proteomics, unlike genomics, does not give full coverage of all proteins 
expressed, but will be able to guide towards pathways and families of proteins that are 
differentially expressed.  
A proteomic method that uses isobaric tags for relative and absolute quantitation (iTRAQ) 
has been used successfully for biomarker discovery in human specimens.307-311 iTRAQ labels 
are isobaric labels that will react with the primary and secondary amines of peptides. iTRAQ 
labels can be purchased as sets of four labels (4-plex) and eight labels (8-plex). Each of the 
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labels has an identical mass, but upon collision induced fragmentation during MS/MS 
analysis, they fractionate differentially, releasing a reporter moiety and balance moiety (Fig. 
4.2 A). This allows the samples to be distinguished. Fractionation of label 113, for example, 
will generate a 113m/z ion in an MS/MS spectrum (Fig. 4.2 A). The peak of this area is 
proportional to the relative abundance of the peptide derived protein from the analysed 
sample. The protein ratio between up to eight samples can be determined using iTRAQ, 
followed by separation and MS/MS analysis; the ratio between the different isobaric reporter 
moieties, which indicate the fragmented peptide’s relative abundance, can be determined in 
a mixed pool of peptides from different samples (Fig. 4.2 B).  
iTRAQ is performed by first trypsinising the individual samples for analysis. The peptides in 
each sample are then labelled with one of the different isobaric labels. For 4-plex the isobaric 
labels are 114, 115, 116 and 117, whereas 8-plex has the additional labels, 113, 118, 119 and 
121. These samples (4 or 8) are then mixed together at equimolar concentrations, and next 
further separated by two-dimensional chromatography. The sample is then run through a 
mass spectrometer, the individual peptides are fragmented and each peptides amino acid 
sequence determined. Whilst at the same time the ratio of that peptide is determined 
between the different samples originally mixed, this is done using the ratio between the 
different iTRAQ reporter ions (Fig. 4.2 B).  
The primary advantage of using iTRAQ over other methods of relative quantitation 
proteomics is that after trypsinisation, iTRAQ labelling and mixing, all the subsequent 
separation conditions are identical for all samples (as they occur at the same time), this 
results in low coefficients of variance and faster analysis. It is also possible to include a 
pooled standard control in multiple plates, this allows all samples to be compared against the 
pooled control, and quantitation can be made between plates allowing larger sample 
numbers to be compared.  
 
4.2 Aim: 





4.3 Materials and Methods: 
Technical acknowledgements: I would like to thank Alice Len, University of Sydney, for her 
extensive work towards the proteomics reported here, the methods carried out by her have 
been clearly labelled in chapter 4.3.3. I would also like to thank Catherine Egan, Moorfields 
Eye Hospital, for her provision of the anonymised clinical images which I have analysed in this 
chapter.  
 
4.3.1 Image analysis from clinical blue light reflectance 
Digital confocal blue reflectance or red-free photos of 35 eyes from 22 patients were aligned 
so that the fovea and centre of the optic disc were on a horizontal line. The distance, in 
pixels, from the edge of the optic disc to the foveal centre was measured for each sample 
and set as 100%, the height (A) and width (B) of the region of increased blue light reflectance 
were determined as a proportion of this distance. Ratios were compared between samples, 
averaged and standard deviations calculated because the centre of the fovea was not always 
obvious, we overlaid the confocal blue reflectance images with colour fundus images using 
the vascular arcades as landmarks.  
The dimensions in µm of the ellipse were measured in 14 samples where a scale was 
available; these were averaged and standard deviations calculated.  
 
4.3.2 Dissection tools 
The dimensions obtained from the confocal blue reflectance/red free analysis were used to 
manufacture a series of four concentric elliptical trephines of dimensions; 1.42mm by 
1.25mm, 2.48mm by 1.60mm, 3.34mm by 2.65mm and 3.93mm by 3.36mm (Fig. 4.3 A-C ) . 
Therefore being able to dissect and collect tissue from within the ‘MacTel area’ and a tissue 
sample from outside (non-‘MacTel area’), with a buffer region between to allow for sample 
variation (Fig. 4.3 D).  
 
4.3.3 Proteomics 
4.3.3.1 Tissue collection and processing - Proteomics 
Control post mortem retinal samples were collected and dissected at the ‘Save Sight 
Institute’, University of Sydney, Sydney, Australia. Tissue was collected from five donors, of 
ages; 21, 63, 64, 72 and 79 years old (Table 4.1). All with no known ophthalmic complaints or 
89 
 
diabetes. Tissue used had a postmortem time of between 3-11 hours; sufficient to maintain 
protein quality for proteomic analysis, as determined from previous publications.302-306 
Whole eye cups were stored in sterile PBS at +4°C until dissected. 
Retinae were removed from the sclera/RPE-choroid complex. The vitreous was dissected 
away. Two regions of retina were isolated using the aforementioned trephines (chapter 
4.3.2). These retinae samples were briefly washed in 0.1X PBS and then fresh frozen in 10µl 
protease inhibitor cocktail (Roche Diagnostics, USA). (Salt can interfere with downstream 
processing in the proteomics protocol, therefore a brief wash in 0.1X PBS is required to 
remove some of the salts prior to snap freezing).  
 
4.3.3.2 Retina: Protein partitioning based on solubility 
Tissue samples were thawed and fractionated on the principle of protein solubility based on 
the methods used by Fujiki et al.312  To each tissue sample 5ml of ice cold 0.1 M Na2CO3 (pH 
11.0) was added, then the sample was sonicated (Branson, Danbury, USA, output control of 
2, 2x 30 seconds, 20–22˚C with cooling on ice between each burst) before being stirred on ice 
for 1 hour.  The carbonate-treated membranes were sedimented by ultracentrifugation at 
120,000g for 1 hour at 4 °C. The supernatant was separated and retained (see below), and 
the membrane pellet was washed once with ice cold 0.1 M Na2CO3 (pH 11.0) and then 
resuspended in 100µL 1% SDS (w/v) in preparation for protein assay and trypsin digestion.  
 
4.3.3.3 Protein quantification and protein reduction/alkylation (performed by Dr. Alice Len) 
Retinal derived protein concentrations were determined through the analysis of the quantity 
of individual amino acids per sample using a precolumn derivatisation HPLC method. An 
aliquot of 5µL of each sample to be analysed was dried down in a SpeedVac® concentrator 
(Savant [GMI, MN, USA]).  Each aliquot of sample was then supplemented with 10µL of 
100pmol internal standard (-amino butyric acid; AABA) prior to derivatising according to 
manufacturer’s instructions using an AccQ Tag Ultra derivatisation kit (Waters Corporation).  
HPLC analysis was based on the method of Cohen (2001) but adapted for use with an 
ACQUITY UPLC system (Waters Corporation). The column employed was an ACQUITY UPLC 
BEH C18 1.7um column with detection at 260nm and a flow rate of 0.7 ml/min. This enabled 
a 10.2 minute analysis time per sample. Each sample was analysed in duplicate and the 
results averaged. Each sample of retinal derived protein sample, 20µg, was diluted to a final 
concentration of 0.1% SDS (w/v), 0.5M TEAB, pH 8.5 and 50% (v/v) methanol.  Protein 
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samples were reduced with 5mM Tris(2-carboxyethyl)phosphine (TCEP) for 1 hour at 60°C, 
and alkylated with 10mM s-methylmethanethiosulfonate (MMTS) at room temperature for 
10 minute in preparation for the digestion of proteins with trypsin. 
 
4.3.3.4 Tryptic digestion and iTRAQ reagent labelling of peptides (performed by Dr. Alice 
Len) 
Two 8-plex experiments were run. Run1 consisted of digested retinal derived protein samples 
obtained from 4 control individuals, pooled with corresponding regions from each individual, 
keeping soluble (S) and less soluble (LS) fractions separate (experiment plan, Run 1, Table 
4.2); the 2 regions indicated in Fig. 4.3, plus two additional regions, one mid-peripheral nasal 
retina and one mid-peripheral temporal retina, were used for labelling with iTRAQ labels 113, 
114, 115 and 116, S fractions and 117, 118, 119 and 121 LS fractions, obtained from iTRAQ 8-
plex reagent kit. Tagging was carried out according to the manufacturer’s instructions (Fig. 
4.2 A [Applied Biosystems, CA, USA]). Less soluble (LS) and soluble (S) fractions obtained from 
partitioning as described in chapter 4.3.3.2. All LS fractions were diluted with 50% (v/v) 
methanol to obtain a concentration of SDS < 0.1% in preparation for trypsin digestion. Run 2 
was performed using only S fractions from two individual donors, one of which was also 
included in the pooled sample. From a 64 year old donor, regions were labelled with iTRAQ 
labels 113, 114, 115 and 116 respectively, whilst tissue from a 72 year old donor was labelled 
with 117, 118, 119 and 121 isobaric tags (as per experimental plan, Run 2, Table 4.2).  MALDI 
TOF/TOF MS was used to verify iTRAQ reagent labelling of each sample’s peptides using a 
4700 Proteomics Analyser (Applied Biosystems/MDS Sciex, CA, USA). Samples were initially 
desalted and concentrated using PerfectPure C18 tips (Eppendorf, Hamburg, Germany) and 
eluted off the column using 0.8µL of 4mg mL-1  -cyano-4-hydroxycinnamic acid in 70% v/v 
acetonitrile (ACN) and 0.1 % trifluroacetic acid (TFA), then  subsequently spotted onto a 4700 
MALDI target plate (Applied Biosystems) for MS/MS analysis. All spectra were acquired 
manually, with typically 200 shots accumulated at each spot. Peptide mass spectra was 
obtained in reflector positive mode, 4 peptides from each sample were then further analysed 
through MS/MS using a positive mode with a 1kV potential to confirm the presence of  
reporter iTRAQ tags.  
 
4.3.3.5 Strong Cation Exchange (performed by Dr. Alice Len) 
Once labelling was verified all 8 labelled samples were combined from each iTRAQ 
experiment and subjected to batch offline strong cation exchange chromatography. A 50µL 
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aliquot of Macro-Prep S Ion Exchange Support (BioRad, CA, USA) homogenous slurry was 
sedimented at 300x g for 30 seconds, washed with Buffer A (5mM K3PO4, 350mM KCl, CH3CN 
25% (v/v), pH 2.7) and equilibrated with Buffer B (5mM K3PO4, CH3CN 25% (v/v), pH 2.7).  
Combined labelled samples were then added to the equilibrated support and incubated on a 
platform rocker for 1hour at RT.  Support bound labelled peptides were then centrifuged 
(300x g for 30 seconds) and the supernatant removed. The support was then gently washed 
with 500µL Buffer B, sedimented (300xg for 30 seconds) and the supernatant removed, this 
step was repeated once more. Peptides were released by adding 50µL Buffer A, vortexing 
briefly, centrifuging (300x g for 30 seconds) and collecting the supernatant. This step was 
repeated three times to obtain a total volume of 200µl of eluted peptides. The sample was 
filtered using a Millipore Ultrafree-MC centrifugal device (Millipore, Billerica, MA, USA) to 
remove residual support. 
 
4.3.3.6 RP nano-LC ESI MS/MS (performed by Dr. Alice Len) 
MS/MS analysis of iTRAQ labelled peptides was carried out using an Agilent 1100 nanoLC 
system (Agilent, Santa Clara, CA, USA) and QStar XL MS/MS system (Applied Biosystems).  
After SCX clean up, the sample was dried with SpeedVac and resuspended with 50µl of 0.1% 
(v/v) TFA and 2% (v/v) ACN. A 3µl aliquot of the sample was taken and further diluted to 40µl 
and loaded onto a reverse phase peptide Captrap (Michrom Bioresources, Auburn, CA, USA) 
and desalted with buffer solution A (97.9% [v/v] 18 MΩH20/0.1% [v/v] TFA/2% [v/v] ACN). 
After desalting, the trap was switched on line with a 150µm x 10cm C18 3µm 300A ProteCol 
column (SGE, Ringwood, Victoria, Australia). The Buffer B (90% [v/v] ACN/9.9% [v/v] 18 MΩ 
H20/0.1% [v/v] formic acid) gradient rose from 5% to 10% in two minutes and then to 50% in 
80 minutes to elute peptides.  
The LC eluent went through positive ion nanoflow electrospray analysis in an information 
dependant acquisition mode (IDA). A TOFMS survey scan was acquired whilst in IDA mode 
(m/z 350-1600, 0.5 second), with the 3 most intense multiply charged ions, those with counts 
greater than 70, in the survey scan sequentially subjected to MS/MS analysis.  MS/MS 
spectra were accumulated for 2 seconds in the mass range m/z 100-1600 with a modified Q2 
transition setting favouring low mass ions so that the reporting iTRAQ tag ion (113, 114, 115, 




4.3.3.7 LC MALDI MS/MS (performed by Dr. Alice Len) 
iTRAQ labelled peptides were also analysed via LC MALDI MS/MS. Sample was resuspended 
in 2% (v/v) ACN/0.1% (v/v) TFA to make a final concentration of 0.5mg ml-1. The iTRAQ 
labelled peptides were separated by LC using a Tempo LC MALDI system (Applied 
Biosystems/MDS Sciex). Sample (10µl) was injected onto a reversed phase column 
(Chromolith® CapRod® Monolith Capillary column, 150 x 0.1mm [Merck, Darmstadt, 
Germany]).  Peptides were eluted from the column using a linear solvent gradient from 2% 
(v/v) ACN (10 minutes) then switching to 50% (v/v) ACN for 60 min and then stepping to 90% 
(v/v) ACN for 5 minutes at a flow rate of 2µl minute-1. Eluent was collected from T = 10 
minutes until T = 77 minutes. The LC eluent was mixed with matrix (α-cyano-4-
hydroxycinnamic acid, 4mg ml-1 in 90% (v/v) ACN, 10% (v/v) 10mM ammonium hydrogen 
citrate) at a flow rate of 1µl minute-1 and spotted onto a MALDI target plate at a rate of 
5025mS spot-1 and allowed to air dry. MALDI MS was performed with an Applied Biosystems 
QSTAR Elite MS (Applied Biosystems/MDS Sciex) operating in an IDA mode. 
In IDA mode a TOFMS survey scan was acquired (m/z 800-3500), with the five largest ions per 
spot (Exit factor 15) with a maximum of 2000 precursors per plate in the survey scan 
subjected to MS/MS analysis. MS/MS spectra were accumulated for 45 seconds (m/z 100-
3500).  
 
4.3.3.8 Bioinformatic analysis 
Protein identification (using Swiss-Prot Homo sapiens database (version 54.8 containing 
18,349 protein sequences) and iTRAQ quantification of peptides was performed with 
ProteinPilot 1.0 (Applied Biosystems/MDS Sciex) using the Paragon algorithm313 where a 95% 
confidence (> 1.3 Protscore) setting was used for protein identification.  Loading error was 
taken into consideration and data were normalised using the bias correction function in 
protein pilot. It has been previously demonstrated from analysing repeat run data generated 
from QStar XL MS/MS system and analysed using ProteinPilot (Applied Biosystems), that it 
provides excellent reproducibility with a coefficient of variance of 11.7%.314  This exact same 
analysis system was employed for our iTRAQ analysis and therefore we have used a fold 





4.3.4.1 Tissue donor information and embedding - Histology 
Retinal tissue was used from 17 anonymous healthy donors with no reported ophthalmic 
complaints (Table 4.1) 
Retinal tissue was wax embedded as per chapter 2.3.1.  
Further retinal samples were embedded for cryosectioning. A region of the posterior globe 
that included the optic disc, fovea and a section of nasal periphery was dissected and the 
vitreous carefully removed from the retinal surface. Tissue was equilibrated in 30% sucrose 
overnight and transferred to optimal cutting temperature compound (Agar, UK), orientated 
and frozen over dry ice. Sections were then cut at 10µm and collected onto Superfrost® plus 
slides (VWR, UK). For tissue orientation please refer to chapter 4.3.4.4. Slides were stored at 
-20°C and dried for at least 2 hours under a fan prior to further processing.  
 
4.3.4.2 Antigen retrieval and Immunohistochemistry 
Antigen retrieval and immunohistochemistry were performed as previously described in 
chapter 2.3. For GFAP, LDHB and CRYAB stains, slides were heated to 135°C in citrate buffer 
for 10 minutes (wax sections), 125°C in citrate buffer for 10 minutes (cryo sections). For the 
sections that were both stained with fluorescence immunohistochemistry and DAB; sections 
were hydrogen peroxide treated to block endogenous peroxidases prior to antigen retrieval. 
Sections were then stained using the standard fluorescence immunohistochemistry protocol 
in chapter 2.3.4. Images were taken, after which the coverslips were carefully removed and 
the sections washed in PBS for 2 hours. The standard DAB immunohistochemistry was then 
carried out as per chapter 2.3.5. Slides were coverslipped and corresponding images taken 
using an Olympus BHX series epifluorescent microscope.  
 
4.3.4.3 Primary antibodies 
GFAP-Cy3 (C9205, Sigma, UK), LDHB (H00003945-M01, Abnova, UK), αB crystallin (Chemicon 
AB1546), all used at 1:200 dilution. 
 
4.3.4.4 Tissue orientation and image analysis  
Tissue shrinkage is a known fixation and processing artefact.315 Absolute measurements from 
retinal sections can therefore not be used for comparison against clinical images. To 
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accommodate for this proportional measurements against landmarks of the tissue assumed 
to remain constant during fixation and processing. The distance between the edge of the 
optic disc and fovea is known to remain relatively constant between people, at 11.8° or 
3.4mm temporal.316 Assuming tissue shrinkage is constant pan retina, it is possible to 
correlate sections with clinical images using the fovea and optic nerve edge as landmarks.  
GFAP stained sections, directly through the centre of the fovea and optic nerve were used for 
analysis. In the naso-temporal axis, 7 donors were analysed. Pixel distances were taken 
between the start of the neural retina at the optic nerve edge, and the point where GFAP 
staining ceases to be positive in all Müller cell processes at the outer limiting membrane. 
From this point to the centre of the fovea, and the distance from the fovea to the extent of 
the GFAP staining at the nasal edge.  
A further 7 donor eyes were sectioned to retrieve the dimension of GFAP staining in the 
inferior-superior axis through the fovea. These sections lack the optic nerve as a landmark to 
establish the degree of shrinkage during processing, therefore sections were taken in the 
inferior-superior axis, staring at the temporal side of the fovea. Once the foveal pit was 
passed, the cryo block was re-orientated 90° so that sections were taken through the optic 
nerve and the nasal edge of the ‘MacTel area’. The distance between the inferior and 
superior extents of the GFAP staining were then measured, whilst still allowing the distance 
between the edge of the optic nerve and nasal extent of the GFAP staining to be measured. 
This third distance then allows the degree of tissue shrinkage to be determined.  
  
4.4 Results: 
4.4.1. The ‘MacTel area’ is consistent between patients 
Measurements from 35 eyes of 22 MacTel type 2 patients revealed that the dimensions of 
hyper reflectivity in confocal blue reflectance images were very consistent between patients. 
This region of hyper reflectivity will be referred to as the ‘MacTel area’ (Fig. 4.4 A). The height 
(A) was 65.3% and the width (B) was 83.8% (Fig. 4.4 A and B) of distance C, the distance 
between fovea and optic disc edge (set at the internal constant standard). This equates to 
2.34mm (height, A) by 3.00mm (width, B) (Fig. 4.4 C), and the distance from fovea to the 
optic disc edge 3.45mm; as determined with 14 images where a scale was available. As the 
images taken clinically reflect a curved surface in 2D, this has to be taken into consideration 
with this type of analysis. It has been previously calculated that the distance between the 
optic disc and the fovea is 3.4mm, using the formula by Drasdo and Fowler316 which corrects 
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for the curvature of the back of the eye using standard imaging distances. The difference 
between the measured result and that given by the formula with curvature correction is 
0.05mm, or 1.47%. This result shows that the difference between 2D image measurements 
and corrected in vivo measurements is smaller than the standard deviation of measurements 
(7%), making measurements from 2D images applicable in this format.  
The area and location affected by MacTel type 2, ‘MacTel area’, is consistent between 
patients.  
4.4.2 Protein identification in retinal tissue 
We collected retinal samples from the two macula regions (Fig. 4.3) and from two mid-
peripheral regions in temporal and nasal retina. The two mid-peripheral retina sample results 
are not reported in this thesis as analysis has yet to be completed, and is not directly relevant 
for the question posed; only data from the comparison of the two macula regions is 
reported.  
Tissue was dissected from 5 donor retinae.  To increase the breadth of the proteome map, 
each tissue region was partitioned into soluble (S) and less soluble (LS) fractions, using 
sodium carbonate treatment312 followed by trypsin digestion. To compare the different 
samples, two iTRAQ runs were performed (Table 4.2). The first iTRAQ run comprised of 
pooled protein from four of the donors; a smaller amount of protein was extracted in LS 
fraction, as such multiple donors LS fraction were pooled to have a sufficient amount (>6 µg) 
to run. After labelling, all samples were further fractionated at a peptide level using SCX 
chromatography, then separated and analysed using 2D LC MS/MS.   
Comparative proteomics identified 419 non redundant proteins in Run 1 and 492 proteins in 
Run 2. The data from the 64yr old single sample shows 66 up and 99 down regulated proteins 
within the ‘MacTel area’, the 72yr old data shows 107 up and 128 down regulated proteins, 
Pooled sample (LS) has 32 up and 41 down regulated proteins and Pooled sample (S) has 28 
up and 26 down regulated proteins. When cross compared, the two runs (4 sample region 
pairs) show 44 proteins identified as up regulated within the ‘MacTel area’ in two or more 
comparisons, and 61 proteins down regulated in two or more comparisons (list of protein 
hits, downregulated inside the ’MacTel area’, Table 4.3 and upregulated within the ‘MacTel 




4.4.3 Sample comparisons  
All proteins that were differentially regulated between samples (i.e. up in the macula of one 
sample, but down in another sample) have been excluded. Only proteins identified in more 
than two comparisons have been investigated further. Proteins that had a restricted 
expression pattern to the macula, when confirmed with immunohistochemistry, were 
mapped against the ‘MacTel area’ to assess if there was any correlation.  
4.4.3.1 Innate immune system proteins 
One protein was identified as differentially expressed in all four samples; Long palate lung 
and epithelial carcinoma protein 1 (LPLUNC1). This protein is known to be a member of the 
innate immune response, normally associated with the respiratory system.317 Other members 
of the innate immune system were also up regulated within the ‘MacTel area’ in two or more 
samples; Leukocyte elastase precursor (ELANE), Bacteriacidal/permeability increasing 
protein-like 1 (LPLUNC2), Lysozyme C precursor (LYZ), Lactotransferrin (LT), Neutrophil 
defensin 3 precursor (DEF3A) and Neutraphil gelatinase-associated lipocalin (LCN2). 
Preliminary investigation showed LPLUNC1 expression in the nuclei of ganglion cells (data not 
shown), and DEF3A expression in ganglion cell nuclei and cone inner segments (data not 
shown). The other proteins of interest have yet to be investigated further. The expression of 
these two proteins in ganglion cell and cone photoreceptors explains the regional differences 
in the proteomic results. Even though effort was taken to reduce cell type concentration 
differences between the two regions compared, there is a significant increase in cone 
photoreceptor and ganglion cell concentration in the ‘MacTel area’ sample. There is no 
distinct boundary seen in the expression of these proteins, the expression followed the 
distribution of cell types and decreased gradually towards peripheral retina as cell numbers 
decreased, thus making them unlikely candidates of interest in determining the susceptibility 
of the macula with respect to MacTel type 2.  
 
4.4.3.2 Aerobic and anaerobic energy 
The glycolytic pathway is known to be predominantly active in retinal glia, 265, 266 while retinal 
neurons generate ATP through oxidative phosphorylation,264 as referred to in chapter 2. The 
proteomic results have shown glycolytic proteins and oxidative phosphorylation proteins 
both up and down regulated in the ‘MacTel area’ with no discernable pattern.  
Cytochrome c oxidase subunit 4 isoform 1, Cytochrome c oxidase subunit VIb isoform 1, ATP 
synthase subunit alpha and beta mitochondrial precursors and ATP synthase-coupling factor 
6, mitochondrial precursor were downregulated whilst cytochrome c and ATP synthase delta 
97 
 
chain are up regulated in the ‘MacTel area’ (Table 4.3 and Table 4,4). The glycolytic enzymes; 
fructose-bisphosphate aldolase C, fumarate hydratase, pyruvate kinase isozymes M1/M2 and 
transaldolase (pentose phosphate pathway but interconverts D-Glucose-6P and 
Glyceraldyde-3P used in glycolysis) were down regulated in the ‘MacTel area’ and yet 
conversely glucose-6-phosphate was up regulated.  
The unclear nature of the results prompted a closer look at the two pathways. An antibody 
directed against cytochrome c oxidase (COX2) showed strong staining within the cone 
photoreceptor inner segments [highest concentration of mitochondria,318 (Fig. 2.8 R) and 
punctate staining within the IPL and OPL (Fig. 2.8 R). Two distinct bands are visible within the 
IPL, this correlates to the ON/OFF layering of bipolar and ganglion cell synapses. COX2 
staining of the plexiform layer thickens with increasing packing density of the ganglion cells 
and interneuron's towards the fovea (Fig. 2.8 I), but absent at the fovea. Cone numbers 
increase in number and packing density towards the fovea, the highest density under the 
fovea, this was reflected by the increased COX2 positive photoreceptor inner segments at the 
fovea. Immunohistochemistry showed an increase in COX2 towards the central macula, 
however this was only a reflection of one protein from the oxidative phosphorylation 
pathway.  
LDHB, down regulated in the ‘MacTel area’ from the proteomic screen, was expressed within 
the ganglion cell layer and throughout the nerve fibre layer, with the dendritic morphology 
consistent with astrocyte processes. There was also a strong expression within the Henlé 
fibre layer (arrowhead in Fig. 4.5 A and B). It is known that the glycolytic pathway is dominant 
in glia of the retina,319 so it stands to reason that LDHB is expressed by astrocytes and Müller 
cells, but Müller cells in Henlé fibre layer have a higher expression than those in the 
periphery (Fig. 4.5. B and C).  
The expression pattern of COX2 and mixed data from proteomics led us to the conclusion 
that oxidative phosphorylation in the retina bared no relation to the ‘MacTel area’. The 
immunohistochemistry with LDHB did however show restricted expression to the Müller cell 
processes within the Henlé fibre layer, implying that differences in glycolytic metabolism 
might be present across the human retina. 
4.4.3.3 Carotenoid binding protein 
Glutathione S Transferase (GSTP1), the Pi isoform has been shown to bind the carotenoid 
zeaxanthin320 and to be located within the IPL and OPL of the retina with the strongest 
staining with immunohistochemistry at the macula.320 It was therefore not surprising that 
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GSTP1 was found to be up regulated within the ‘MacTel area’ in our proteomic screen. It has 
been shown previously that there is no distinct boundary in the expression of this protein. 
4.4.3.4 Lens proteins 
The well-established lens proteins, αA crystallin and αB crystallin, are both up regulated 
within the ‘MacTel area’. αB crystallin is known to be widely spread throughout the body in 
different organs, however αA crystallin expression was more restricted. 
Immunohistochemical confirmation of αB crystallin expression in the retina revealed staining 
of the astrocytes and Müller cell processes.  There was increased staining within the Henlé 
fibre layer (Fig. 4.6). αA crystallin expression will be discussed in more detail in chapter 5.   
4.4.3.5 Reactive Müller cell and classic astrocyte protein 
The proteomic data showed GFAP was downregulated within the ‘MacTel area’. GFAP is 
primarily expressed by astrocytes in the human retina, however gliotic Müller cells 
upregulate GFAP. The foveal avascular zone (FAZ) at the fovea is devoid of astrocytes, which 
could explain the decrease in GFAP expression, however the FAZ is only 0.7mm in 
diameter,321 significantly smaller than the inner edge of the ‘MacTel area’ ring sample 
(1.42mm x 1.25mm, Fig. 4.3), so this will not have had an impact on the astrocyte content of 
the sample. It is also unexpected as the anti-GFAP antibodies used in chapter 1 show a faint 
GFAP positive stain in the Henlé fibre layer but no expression in the outer plexiform of the 
peripheral retina. 
Fluorescent immunohistochemistry with an antibody directed against GFAP showed strong 
staining of astrocytes within the ganglion cell and upper half of the inner nuclear layer (Fig. 
2.6 A-D). There was a significant number of GFAP positive astrocytes surrounding the 
ganglion cell projections in the nerve fibre layer. The nerve fibre layer was relatively thin on 
the temporal side of the fovea and in the immediate parafoveal region. The GFAP positive 
astrocytes revealed that the nerve fibre layer rapidly increased in thickness from the apex of 
the foveal pit towards the optic nerve. A faint GFAP positive stain was found in the Henlé 
fibre layer (arrow in Fig. 2.6 B).  
A more sensitive immunohistochemical approach (that utilises amplification to generate a 
greater intensity stain per bound primary antibody) was used to investigate the faint GFAP 
expression within the Henlé fibre layer. This revealed that GFAP expression was not 
restricted to astrocytes, processes were revealed that span the entire depth of the retina and 
formed part of the Henlé fibre layer, consistent with Müller cell morphology. However the 
stain was restricted to parafoveal retina (Fig. 4.7 A-D).   
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The finding of increased LDHB staining within the Henlé fibre layer was opposite to the 
proteomic data for LDHB. This was most likely due to expression of LDHB within retinal 
astrocytes, seen with immunohistochemistry. The number of retinal astrocytes increased 
within the nerve fibre layer towards the optic disc form the fovea. This was due to the 
increase in the number of ganglion cell axons merging and projecting back to the brain, and 
subsequent increase in the number of associated astrocytes which are essential in 
maintaining neuronal homeostasis. Therefore the increased number of astrocytes, that 
express LDHB, outside of the ‘MacTel area’ had masked the increase in LDHB expression 
within the Henlé fibre layer.    
4.4.4 A sub population of macula Müller cells  
αB crystallin positive staining co-labelled with the Müller cell specific marker vimentin within 
the Henlé fibre layer (Fig. 4.8). While the expression of vimentin persisted into peripheral 
retina, the expression of αB crystallin was restricted to Müller cells within the Henlé fibre 
layer. The expression patterns of GFAP, LDHB and αB crystallin correlate with each other, and 
all have morphology expectant of Müller cells. Expression of all three markers stopped prior 
to the edge of the Henlé fibre layer, there we found a small population of laterally displaced 
Müller cells that do not express GFAP at the outer edges of the Henlé fibre layer. 
In summary, we found a sub population of Müller cells in the central macula that has a 
different molecular expression pattern to adjacent Müller cells in the peripheral retina. 
 
4.4.5 ‘MacTel area’ correlates to the sub population of Müller cells 
Clinical observations indicate that the elliptically shaped ‘MacTel area’ extends about half 
way from the fovea to the edge of the optic disc. Our GFAP immunohistochemistry staining 
was strikingly similar (Fig. 4.9 A).  
Taking measurements at the outer limiting membrane (Fig. 4.9 B and B’), GFAP stained 
sections through the fovea from 7 donors (naso-temporal axis) and 7 donors (inferior to 
superior axis) revealed that the dimensions of GFAP stained Müller cells, as a ratio of the 
distance between the optic disc edge and fovea centre, directly correlated with the confocal 
blue reflectance dimensions from MacTel type 2 patients (Fig. 4.9 A). The correlation showed 
no statistically significant differences (A/C p = 0.9, B/C p = 0.9). Although this was not a 
formal proof that the Müller cell sub population and ‘MacTel area’ were statistically similar, 
the high p value and spread of results shown by the graphs (Fig. 4.9 C and D) strongly 




We chose quantitative peptide labelling with iTRAQ because it does not discriminate against 
peptides with certain physiochemical properties as much as other quantitative protein based 
techniques do. Increasing the number of proteins that can potentially be identified, and this 
approach is compatible with proteins derived from human tissue. In retrospect 4-plex rather 
than 8-plex would have been more appropriate for this study. Although it allows fewer 
samples to be compared at once, 4-plex has since been shown to obtain more protein and 
peptide identifications than 8-plex; by our collaborators in Sydney, Dr. Alice Len and Prof. 
Mark Gillies (data not shown) and by others.264 The S and LS fractions should also have been 
run on different plates; when the fractions are split, different protein populations are likely 
to be collected in the different fractions (due to the properties of membrane bound verses 
cytosolic proteins) therefore the probability that the same protein was identified in all 8 
samples on one plate was decreased. 
Although GFAP and LDHB were downregulated in the proteomic data, immunohistochemistry 
revealed that they were expressed in a population of cells only present at the macula. We 
know that the expression within these cells is comparatively low as it can only be visualised 
using amplification immunohistochemistry, therefore the difference seen with proteomics is 
likely a consequence of other cell types in the retina masking the expression of GFAP and 
LDHB in the macula Müller cell. GFAP is highly expressed, and LDHB to lesser extent in the 
retinal astrocytes. Astrocytes increase in number significantly on the nasal side of the fovea 
towards the optic nerve within the nerve fibre layer, where they ensheathed ganglion cell 
axons, aiding in signal conduction and cellular homeostasis. The ganglion cell axons project 
back to the optic nerve from all aspects of the retina, as such the density increased 
dramatically towards the optic nerve head. Although regions were dissected very close 
together to minimise the masking effects of changes in photoreceptor and ganglion cell 
distribution; the nerve fibre layer is a feature that also changes significantly over a short 
distance parafoveally. It is therefore likely that in our experiment macular expression 
changes were masked by other cell types. 
The three markers that distinguish a new sub population of macula Müller cells have all been 
shown to be up regulated in retina as a stress response.257, 322 Provis and colleagues have also 
previously shown that GFAP is specifically expressed within parafoveal Müller cells in late 
gestation/ new born healthy human retinae,110 however they also report a loss of expression 
soon after birth. They have speculated that this represents localised stress within the 
developing macula that might cause an inherent weakness that persists into adulthood and 
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could be the reason for the susceptibility of the macula to disease.104, 245 It cannot be ruled 
out that the expression of GFAP, LDHB and αB crystallin in the Henlé fibre layer does 
represent a localised stress response, be it postmortem or persistent in living tissue due to 
the higher metabolic demands of central retina. What can be stated is that the specificity of 
the region of GFAP, LDHB and αB crystallin expression does still imply that this is a sub 
population of Müller cells that differ from those that are adjacent. Müller cells have been 
shown to up regulate GFAP after laser photocoagulation, in Müller cells distant from the site 
of injury,70, 71 in this respect such a consistent site of stressed Müller cells is unlikely. Our 
findings suggest that Müller cells in the macula are a differentially differentiated population 
of Muller cells that either; express GFAP, LDHB and αB crystallin constitutively, or that are 
more prone to stress and up regulation of these proteins in response.  
The results of this chapter are a first on two accounts; it is the first time that biochemical 
markers for a specific region of the macula has been identified that are not based upon 
photoreceptor distribution. Further still it is the first time that a grouping of specialised 
Müller cells has been identified within the retina. Based on marker expression, Müller cells 





Figure 4.1. MacTel type 2 disease phenotype.  
A parafoveal region of hyper reflectance is apparent on confocal blue light reflectance (A), a 
ring of macular pigment (imaged with DWAF) is left through central macular pigment loss (B). 
Telangiectatic vessels are visible with fundus photography (arrow in C, and pigment 
epithelium infiltration denotes a right angled venule temporal to the fovea (arrow head in C. 
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Late phase fluorescence angiography reveals parafoveal vascular leakage (D), primarily at the 
point of telangiectatic vessels (C, D). Vessel patterns (red lines E-H) allow the region of hyper 
reflectivity (blue line E-H) to be superimposed onto other imaging modalities. All clinical 
phenotypes of MacTel type 2 lie within the region of hyper reflectivity (E-H), including retinal 
crystals (arrow heads in E). Scale bar is 400µm. Clinical images from an anonymous MacTel 





Figure 4.2. Overview of iTRAQ labelling and workflow.  
iTRAQ isobaric tags consist of a reporter moiety of m/z 113-119 or 121, and a balance moiety 
which balances the total m/z of each tag to 145 m/z (A), linked to an N-hydroxy-succinimide 
ester allowing binding to a peptide. Labelled samples are mixed, fractionated by nanoLC and 
analysed by tandem mass spectrometry (MS/MS) (duplex experiment as example, B). 
Fragmentation data is then interpreted using established databases, and protein 
identifications made. The fragmentation of each moiety tag is measured and enables relative 







Figure 4.3. Retinal dissection trephines.  
(A,B) Four trephines (dimensions C) designed to dissect retina. (D) Two regions are isolated 





Table 4.1: Donor tissue information 
Age 
(yrs) 




Fresh frozen for Proteomic analysis 
21 Subdural haemorrhage 11 hours Protein extraction None reported 
63 Heart attack 7 hours Protein extraction None reported 
64 Heart attack 3 hours Protein extraction None reported 
72 Colon cancer 8 hours Protein extraction None reported 
79 Ovarian cancer 6 hours Protein extraction None reported 
Fixed tissue for immunohistochemistry (2% PFA) 
54 Breast cancer 7 hours Wax sectioned None reported 
56 Colon cancer 6 hours Wax sectioned None reported 
61 Heart attack 18 hours Cryo sectioned  None reported 
62 Unknown 14 hours Cryo sectioned  None reported 
66 Stroke 13 hours Cryo sectioned  None reported 
66 Heart attack 8 hours Cryo sectioned  None reported 
67 Subdural haemorrhage 8 hours Cryo sectioned  None reported 
68 Heart attack 11 hours Cryo sectioned  None reported 
68 Heart attack 7 hours Cryo sectioned  None reported 
70 Subdural haemorrhage 20 hours Cryo sectioned  None reported 
75 Unknown 24 hours Cryo sectioned  None reported 
76 Heart attack 16 hours Cryo sectioned  None reported 
79 Colon cancer 12 hours Cryo sectioned  None reported 
86 Heart attack 12 hours Cryo sectioned  None reported 
92 Unknown 8 hours Cryo sectioned  None reported 
93 Stroke 9 hours Cryo sectioned  None reported 
 






Table 4.2: Experimental plan for two 8-plex iTRAQ runs. 
Run 1: (Pooled samples) 
Isobaric tag 113 114 115 116 117 118 119 121 








































































 21 yr old 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 
63 yr old 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 
64 yr old 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 
79 yr old 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 2.60µg 
Total amount 
of protein run 


















Run 2:  
Isobaric tag 113 114 115 116 117 118 119 121 










































































64 yr old 8.71µg 8.71µg 8.71µg 8.71µg     
 
72 yr old     8.71µg 8.71µg 8.71µg 8.71µg 
  
Table 4.2. Experimental plan for two 8-plex iTRAQ runs, including the amount of each sample 
run. In Run 1, four donor samples were pooled for each sample region, in Run 2, two 




Figure 4.4. The ‘MacTel area’ is consistent between MacTel type 2 patients.  
Area of hyper reflectivity in central retina (A) surrounds the fovea (arrow head), temporal to 
the optic disc (OD). Dimensions, A (inferior-superior axis), B (naso-temporal axis) and C (OD 
edge to fovea)(A’) were measured and found to be consistent between MacTel type 2 
patients (B), n= 35 images. Dimensions were scaled as a proportion to distance C. These 
dimensions equate to actual distance of 2.34mm, A and 3.00mm, B (C), n= 14 images where a 
scale was available. Error bars; standard deviations from the mean. Clinical blue reflectance 





















Down regulated in 3 of the 4 comparisons 
Band 4.1-like protein 3   1.41 1.59 1.68 
Guanine nucleotide-binding protein G(T) subunit 
gamma-T1 precursor  
1.96 1.91  1.55 
High mobility group protein B2  1.42 2.23  1.30 
Non-histone chromosomal protein HMG-14  1.69 4.66  1.31 
Splicing factor, arginine/serine-rich 3  1.56 2.73 1.45  
Heterogeneous nuclear ribonucleoprotein   3.05 1.34 1.43 
 
Down regulated in 2 of the 4 comparisons 
10 kDa heat shock protein, mitochondrial  1.50 2.01   
14-3-3 protein eta  2.09 5.60   
14-3-3 protein gamma 1.47 1.54   
14-3-3 protein zeta/delta  1.49 1.57   
40S ribosomal protein SA  1.75 1.54   
Actin, cytoplasmic 2  1.64 9.12   
Aryl-hydrocarbon-interacting protein-like 1  2.33 1.33   
Aspartate aminotransferase, mitochondrial 
precursor  
1.53 2.75   
ATP synthase subunit alpha, mitochondrial 
precursor  
2.61 2.96   
ATP synthase subunit beta, mitochondrial 
precursor 
2.63 6.85   
ATP synthase-coupling factor 6, mitochondrial 
precursor  
1.39 1.64   
ATP-dependent DNA helicase 2 subunit 1 1.61 2.27   
Carbonic anhydrase 2  1.34 2.94   
Core histone macro-H2A.1  3.22 8.47   
Cytochrome c oxidase subunit 4 isoform 1  1.31 1.57   
Cytochrome c oxidase subunit VIb isoform 1  1.45 2.36   
Cytosolic non-specific dipeptidase  1.69 4.41   
Elongation factor 1-delta  2.68 1.91   
Fatty acid-binding protein, brain  1.45 4.70   
Fructose-bisphosphate aldolase C  1.85 3.37   
Fumarate hydratase, mitochondrial precursor  1.66 3.02   
Glial fibrillary acidic protein 1.89 3.08   
Guanine nucleotide-binding protein G(t) subunit 
alpha-1  
4.13 1.91   
Heat shock cognate 71 kDa protein  1.46 2.31   
Heterogeneous nuclear ribonucleoproteins 
C1/C2  
1.49 1.75   
High mobility group protein HMG-I/HMG-Y 2.09 6.31   
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Histone H4  2.75 1.87   
Keratin, type I cytoskeletal 10  2.25 1.84   
Keratin, type II cytoskeletal 2 epidermal 1.38 1.33   
Lamin-B2 1.61 11.59   
L-lactate dehydrogenase A chain  1.66 4.53   
L-lactate dehydrogenase B chain  1.58 1.39   
Neurofilament light polypeptide  1.47 3.53   
Non-POU domain-containing octamer-binding 
protein 
1.41 3.53   
Nucleoside diphosphate kinase B  1.66 10.57   
Poly(rC)-binding protein 2 1.39 2.99   
Protein DJ-1  1.37 2.13   
Pyruvate kinase isozymes M1/M2  2.11 3.80   
RNA-binding protein Raly  1.75 1.58   
Stathmin  2.07 1.46   
Stress-induced-phosphoprotein 1 1.51 2.75   
T-complex protein 1 subunit zeta  2.70 3.40   
Transketolase 1.33 1.85   
Tubulin alpha-1A chain  2.61 4.41   
Tubulin beta-2C chain  4.29 2.09   
Ubiquitin  1.58 4.02   
Vesicle-fusing ATPase  1.31 1.87   
Stress-70 protein, mitochondrial precursor  1.45  1.35  
Cell adhesion molecule 2 precursor  2.56 1.55  
Heterogeneous nuclear ribonucleoprotein A3   1.53 1.53  
Peptidyl-prolyl cis-trans isomerase A   1.85 1.36  
Synaptophysin   1.31 1.58  
T-complex protein 1 subunit theta  3.16 1.34  
Spectrin alpha chain, brain   1.61  1.37 
Spectrin beta chain, brain 1   2.63  1.33 
Transaldolase  1.53   1.32 
 
Table 4.3. Proteomic results. List of proteins down regulated within the ‘MacTel area’. Values 
indicate fold change compared to non-‘MacTel area’ sample. Greyed out cells are proteins 
























Up  regulated in all 4 comparisons 
Long palate, lung and nasal epithelium 










Up  regulated in 3 of the 4  comparisons 
60S ribosomal protein L7a  1.34 1.31 
 
1.89 
αA crystallin  2.19 3.73 
 
1.51 
Leukocyte elastase precursor  3.37 8.39 1.80 
 Polymeric immunoglobulin receptor precursor  2.29 3.19 1.56 
 Tubulin-specific chaperone A  2.23 1.67 2.43 
  
Up  regulated in 2 of the 4  comparisons 
Glutathione S-transferase P  
 
1.79 1.32 
 Superoxide dismutase [Cu-Zn]  1.63 
  
1.31 
Centromere protein F 
  
1.59 1.59 
Endoplasmic reticulum protein ERp29 precursor 
  
2.77 1.39 
Glucose-6-phosphate isomerase  
  
1.34 1.31 
Keratin, type I cytoskeletal 19 
  
1.42 1.57 
Tubulin beta-2B chain  
  
1.30 1.45 
αB crystallin B chain  2.44 4.25 
 
 
Antileukoproteinase precursor  2.36 8.09 
 
 
















Calretinin  1.56 4.06 
 
 
Cytochrome c  1.47 11.91 
 
 
DNA-(apurinic or apyrimidinic site) lyase  1.61 2.11 
 
 
Elongation factor 1-alpha 1  1.82 1.46  
Glutathione S-transferase Mu 5  1.33 1.92   
Heterogeneous nuclear ribonucleoprotein D0  1.31 1.74   
Heterogeneous nuclear ribonucleoprotein K 1.53 2.83   
Ig alpha-1 chain C region  3.08 5.65   
Ig lambda chain C regions  1.41 1.46   
Lactotransferrin precursor  1.87 3.05   
Lysozyme C precursor  3.22 5.40   
Mitogen-activated protein kinase 1 1.75 1.33   
N(G),N(G)-dimethylarginine 






Neuroepithelial cell-transforming gene 1 protein  1.46 1.41   
Neutrophil defensin 3 precursor  11.59 12.13   
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Phenylalanyl-tRNA synthetase beta chain  1.39 1.75   
Proline-rich protein 4 precursor  3.28 4.37   
Proteasome subunit alpha type-6  1.50 1.66   
Protein S100-A8  3.91 23.12   
Protein S100-A9  2.01 4.83   
Protein UNQ773/PRO1567 precursor 1.57 14.45   
Purine nucleoside phosphorylase  3.31 1.42   
Ras-related protein Rap-1A precursor  5.01 9.82   
Small ubiquitin-related modifier 3 precursor  1.32 1.91   
Uteroglobin precursor  1.37 2.49   
WD repeat-containing protein 1 1.82 1.94   
 
Table 4.4. Proteomic results. List of proteins up regulated within the ‘MacTel area’. Values 
indicate fold change compared to non-‘MacTel area’ sample. Greyed out cells are proteins 





Figure 4.5. Lactate dehydrogenase expression in human retina. 
Immunohistochemistry revealed lactate dehydrogenase (LDHB) expression in retinal glial 
cells (A). Ganglion cells appeared to uniformly express LDHB throughout the retina. 
Expression in Müller cells however was increased in processes of the Henlé fibre layer (region 







Figure 4.6. αB crystallin expression in the adult human macula.  
Anti-αB crystallin immunohistochemistry revealed αB crystallin expression in retinal 
astrocytes pan retina, and an increase in expression in Henlé fibre layer, arrowheads in A 
mark the boundary of increased expression. Specific cell processes can be seen in the Henlé 
fibre layer at the fovea, arrow in B. The expression within the Henlé fibre layer stopped in 
mid-macula (right arrow in C). No processes were evident in the outer plexiform layer of the 
periphery (D). Expression in astrocytes is present in all aspects of the retina. Scale bars are 







Figure 4.7. Glial fibrilliary acidic protein in macula Müller cells.  
Anti-glial fibrilliary acidic protein (GFAP) immunohistochemistry with product amplification 
revealed a subpopulation of Müller cells in the Henlé fibre layer, HFL, of the human retina 
(arrows in A). All Muller cell processes at the fovea expressed GFAP (B). Muller cell GFAP 
expression stopped abruptly in the Henlé fibre layer (arrowhead in C) and was only expressed 





Figure 4.8. αB crystallin was expressed in Müller cell processes in the Henlé fibre layer. 
Within the Henlé fibre layer, αB crystallin (green, A) and the Müller cell marker vimentin (red, 
B) co-localised (arrows in A-C). Müller cells of the peripheral retina did not express αB 





Figure 4.9. A sub population of Müller cells at the macula correlate in size and shape to the 
‘MacTel area’.  
Measurements for the height (A) and width (B) from blue reflectance images can be scaled to 
measurements from immunohistochemistry A’ and B’, using the difference in distances C and 
C’ as scaling factors (A). Measurements from GFAP immunohistochemistry stains are taken at 
the outer limiting membrane (arrow head in B); the Müller cell morphology shown in B’, blue 
line. Comparison of clinical data and histological data shows that there is no significant 
difference in the dimensions of the ‘MacTel area’ and GFAP stained Müller cells, height, A/C, 
p=0.9 (C) and width, B/C, p= 0.9 (D). Error bars; standard deviations from the mean. Clinical; 
confocal blue light reflectance, GFAP; immunohistochemical stain against GFAP on human 




5. αA crystallin in central macula 
5.1 Introduction: 
The proteomic screen previously described in chapter 4 revealed a concentration of αA 
crystallin in central macula. In this chapter we will verify this finding with 
immunohistochemitry. Since macular pigment is also concentrated at the centre of the 
macula we also investigated a possible connection between αA and αB crystallins and 
macular pigment. 
 
5.1.1 Crystallins  
Crystallin can form very stable, strong complexes and yet are also water soluble proteins. 
There are two families of crystallins; α crystallins and βγ crystallins. Crystallins form a 
significant proportion of the lens of the eye where they help to maintain lens transparency 
by aggregating degenerating proteins and keeping them soluble, thus preventing cataract 
formation and loss of vision.  
Ancestral stress proteins have been shown to regulate the gene expression of crystallins in 
the lens. Crystallins also have enzymatic activities  in other species, and this concept of the 
use of an enzyme as a crystallin has been termed gene sharing.323-325 Crystallins were 
evolutionarily recruited from enzymes and stress proteins. Some examples of these include 
argininesuccinate lysase (δ-crystallin in birds), glutathione-S-transferase (S-crystallins in 
cephalopods), duck lactate dehydrogenase (ε-crystallin), and α-enolase (τ-crystallin). 
 
α crystallin  
There are two α crystallins, αA crystallin (acidic) and αB crystallin (basic). In humans the αA 
crystallin gene (CRYAA) is located on chromosome 21 and encodes a polypeptide of 173 
amino acids, while the αB crystallin gene (CRYAB) is located on chromosome 11 and encodes 
a 175 amino acid chain. There is ~58% sequence homolgy between the two α crystallin 
genes.327 Both genes have similar 5’ flanking sequences of -111/-18 core promoter region.328 
The α crystallins share an homologous domain, known as the conserved heat shock domain 
or α crystallin domain, with the other small heat shock proteins. This conserved domain is a 
large proportion of the gene, at ~80 amino acids, spanning amino acids 63 – 144 in αA 
crystallin and amino acids 68 – 148 in αB crystallin.326 Studies from the 1980's have shown 
that the gene structure of CRYAA is highly conserved between various species, including 
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chicken and rodents.329-332 This would imply that the rate of substitutions during evolution 
have been relatively low, at approximately 3 amino acids per 100, over 100 million years. 330 
 
Crystallins in the lens are regulated at a transcriptional level. Common transcription factors 
associated with crystallins are PAX6, retinoic acid receptors, MAF, SOX, CREB and AP1.333-335  
Five DNA binding transcription factors have been implicated as regulators specifically of 
CRYAA, these being Pax6, c-Maf, CREB, CREM and USF.335-339  
 
αA crystallin has taken on many functional roles throughout the body. A primary function 
seen is that of a chaperone. In vitro they have been shown to interact with non-native 
proteins or degenerating proteins and in doing so, maintain that protein as soluble.332, 340 This 
is a function that it shares with αB crystallin, other small heat shock proteins and the ATP-
dependant chaperones GroE and Hsp70.341-344 The conserved C-terminal sequence that it 
shares with small heat shock proteins is believed not to be directly involved in substrate 
binding, but is thought to be essential for increasing the solubility of the protein, and thus 
contributing directly to its chaperone function.345 α crystallin has an extremely high binding 
capacity for substrates; it has been shown that substrates will preferentially bind to α 
crystallins, even if other chaperones are available.346 These crystallin-substrate complexes 
can form higher order aggregates, and it has been suggested that hereditary cataract 
formation might be caused by a mutation in α crystallin which makes the oligomer have a 
higher binding capacity, leading to the loss of solubility and lens fibre opacification.347 The 
exact binding substrates of the two α crystallins have yet to be determined.  
An anti-apoptotic function of α crystallins has been proposed.348-350 Over expression of αB 
crystallin in muscle cells subjected to stress, showed that this protein can stall the maturation 
of the protease involved in apoptosis, caspase 3.348 These studies have now been confirmed 
in lens epithelial cells. Cells induced to over express αA or αB crystallin have been shown to 
have enhanced resistance to stress conditions, including thermal and photochemical.351, 352 
αA crystallin was better at protecting against apoptosis compared to αB crystallin in cultured 
cells.352  αA crystallin knockout lens epithelial cells were also found to have a higher level of 
cell death compared to wild type cells, even under normal (non-stressed) conditions.353  A 
possible mechanism of action may be through binding to proapoptotic proteins such as 
p53.354 Researchers have found that the mechanisms by which αA and αB crystallins suppress 
stress induced apoptotic pathways are distinctly different.349  While these effects are 
essential in the lens, it can be suggested that the ability of αA and αB crystallin to interfere 
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with apoptosis in the retina would offer a novel way to suppress age related cell death of 
retinal photoreceptor cells in patients with AMD and in models of retinal dystrophy. 
αB crystallin has also been shown to play a role in protein degeneration. It acts by binding to 
the C8/alpha7 subunit of the 20S proteasome (shown in vitro and in vivo)355 and by doing so 
either affects the proteasome complex, or facilitates the degeneration of the αB crystallin 
bound unfolded substrate. 
 
5.1.2 Macular pigment  
Macular pigment consists of two xanthophylls carotenoids, lutein and zeaxanthin. There are 
over 600 carotenoids known to exist, of which 30-50 are in the human diet, yet only 15 of 
these have been found in human serum356 showing the selectivity of the body to carotenoids. 
Further still only the two macular pigments and their metabolites are present within the 
retina.357-360 The carotenoid concentration is maximal at the fovea, where it reaches ~1mM 
and the ratio of lutein:zeaxanthin:meso-zeathanthin is 1:1:1.361 Macula pigment 
concentration rapidly decreases with eccentricity from the fovea and within a few 
millimetres the concentration drops 100 fold.357 Lutein persists into the peripheral retina 
while zeaxanthin and lutein’s metabolite meso-zeaxanthin concentration decreases more 
rapidly, at a 3:1:0 ratio.357 The main location of macular pigment is the Henlé fibre layer and 
the parafoveal inner nuclear layer,256, 362 when seen in cross section, and can span anything 
from 200-900µm diameter from the fovea.362-364  The macular pigment concentration of the 
retina is dependent upon dietary supplement365-367 and the amount seen in the retina varies 
significantly between people. At the centre of the fovea there is a Müller cell cone, it has 
been proposed that this structural feature maintains the pit formation and also a primary 
reservoir for macular pigment. 256, 368  
Mechanisms of macular pigment deposition parafoveally are unclear. The function of 
macular pigment is also a matter of debate, its absorption at ~460nm means that it acts as a 
blue light filter reducing photopic damage and glare, it might also minimise the effects of 
chromatic aberration and thus improve visual acuity (fine detail and contrast sensitivity).359, 
362, 363 Another proposed theory is that it acts as an anti-oxidant, neutralising free radicals 
produced in the human retina thus protecting the outer retina, RPE and choroidal 
vasculature from oxidative damage.358, 362 
Bernstein and colleagues have identified two carotenoid binding proteins within the human 
macula; glutathione s transferase (GSTP1) which binds zeaxanthin and StARD3 which binds 
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lutein. GSTP1 has been shown to be located within the Henlé fibre layer and the IPL,320 a 
pattern that correlates with the cross sectional distribution of macular pigment by 
Snodderly,369, 370 whilst Bernstein has recently located StARD3 primarily within the inner 
segments of the photoreceptors and neurons.371 This recent binding protein distribution does 
not correlate with the distribution of maximal macular pigment seen in cross section. This 
does not mean that the data is wrong, but could imply that lutein and zeaxanthin have 
distinctly different patterns of distribution in the retina; GSTP1 localisation does correlate 
with macular pigment cross sectional distribution, implying perhaps that zeaxanthin is the 
main component of the intensely visible carotenoid. 
DL-α-aminoadipic acid (DL-α-AAA) has been reported as a glial specific toxin and acts by 
suppressing GS function.67, 372-374 Retinal cultures with DL-α-AAA show that Müller cells are 
the primary site of DL-α-AAA accumulation,375 not surprising as DL-α-AAA is a homologue of 
the excitatory amino acid L-glutamate and Müller cells sequester excess L-glutamate. 37, 38 To 
investigate the relationship between Müller cell loss and a proposed Müller cell dysfunction 
in MacTel type 2, Gillies and colleagues attempted to selectively target Müller cells in 
primate central retina.376 They injected DL-α-AAA into the sub retinal space below the 
macula. However, unlike in rat models, DL-α-AAA did not result in Müller cell dysfunction in 
primates; it instead disrupted the cone photoreceptors.376 It is interesting that in this study, 
although selectively killing the cone photoreceptors (the main axonal component of the 
Henlé fibre layer), there was no effect on macular pigment distribution. The Henlé fibre layer 
appears thinned whereas the sites of inner and outer photoreceptor segment loss in their 
study376 implying axonal degeneration as well, seeing as GS staining was unaffected. This 
could have implications regarding the debate over macular pigment deposition sites, 
implying a Muller cell storage site. However, no marker was used to target the neuronal 
axons, such as ml-opsin, so they might still persist after cell death and have macular pigment 
bound. It could be that macular pigment is found in both Müller cells and photoreceptor 
axons, and when photoreceptors are affected then there is no visible loss, whereas if there is 
Müller cell dysfunction then the route for macular pigment transport from the blood system 
to the retina is affected and as such no macular pigment can be transported into the retina 
for it to become bound to Müller cells or photoreceptor cells. Although it has also been 
proposed by Bernstein and colleagues that macular pigments enter the retina not through 
the retinal vasculature, but via the choroidal vasculature through the RPE. They speculate 
that the carotenoids, having similar chemical structures to retinoic acid, are transported to 




5.2 Aim:  
Establish the distribution of αA and αB crystallins in the human retina and test a potential 
link to retinal pigment distribution 
 
5.3 Materials and Methods: 
Technical acknowledgements: I would like to thank Glen Jeffery, University College London, 
for the provision of the marmoset tissue used in this chapter. Also thanks to Preejith Vachali 
and Paul Bernstein, University of Utah, for undertaking the Surface Plasmon Resonance (SPR) 
binding studies for us.  
 
5.3.1 Tissue and processing 
5.3.1.1 Tissue information 
Fixed adult human tissue was used (Table 4.1). 
Retinal tissue was obtained from Rhesus Macaque (17 year old), Marmoset, Pig and a 12 
month old C57B6 mouse, and also from embryonic day 21 chick and embryonic day 26 duck.  
 
5.3.1.2 Embedding and sectioning 
Human tissue and marmoset tissue was embedded in wax, as described in chapter 2.3.1, all 
animal tissue was fixed for 2 hours in 4% PFA, equilibrated in 30% sucrose, orientated and 
embedded in optimal cutting temperature compound (Agar, UK) and frozen on dry ice. Tissue 
was then sectioned through the area centralis/visual streak/fovea as appropriate. Sections 
were cut at 10µm and collected onto Superfrost® plus slides (VWR, UK).  
 
5.3.2 Antigen retrieval and Immunohistochemistry 
Antigen retrieval and immunohistochemistry were performed as previously described in 
chapter 2.3. For human, marmoset and rhesus macaque tissue, slides stained for anti-CRYAA 
were heated to 130°C in citrate buffer for at least 10 minutes. Antigen retrieval was not 
required for other species.  
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5.3.3 Primary antibodies 
αA crystallin (Santa Cruz, Sc-22743), αA crystallin (Abcam, ab14821), αB crystallin (Chemicon, 
AB1546), all diluted 1:200. Vimentin, LDHB and COX2, as per Table 1.2. 
 
5.3.4 Surface Plasmon Resonance (SPR) binding studies (performed by Dr. Preejith Vachali 
and Prof. Paul Bernstein) 
The amine coupling reagents; N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride, the GST coupling kit and 1M sodium ethanolamine 
hydrochloride pH8.5, were used as per manufacturers recommendations (Biacore AB, 
Sweden). αA and αB crystallin proteins (Abcam, Cambridge, MA, USA) were used. Gifts of 
carotenoids (3R,30R)-zeaxanthin (ZeaVision, USA), (3R,30S)-mesozeaxanthin (DSM, Basel, 
Switzerland), (3R,30R,60R)-lutein (Kemin Health, USA), and (3S,30S)-astaxanthin (Cardax 
Pharmaceuticals, USA). All carotenoids were crystalline, with >98% isomeric and chemical 
purity confirmed by HPLC.371  
 
αA  and αB crystallin were immobilised on a COOH-5 SPR chip using a standard amine 
coupling protocol.371 The crystalline carotenoids were dissolved in running buffer (10mM PBS 
(pH 7.4), 0.01% TritonX-100, 1.26mM EDTA and 0.4mM sucrose monolaurate) and were 
tested in a 2-fold dilution series (0.1µM-10µM concentration range).  Blanks were included in 
each analysis. The analyte concentration series was injected as two-fold dilutions in running 
buffer using the FastStep™ gradient injection mode with a flow rate of 200μl/minute. A 
FastStep™ concentration series of sucrose [20% (w/v) sucrose in running buffer] was injected 
to create the concentration gradient for analysis.371    
 
SPR measurements were recorded on a SensiQ (ICx Nomadics, Oklahoma City, OK, USA) 
instrument at 25°C. SensiQ employs a miniature SPR-based sensor, designed in a 
Kretschmann’s configuration, where monochromatic light is reflected from the sensing 
surface over a range of incident angles, and the reflectance minimum will occur with respect 
to the incident angle and is detected by a photodiode array. A planar glass chip with a 
∼50nm gold film coating is the sensing surface.371 
 
Affinity determination SPR response data (sensorgrams) were zeroed on both the response 
and time axes at the beginning of each injection and double referenced. First, bulk refractive 
index changes were corrected by subtraction of the responses generated over an unmodified 
reference surface from the binding responses generated over the protein surfaces. Any 
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systematic artifacts between the proteins and reference flow cells were corrected by 
subtraction of the response generated by an average of the buffer injections from the 
binding responses generated by carotenoid injections. Simple interactions were adequately 
fit to a steady-state, single-site, bimolecular interaction model (A + B = AB),371 yielding a 






5.4.1 Foveal αA crystallin 
The proteomic screen highlighted αA crystallin as up regulated in central macula, as such we 
wanted to investigate the distribution further in adult human retina, using 
immunohistochemistry. 
αA crystallin is highly expressed within the ocular lens, it constitutes up to 40% of all 
protein.378 Therefore in all eyes studied lens tissue was used as a positive control for 
antibodies directed against αA crystallin. 
In adult human retina, anti-αA crystallin antibodies revealed a high concentration of αA 
crystallin at optic nerve edge and fovea (Fig. 5.1 A). The foveal expression was concentrated 
in the pit, and spread into the parafoveal plexiform layers (Fig. 5.1 B). Co-labelling with anti-
vimentin showed that αA crystallin was expressed within a subpopulation of the macular 
Müller cells described in the previous chapter. The expression pattern from both αA crystallin 
antibodies listed previously was identical (data from only one antibody shown).  
 
5.4.2 αA crystallin expression in other animals.  
In order to establish whether αA crystallin is also marker for central vision in other animals, a 
variety were investigated using immunohistochemistry; including old and new world 
monkeys, mouse, pig and squirrel, and also retina from chicken and duck.   
In a Rhesus Macaque (17 yr old, old world monkey) which has a fovea and macula similar to 
humans, αA crystallin is expressed by Müller cells at the fovea. A marmoset monkey (new 
world monkey) showed the same foveal  expression pattern for αA crystallin. Primates are 
the only mammals with a foveal specialisation. Other mammals do have visual streaks/area 
centralis’, which are regions of the retina with an increase in cone number and/or ganglion 
cell density and are believed to be responsible for higher acuity vision in those animals. αA 
crystallin was only expressed in foveal Müller cells of the primate retina, so are their 
equivalent Müller cells in lower mammals. A C57B6 mouse (12 month old) showed αA 
crystallin expression diffusely within the ganglion cell and inner nuclear layers throughout 
the retina, this corresponds to previously published data.353 The expression level between 
litter mates was variable, and as reported in the literature,353 this was possibly a result of a 
light induced stress response. Pigs have a more pronounced visual streak, and being diurnal 
have a higher concentration of cone photoreceptors in central retina. Control lens tissue 
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confirmed αA crystallin antibody specificity, however no crystallin was seen within peripheral 
retina or visual streak (data not shown). 
Birds have a highly developed visual system, the majority have a cone rich area centralis and 
some, including raptors also have a central foveal pit (or more). E21 chicken, and E26 duck 
retina have a fully formed retina and defined area centralis. Cross sections through the area 
centralis and optic nerve showed no expression of αA crystallin within the retina (data not 
shown), whilst lens tissue showed Immunoreactivity (Supplementary Fig.1).  
We found that αA crystallin expression is limited to Müller cells of the primate fovea; there is 
no expression in other animals, even though lens expression was confirmed.  
 
5.4.3 α crystallin interactions with carotenoids 
There is no known cellular specialisation in the αA crystallin expressing location around the 
fovea. The only other restricted specialisation of the fovea is the high concentration of 
zeaxanthin, meso-zeaxanthin and lutein, the macular carotenoid pigments. The distribution 
of αA crystallin at the fovea resembles the expression pattern of macula pigment seen in 
cross section (Fig. 5.2 A-D), with a wedge of pigment and αA crystallin at the foveal slope at 
the level of the Henlé fibre layer and IPL (Fig. 5.2 C and D).  
Because of the similar distribution it is possible that the crystallins interact with the macular 
pigment carotenoids. Therefore we have studied the in vitro binding potential between 
crystallins and carotenoids.  The binding between crystallin proteins and macular pigment 
carotenoids (lutein, zeaxanthin and meso-zeaxanthin) has been determined, along with two 
control carotenoids not found in the retina; β-carotene and astaxanthin.   
 αA crystallin and αB crystallin bound the carotenoids tested, with differing levels of affinity 
(Fig. 5.3). The macular pigment carotenoids, lutein and zeaxanthin, showed a slightly stronger 
affinity (~ 1µM) compared to non-macular pigment carotenoids, beta carotene and 
astaxanthin (Fig. 5.4 A-D). The KD values (Table 5.1) were close to that of human serum 
albumin previously reported by Bernstein and colleagues, (lutein, 1.69±0.05 and zeaxanthin, 
1.11±0.03 and meso-zeaxanthin, 1.12±0.05)371 and lacto-globulin (personal correspondence, 
unknown specific KD values); they classified both human serum albumin and lacto-globulin as 
Class 2 carotenoid binding proteins.  Class 1 carotenoid binding proteins such as GSTP1 
(strong affinity for zeaxanthin and meso-zeaxanthin) and StARD3 (strong affinity for lutein) 





The specificity of the αA crystallin was established by using lens tissue from each species as a 
control (Supplementary Figure 1), as αA crystallin has been reported to make up, up to 40% 
of total lens protein, it is a valid control to use. The expression pattern in human and both 
monkey tissues was verified by two antibodies directed against αA crystallin from different 
suppliers.  Both αA crystallin antibodies used are raised against the full length recombinant 
protein (amino acids 1-173) of human origin, and therefore both recognise the conserved 
heat shock domain of αA crystallin. The CRYAA gene, as previously stated, is known to be 
highly conserved between species329, 331 and as such the antibody recognising multiple 
species is not unexpected.  Further discussion about the specificty of the αA crystallin 
antibodies against human tissue will be covered in chapter 6.5.  
Immunohistochemistry verified the proteomic results from chapter 4. In the adult human 
retina, αA crystallin had a peak of expression in the fovea. This expression pattern was 
further determined in both old world, (Rhesus macaque) and new world monkeys 
(marmoset). At the visual centre of other animals (area centralis or visual streak) no peak in 
αA crystallin expression was found, although we were able to confirm αA crystallin 
expression in the lens. The finding that crystallin was restricted to the fovea of primate retina 
and was not found within the central retina of other animals implies expression was possibly 
induced during the evolution of foveal pit in primates. The primate foveal pit contains an 
inverted Müller cell cone.368 The precise function of this cone is unknown, it might serve a 
structural role but it has also been proposed as a reservoir for macular pigment.256, 368 
A unique primate foveal specialisation (compared to other animals) is a high concentration of 
macular pigments. We tested to see whether αA crystallin might be involved in the transport 
of macular pigments in the retina. The affinity between both crystallin proteins to the two 
dietary retinal carotenoids (lutein and zeaxanthin) was higher than the affinity for β-carotene 
and astaxanthin (non retinal carotenoids) and meso-zeaxanthin (Table 5.1), this implies some 
degree of specificity towards the retinal macular carotenoids. Furthermore the KD values at 
~1µM were lower than that shown by Bernstein and colleagues between human serum 
albumin and lutein and zeaxanthin (lutein, 1.69±0.05 and zeaxanthin, 1.11±0.03). 
Carotenoids are transported around the body within blood serum.356, 379 This leaves a 
potential role for αA and/or αB crystallin in the transport of lutein and/or zeaxanthin from 
the blood serum into the Müller cell, and potentially shuttling the carotenoid to GSTP1380 or 
StARD3371 which have been shown by Bernstein ad colleagues to be Class 1 carotenoid 
binding proteins. This possible mechanism for carotenoid transport into the retina does not 
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negate the model proposed by Bernstein and colleagues377 whereby carotenoids enter 
through the RPE and are transported by interphotoreceptor retinoid binding protein to the 
photoreceptor cells, it is possible that two different supplies are at work.  
To summarise, α crystallins are located only in Müller cells at the fovea of primate retina. α 
crystallins are not a class 1 carotenoid binding proteins, however the binding affinities could 





Figure 5.1. Foveal αA crystallin expression in adult human retina.  
Immunohistochemistry with an anti-αA crystallin antibody revealed expression at the optic 
nerve (arrow in A) and at the fovea (arrowhead in A), localised to the foveal pit and 
parafoveal plexiform layers (B). αA crystallin (arrowheads in C) and vimentin (arrowheads in 
D) co-localised (arrowheads in E), which showed that αA crystallin is expressed in foveal 
Müller cells. Scale bars are 500µm in A and 100µm in B. IPL; inner plexiform layer, HFL; Henlé 




Figure 5.2. Macular pigment and αA crystallin distributions in primate retina are similar.  
Macular pigment distribution (A) adapted from Snodderly370 shows localisation to the 
primate fovea with wedges extending into the Henlé fibre layer and inner plexiform layers. 
This pattern is mirrored in αA crystallin expression, localisation at the fovea (B) and 
expression into the parafoveal plexiform layers (arrow heads in C and D). GCL; ganglion cell 
layer, IPL; inner plexiform layer, INL; inner nuclear layer, OPL; outer plexiform layer, HFL; 

















Figure 5.3. α Crystallin-Carotenoid interactions. 
 Surface Plasmon resonance (SPR) sensorgrams of astaxanthin, β-carotene (BetaC), lutein, 
meso-zeaxanthin and zeaxanthin binding to immobilised αA crystallin (CRYAA, A) and αB 
crystallin (CRYAB, B) proteins. C and D; Binding isotherm fit of the responses shown in panels 
A and B. Plotted versus injected carotenoid concentration and fit to a 1:1 binding isotherm.  












Table 5.1. Equilibrium dissociation constants (KD).  
Equilibrium dissociation constants (KD) for αA crystallin and αB crystallin were determined in 
relation to 5 carotenoids. KD values were determined using the SensiQ Pioneer Surface 
Plasmon resonance biosensor platform, at 250C. 







Equilibrium dissociation constant (KD) 
αA Crystallin αB Crystallin 
Zeaxanthin 1.00 ±0.10µM 1.04 ±0.10µM 
meso-Zeaxanthin 1.38 ±0.01µM 1.10 ±0.01µM 
Lutein 0.97 ±0.10µM 0.92 ±0.10µM 
Astaxanthin 1.80 ±0.02µM 1.66 ±0.02µM 
β-Carotene 1.90 ±0.02µM 1.78 ±0.02µM 
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6. Macula development 
6.1 Introduction: 
To better understand the macula in adults we have also to investigate how it develops. In this 
chapter I will therefore focus on the embryonic eye development. Because our investigation 
directed us towards retinoic acid signalling in the retina, details about retinoic acid in 
development and how it acts as a morphogen will also be discussed. 
 
6.1.1 Eye development 
The optic cup forms from the developing diencephalon (forebrain); the optic placode begins 
to develop during neural tube formation, a stage called neurulation, at post conception day 
22 (CS10)381 and then starts to evaginate at day 24 (CS11) to form the optic vesicles. At the 
point when the optic vesicle comes in contact with the overlying surface ectoderm and the 
lens placode forms, the optic vesicle is triggered to invaginate to form a bilayered optic cup. 
The lens placode itself is also triggered to invaginate, pinch off and form the lens.382 
The neural retina and RPE originate from the same sheet of ectoderm. The neural retina 
develops from the ventral side of the optic vesicle and the RPE from the dorsal.383, 384 The 
homeobox gene VSX2 (formerly CHX10) and bHLH transcription factor MITF are the first 
genes to show domain specific expression. VSX2 localised to the developing neural retina, 
whilst MITF specifies developing RPE.385-387 VSX2 and MITF are both essential in patterning 
and cell fate in the developing optic vesicle, VSX2 has also been shown to play a role in 
regulating proliferation.387, 388  
LIM homeobox transcription factor LHX2 is the earliest patterning gene involved in eye 
development, it is expressed during eye field determination.389, 390 In LHX2  knockout mice, 
optic vesicle patterning has been shown to be greatly disturbed; expression of MITF, VSX2 
and TBX5 are not initiated, whilst expression of RAX, PAX2 and VAX2 (eye field determinants) 
are initiated but not maintained.390  
RPE differentiation is essential for the proper formation of the neural retina; it controls 
lamination of the retina and regulates differentiation of the photoreceptors.391-393 MITF and 
OTX2 are the key regulators of RPE specification. They are turned on throughout the optic 
vesicle prior to pigmentation of the cells; however they are down regulated in presumptive 
neural retina in the same pattern that MITF is down regulated.392, 394, 395 Patterning of the 
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neural retina from the anterior optic vesicle requires the MAP kinase FGF signalling pathway. 
FGF signalling from the lens is crucial in determining retinal neurogenesis, the lens (surface 
ectoderm) is a source of FGF1 and FGF2.396, 397 It has been demonstrated that the removal of 
lens surface ectoderm in chick embryos interferes with neuronal marker expression in the 
neural retina397, 398 But at the same time some studies in zebrafish and chick have shown that 
the ocular neuroepithelium acts itself as an FGF signalling centre.399-402 Mouse retinogenesis 
has however been shown to not be patterned by FGF/tyrosine receptor signalling, so there 
might be species specific adaptations.403  
MAPK FGF signalling is known to be essential for retina/ RPE specification FGF9 knockouts 
show RPE domain expansion into presumptive retina in the optic vesicle, therefore FGF9 has 
a role in retina/RPE boundary establishment.404 Cai et al. (2010)403 further defined the role of 
FGF in retina specification by manipulating tyrosine phosphatase SRC homology 2 (SHP2), a 
protein that is required for activation of FGF signalling through association with FGF tyrosine 
kinases.403 Conditional inactivation of SHP2 prior to retinal specification in early optic vesicle 
development in mouse results in a lack of VSX2 expression in presumptive retina and 
persistence of MITF expression in the anterior optic vesicle. The entire optic vesicle remains 
RPE like and all cells develop pigment.403 Likewise in reverse the presumptive RPE can be 
induced to transdifferentiate into retina with fully developed retinal layering, by gain of 
function mutants and over expression of the MAPK FGF pathway.386, 397, 398, 404-416 VSX2 
mediates FGF activity, shown by the fact that VSX2 null mutant mice cannot induce retina 
from RPE in the optic vesicle,417 and supported by VSX2 knockout mice which maintain pure 
RPE phenotype to the optic vesicle and do not induce retina specification.417, 418 It has been 
suggested that MITF gene activation can suppress VSX2 action in anterior optic vesicle,419 
indicating that FGF is upstream of VSX2. FGF is not the only growth factor to have been 
shown to be essential in neural retina development. BMP signalling has been implicated to 
play a role; BMP7 null mice display microphthalmia and anophthalmia. In the anophthalmic 
mice the lack of BMP7 results in a downregulation of retina specifying genes and 
maintenance of the MITF and subsequent RPE phenotype in the whole optic vesicle.420 
However, due to the lack of lens formation within these mice it is possible that induction of 





6.1.2 Retinal cell differentiation 
Experiments to trace cell fate determination of retinal cells during development using [3H]-
Thymidine labelling and autoradiography, has revealed an evolutionary conserved 
mechanism of cell fate determination.421 Retinal cells differentiate in sequence, with 
initiation of their first mitotic events in the optic vesicle. In mammals, RGCs differentiate first 
followed by cone photoreceptors and amacrine cells, with horizontal and rod photoreceptor 
cells next. Bipolar cells and Müller cells are reportedly the last cells in retinal histogenesis.422-
427 The differentiation time points of different cells types overlap during development. It is 
possible that the timing of cell type differentiation is triggered or hindered by the other 
differentiating cell populations. However, this would also lead to the assumption that if 
postnatal neural epithelial progenitor cells were cultured with early embryonic retinal 
progenitors, the cell fates at the earlier stage of development would be adopted. 
Experimental data has however revealed that intrinsic “barriers” in neural epithelial 
progenitor cells halt their re-specification capability, if they had any to begin with that is.427 
This co-culture does however block the differentiation of later time point cell types. Similarly, 
embryonic retinal neural epithelial progenitor cells fail to adopt later cell fates when cultured 
in excess with postnatal progenitor cells from mice. Therefore, intracellular signalling 
pathways are essential retinal neural progenitor cell differentiation and preservation of stem 
cell properties. 
Ablation and transplantation studies have shown that the retinotectal projection pattern 
along the anterior-posterior axis is established during the optic vesicle stage in chick,428, 429 
however the dorsal-ventral axis not established until optic cup formation.430, 431 Both events 
occur before the first mitotic events in retinal cell fate determination, and therefore the 
positional identity of the progenitor cell already directs the final cell fate, and is instrumental 
in retinal patterning.432  
 
6.1.3 Retinoic acid in development 
Vitamin A (retinol) is the precursor to retinoic acid; retinol is oxidised to retinaldehyde by 
retinol dehydrogenases, following this conversion retinaldehyde dehydrogenses 
subsequently covert retinaldehyde into all-trans retinoic acid. Retinoic acid can then bind to 
the cellular retinoic acid binding proteins, CRABP1/2. Ligand binding induces a 
conformational change which exposes a nuclear localisation motif on CRABP2 and the 
complex is then shuttled transported into the nucleus. Retinoic acid then interacts with its 
receptors to activate the transcription of target proteins. 
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There are two protein families involved in retinoic acid signalling; the retinoic acid receptors, 
RARα, β and γ, and the retinoid X receptors, RXRα, β and γ. RAR and RXR form heterodimers 
(RAR/RXR) when bound to a retinoic acid response element of a target gene.433, 434 RARα, β 
and γ, in the developing eye are expressed in overlapping domains resulting in functional 
redundancy;435 mice lacking individual RAR receptors show minor phenotypes436, 437 whilst a 
double knockout or RAR receptors leads to significant phenotypes and lethality.438, 439 
Retinoic acids ability to act as a morphogen in development has been controversial. It has 
been reported to be essential in anterior-posterior patterning; however whether it 
determines cell fate or is merely permissive for specifying cell fate has been up for debate. 
Classical morphogens specify a cells fate in a concentration dependant manner, and 
receptors on the cells stop migration or interpret cell fate dependent upon the 
environmental concentration. Observations in retinoic acid deficient mice, quail, rat and 
zebrafish have implied that retinoic acid only acts permissively in the patterning of hindbrain; 
as it has been shown that the normal patterning can be rescued when exposed to a uniform 
concentration of retinoic acid across the hindbrain.440-447 Other experiments have determined 
the opposite, showing retinoic acid does function like a classic morphogen. For example, 
retinol deficient embryos, or loss-of-function mutants in the retinoic acid synthetic enzyme 
aldehyde dehydrogenase 1A2 (ALDH1A2 or RALDH2), show loss of posterior hindbrain 
rhombomeres 5-7, and expansion of anterior rhombomeres 2-4.441-443, 447, 448 RAR antagonists 
in chick embryos also cause a progressive anteriorisation in a concentration dependent 
fashion.449 Conversely, embryo exposure exogenous retinoic acid causes a concentration 
dependent loss of forebrain and subsequent eyes, and ultimately a progressive 
posteriorisation of rhombomere identities.444, 450-453 Loss of cytochrome P450 A1 (CYP26A1), a 
retinoic acid degrading enzyme also causes rhombomere 5-7 to develop anteriorly in mice 
and zebrafish,454-456 and the combined depletion of CYP26A1 and related enzymes CYP26B1 
and CYP26C1, and subsequent loss of available retinoic acid, results in severe posteriorisation 
of the zebrafish hindbrain.440 This evidence suggests that retinoic acid can act like a classic 
morphogen, and that gradients can be established across a tissue by the action of localised 
retinoic acid degrading enzymes.  
CRABP1 is likely involved in the regulation of retinoid homeostasis in cells that are the targets 
for retinoid. In the anteroposterior axis formation in chicken limb development, two 
opposing gradients have been observed, one of retinoic acid and another reciprocal gradient 
of CRABP1. It was proposed that these opposing gradients would result in an even 
distribution of retinoic acid-CRABP1 complex, but in a steeper gradient of free retinoic acid 
available for binding to retinoic acid receptors (RARs).457 Boylan and Gudas458 also showed 
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that an increase in expression of CRABP1 reduces the expression of retinoic acid induced 
genes, thus further showing that CRABP1 influences the availability of free retinoic acid 




6.1.4 Retinoic acid in retinal morphogenesis and patterning 
Expression patterns of components of retinoic acid signalling are temporally and spatially 
restricted. Transgenic mouse and fish reporter strains have been used to study retinoic acid 
signalling in development based on the ability of multiple retinoic acid response elements 
(RAREs) to direct expression of a linked lacZ reporter gene (in transgenic mice)460-463 or a 
green fluorescent protein (GFP).464 These transgenic strains, coupled with knockouts for 
retinoic acid signalling components, such as RALDH1-/-,465 RDH10-/-,466 or knockouts for genes 
that control eye development, such as PAX6,461 have shown active retinoic acid signalling in 
the optic vesicle, in patterning presumptive retina/RPE and continued expression in 
developing retina. 
Raldh3 is present in the RPE467 and can therefore signal via retinoic acid to the retina and 
dictate morphogenesis in the retina that subsequently leads to invagination of the anterior 
optic vesicle.467 Retinoic acid is also required to induce apoptosis in the extraocular 
mesenchyme, one gene that is targeted is PITX2, a transcription factor required in RPE 
differentiation468-470 
Raldh3 is expressed in mouse and chick ventral retina during development. Shortly after the 
expression of Raldh3 in ventral retina, the retinoic acid degradation enzyme CYP26A1 is 
upregulated in dorsal retina, just hours after this Raldh1 expression is induced in the far 
dorsal retina.471-473 Initially RALDH1 and CYP26A1 expression overlaps, but before retinal 
neurogenesis begins the two expression patterns become clearly defined, with CYP26A1 
expression becoming limited to the central, horizontal meridian, CYP26C1 expression has 
been identified in a further band across the retina of both mice and chickens, restricted to an 
even thinner region across the retina (Fig. 6.1 A-C). This generates a gradient of retinoic acid 
across the retina. Raldh3 produces retinoic acid in ventral retina, but the levels would 
decrease towards the central meridian, where CYP26A1 degrades any free retinoic acid in the 
environment, and CYP26C1 completely degrades any free retinoic acid in a strip across the 
very central retina.474 Towards dorsal retina, retinoic acid levels increase due to production 
by RALDH1 and reduction by CYP26 enzymes.463, 475 The regions occupied by both RALDH’s 
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have many morphologic markers in common, to date though no morphogenetic marker has 
been correlated with the expression pattern of CYP26A1 and C1.  
6.1.5 Macula development 
Macula specification and development is not well understood and largely characterised on 
the basis of the structural morphology and differentiation of specific cell types. 
The optic vesicle is formed at 4 weeks post conception (Carnegie Stage 13, CS13) but the 
fovea is not fully formed until 4 years of age;476 a large time frame in which the macula/fovea 
can develop. During development, the prospective macula first goes through a phase of 
ganglion cell proliferation, the ganglion cells in central retina start to double at 4.5 months,477 
by 6 months gestation they have reached 8-9 cells deep477  at the centre of the ‘mound’. By 
the seventh month the cells within the inner nuclear layer and the ganglion cell layer at the 
centre of the prospective macula start to migrate radially, beginning the formation of the 
foveal depression. This process is known as lateral displacement.477 Lateral displacement 
leaves only 2 ganglion cells at the fovea by the eighth month of gestation and a single cell 
deep by the ninth;477 the fovea continues to develop through to 4 years after birth though. A 
closer study of retinal morphology however shows that the earliest time point where the 
presumptive macula can be identified is at 9-10 weeks (F2). Lineage tracing identified the 
incipient macula as the region of the retina that matures first, cells start to differentiate and 
then there is a wave of differentiation radially through the retina. As cells differentiate from 
the progenitor epithelia they start to form the different retinal layers. This will occur first at 
the presumptive macula following the line that cells here differentiate first. Hendrickson and 
colleagues478 identified this at 9-10 weeks gestation (WG); the stage where the outer nuclear 
layer is visible in central retina, and peripheral retina still contains two neuroblastic layers.478 
(summarised in Fig. 6.2 A)  
Immunostaining for synaptic proteins479, 480 highlighted that the first synapses are formed in 
the IPL of the primate retina at the incipient fovea, but data as to whether these synapses 
are amacrine and/or bipolar is conflicting.481-484 Followed by synaptogenesis in the OPL, which 
in humans occurs at 11WG in foveal cones.482 Rods generate synapses later in development 
than cones.480 It is known that the incipient fovea differentiates first in human 
development,482, 485 as such photoreceptor differentiation occurs here first. This can be used 
to pinpoint the incipient fovea. ML opsin (red/green photoreceptors) and rhodopsin are first 
detected with immunohistochemistry at 16WG478 at the incipient fovea/prospective macula. 
S opsin is expressed earlier in development at 14WG.478 So photoreceptor opsin expression 
can track the developing fovea/macula back to 14WG, opsins however are not the first 
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markers of photoreceptors to be expressed. Interphotoreceptor retinoid binding protein 
(IRBP), tubby-like protein (TULP) and neural retina-specific leucine zipper protein (NRL) can 
all be detected during the 9th week of gestation by immunohistochemistry.478 These are the 
earliest known photoreceptor proteins to be expressed in the human retina, as such we can 
trace the location of the macula back to 9WG, the same time point at which morphologically 
the outer nuclear layer forms (summarised in Fig. 6.2 B). Lineage tracing shows that ganglion 
cells are the first cells to become postmitotic, and primates studies have shown this to be at 
foetal day 33,424, 486  which corresponds to >7-8WG. Ganglion cell differentiation therefore is 
the earliest indicator for the incipient fovea known to date.   
Current knowledge of the position of the developing macula all stems from differentiation 
initiating at that point. There has to date been no data answering the question as to why this 
is the region that differentiates first, and more so there is no data published that shows any 
macula specialisation compared to peripheral retina during development.      
 
6.2 Aim: 
To characterise embryonic development of the macula and find potential signalling pathways 
that regulate this. 
 
6.3 Materials and Methods: 
Technical acknowledgements: I would like to thank Dianne Girrelli and her team at the 
London HDBR for the provision of and staging of the embryonic/foetal tissue used.  
6.3.1 Tissue and processing 
6.3.1.1 Samples 
Embryonic/foetal eye tissue was obtained from London HDBR facility at the UCL Institute of 
Child Health, UK. Tissue was staged at the HDBR prior to organ distribution; staging was done 
according to the Carnegie Stages (CS) and Foetal developmental protocol (F) (Supplementary 
Table 1). 
6.3.1.2 Fixed samples 
Immunohistochemistry- sections 
Whole eye globes were fixed in 4% (w/v) PFA overnight and transferred into 30% (w/v) 
sucrose/ PBS-DEPC to equilibrate. Globes were orientated and embedded in OCT compound 
(Agar, UK) on dry ice. Sections through the optic nerve and prospective fovea were cut and 
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mounted onto Superfrost® plus slides (VWR). 3 eyes from each developmental stage, CS19-
F2, were investigated for immunohistochemistry in sections. 
Immunohistochemistry- flatmount 
Whole eye globes were fixed in 4% (w/v) PFA overnight, the cornea/lens removed and the 
retina was dissected out. Vitreous and hyloid vasculature were also removed. 3 eyes from 
each developmental stage, CS19-F2, were investigated for flatmount immunohistochemistry. 
In situ hybridisation 
The retina was dissected from the whole globe, four radial incisions made and flattened. 
Vitreous and hyloid vasculature removed. It was then fixed in 4% (w/v) PFA for 20 minutes, 
transferred through graded methanol concentrations/DEPC treated dH2O, into 100% glacial 
methanol, and stored at -20°C. 3 eyes (CS23/F1) were studied using in situ hybridisation.  
 
6.3.1.3 RNA extraction (Trizol extraction) 
For RNA purification from retinal tissue, TRI ReagentTM (Sigma-Aldrich, UK) was used. Table 
6.1 lists the reagents used for RNA extraction.  
Tissue was removed from -80°C and 1ml TRI ReagentTM was added immediately to the still 
frozen sample. Samples were allowed to stand for 5 minutes at room temperature to allow 
lysis to start. The solution was repeatedly passed through a needle to completely 
disaggregate the tissue. 0.2ml of chloroform was added and shaken for 15 seconds. Lysates 
were left at room temperature for 10 minutes and centrifuged at 12,000g for 15 minutes at 
4°C. Centrifugation separated the solution into 3 layers; a pink phase containing protein, an 
interphase containing DNA and an upper phase (aqueous) containing the RNA. The upper 
phase was collected into a new eppendorf (the remaining two layers are discarded). To 
precipitate the RNA, 0.5ml isopropanol and 1µl glycogen was added, mixed and left at room 
temperature for 15 minutes. The sample was centrifuged at 12,000g for 10 minutes at 4°C so 
that a pellet forms. Supernatant was discarded and pellet washed with 1ml 75% Ethanol 
before vortexing and centrifuging again at 7,500g for 5 minutes at 4°C. Supernatant was 
poured off and the pellet was air dried to remove all ethanol. The pellet was then 
resuspended in RNAsecure and placed on a heat block at 50°C for 10 minutes to ensure 
complete resuspension. The RNA was kept on ice and the concentration measured with a 
NanoDrop® Spectrophotometer ND-1000 and NanoDrop® 1000 v3.7.1 software (LabTech 
International, UK).  
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6.3.1.4 Reverse transcription 
cDNA was transcribed using Quantitect® reverse transcription kits (Qiagen, UK), as per 
manufacturer’s instructions.  
Samples were kept on ice at all times. 1µg RNA (in 12µl) was first incubated with 2µl gDNA 
wipeout for 5 minutes at 42°C, to remove any contaminating genomic DNA. Next the reverse 
transcription master mix was added, consisting of 4µl Quantiscript RT buffer (5X), RT 1µl 
Primer mix (primers and dNTPs) and 1µl of the enzyme, Quantiscript Reverse transcriptase. 
This mix was then incubated at 42°C for 15 minutes, and then ramped up to 95°C for 3 
minutes to inactivate the enzyme. cDNA was now prepared ready for use in quantitative real 
time polymerase chain reaction (qPCR).  
 
6.3.2 Immunohistochemistry 
6.3.2.1 Primary antibodies 
αA crystallin (Santa Cruz, Sc-22743), αA crystallin (abcam, ab14821), Ki67 (Vector labs, 
vpk451), CD44 (AbD Serotec MCA89T), Nestin C-20 (Santa Cruz, Sc-21247). All used at a 1:200 
dilutions. CRALBP, GS, vimentin and GFAP as per Table 2.1.  SOX9 was a gift from Dagmar 
Wilhelm, University of Queensland, Australia.   
 
6.3.2.2 Antigen retrieval 
Mild antigen retrieval was required for anti-CD44 labelling of foetal sections. Sections were 
dried overnight under a fan and washed in PBS to remove OCT. They were then placed in a 
solution of 90% glycerol (molecular grade, Sigma, UK), 10% 0.01M citrate buffer pH6.0, and 
heated to 95°C in a microwave for 5 minutes. Allowed to cool for 30 minutes and washed in 
PBS prior to immunohistochemistry.  
 
6.3.2.3 Flatmount 
Whole retinas were incubated in flatmount block (1% (w/v) BSA, 0.5% (v/v) TritonX-100 /PBS) 
for 2 hours at room temperature. They were then transferred into flatmount block plus 
primary antibody and left over night at room temperature on a mild shaker. Tissue was 
washed 3 times, 40 minutes each wash in flatmount block at room temperature, and it was 
next incubated in secondary antibody, (diluted in flatmount block), for 3 hours at room 
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temperature. Finally tissue was washed overnight at room temperature in excess whole 
mount block.  4 radial incisions were made in the retina to allow the tissue to flatten on a 
slide. They were then mounted in mowiol and coverslipped. Imaged using an Olympus 
dissection stereo microscope (SZX16) with an Olympus fluorescent lamp (U-RFL-T), fitted with 
a Hamamatsu camera (C4742-95) and Simple PCI software v6.6. 
6.3.2.4 Sections 
Both fluorescent and HRP-DAB immunohistochemistry was carried out as previously 
described in chapters 2.3.3 and 2.3.4. Sections were dried for 2 hours under a fan before 
blocking was started/or antigen retrieval if necessary. 
 
6.3.3 Quantitative Real Time Polymerase Chain reaction (qPCR) 
cDNA from foetal retina samples were used. SYBRTM Green (Qiagen, UK) was used for qPCR 
analysis.  
SYBRTM Green I is a cyanine dye that when bound to DNA will absorb light at ~497nm and 
emit green light at 520nm. It is used as a measure of double stranded DNA production. 
SYBRTM Green preferentially binds to double stranded DNA, therefore as the PCR progresses 
the light emitted is proportional to the amount of double stranded DNA amplified.  
1µl cDNA was mixed with 43.75µl Power SYBRTM (Qiagen, UK) and 0.6µM of both forward and 
reverse primers in dH2O to a total volume of 87µl. 20µl of this master mix was loaded into 
each of three wells in a 96 well PCR plate, so that each gene was checked in triplicate per 
sample. The primers used are listed in Table 6.2. Beta Actin (ACTB) was used as an 
endogenous baseline control for each sample run. The PCR reaction was loaded into a BioRad 
DNAEngine® Peltier Thermal Cycler (BioRad, UK) and run with the cyclic conditions listed in 
Table 6.3.   
Primer pairs were checked for efficiency using the stage 3 of the PCR sequence (Table 6.3) 
and run with a whole foetal (CS23) retina cDNA sample. Primers were checked that they had 
a strong peak at a single dissociation temperature; multiple peaks showed multiple PCR 
product formation and non-specificity of primers. Primer dimer formation can also be 
assessed. Primers were redesigned if multiple products or primer dimers were found.  
Collected data was analysed using DART-PCR software,487 data sets for genes of interest were 
standardised using ACTB.  
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6.3.4 Differential gene display 
GenefishingTM DEG premix kit (Seegene Inc, Korea) was used to carry out differential gene 
display.  
GenefishingTM DEG premix kits are designed to identify differentially expressed genes 
between two or more nucleic acid samples. The process consists of three steps (ACP; 
annealing control primer). 
Step 1: Reverse transcription creates first strand cDNA, the 3’ end core portion of the dt-
ACP1 primer used contain a poly-T tail which will bind to the poly-A tail of the mRNA 
transcripts. The first strand cDNA therefore bears the universal sequence of dT-ACP1 at its 5’ 
end.  
Step 2: The first strand cDNA is mixed with arbitrary ACP (5’ primer) and dt-ACP2 (3’ primer). 
The 3’ end core portion, 10-mer, of the arbitrary ACP consists of a hybridising sequence that 
is sufficiently complimentary to a region on the first strand cDNAs. The first stage of the PCR 
sequence is conducted under conditions that allow only the arbitrary ACP to anneal with its 
3’ end core to the first strand PCR.  The conditions used do not allow the binding of the 3’ 
end core portion of dT-ACP2 to anneal to first strand cDNA. The result is that second strand 
cDNA is synthesised that bears the complementary sequence of the universal sequence of 
dT-ACP1 on its 3’ end and the universal sequence of the ACP on it 5’ end.  
Step 3: The PCR then enters a third stage, which has higher stringency conditions that allows 
both dT-ACP2 and the arbitrary ACP to bind to the 3’ and 5’ ends (generated in steps 1 and 2) 
respectively. These annealing events exclusively involve the universal sequences of the two 
primers. This results in amplification of the targeted PCR products only.   
 
6.3.4.1 Primers 
Refer to Table 6.4 for a full list of primers. 
 
6.3.4.2 Reverse transcription 
Reverse transcription was carried out using Quantitect® Reverse transcription kit (Qiagen, 
UK) with the following adaptations; the RT primer mix was replaced with the RT primer 
(10µM dt-ACP1) supplied with GenefishingTM DEG premix kit (Seegene Inc, Korea), 2mM 
dNTP’s (Biolabs, UK) and 0.5µl RNase inhibitor (40U/µl RNAaseOUT, Invitrogen, UK).  
144 
 
The same method was used for RNA extracts from presumptive macula and peripheral retina. 
Total RNA from Trizol® extraction was first treated to eradicate contaminating DNA; 
911.25ng RNA was incubated with 7X gDNA Wipeout Buffer, in a total of 7.5µl, for 5 minutes 
at 42°C. 2ul of 10µM dt-ACP1 was added on ice and incubated for 3 minutes at 80°C. On ice 
4µl 5xQuantiscript RT buffer, 0.5µl RNaseOUT, 5µl 2mM dNTP and 1µl Quantiscript Reverse 
transcriptase is added and the mix incubated at 42°C for 90 minutes. It was heated to 94°C 
for 2 minutes to inactivate the enzyme. cDNA is now prepared.  
 
6.3.4.3 GenefishingTM PCR 
The cDNA preparation was diluted to a concentration of 45.5ng/7µl for the two regions 
separately. 7µl of this cDNA was mixed 2µl of one of the 20 annealing control primer (5µM 
ACP [3’ primer]), 1µl 10µM dT-ACP2 (3’ primer) and 10µl 2X SeeAmpTM ACPTM MasterMix 
(Seegene Inc, Korea). The PCR was then run following the cyclic conditions in Table 6.5. 10µl 
of the resultant 20 PCR products from presumptive macula and 20 PCR products from 
peripheral retina was run on a 2% agarose gel containing ethidium bromide. PCR products 
from presumptive macula and peripheral for each individual ACP were run in adjoining wells 
to ease comparisons.    
 
6.3.4.4 Gel extraction 
Gel extraction was carried out using a GENECLEAN® Turbo kit (1102-200, MP Biomedicals, 
UK). Agarose gel pieces were weighed and 100µl of GENECLEAN® Turbo salt solution was 
added per o.1g of gel. The gel was then dissolved at 55°C for 5 minutes. The solution was 
then transferred to a GENECLEAN® Turbo cartridge (column) and spun for 5 seconds at 
12,000rpm. Eluate was discarded and 500µl GENECLEAN® Turbo wash solution was spun 
through the column at 12,000rpm for 5 seconds. Eluate was discarded and the column spun 
for a further 4 minutes to remove all residual wash solution. The column was transferred to a 
collection tube and 30µl GENECLEAN® Turbo elution solution was added directly to the 
GLASSMILK®-embedded membrane, incubated at room temperature for 5 minutes and then 
the DNA was eluted by spinning for 1 minute at 12,00rpm. DNA was stored at 4°C until 
needed. 
6.3.4.5 Ligation/Cloning/Transformation  
TOPO TA cloning kit (Invitrogen, UK) was used to clone the GenefishingTM PCR products. 2µl 
of gel extract was mixed with 1µl dilute salt solution, 2µl RNAase free water and 1µl TOPO® 
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vector. This was then left at room temperature for 15 minutes. One shot® Electroporation 
was then used to transform the bacteria. One shot® Electrocomp® cells were defrosted on 
ice, diluted 1:3 with dH2O. 40µl was transferred to a cuvette with 1µl TOPO® Cloning 
reaction. They were then electroporated at Eco1 setting on a BioRad MicroPulserTM (BioRad, 
UK). Cells were then recovered with 200µl LB and incubated in a water bath at 37°C for 1 
hour. Cells were  then plated  onto pre warmed LB agar plates with 100µg/µl ampicilin, 
inverted and incubated at 37°C overnight. Colonies were picked and grown up in 4ml LB plus 
ampicillin, overnight shaking vigorously at 37°C.  
 
6.3.4.6 Extraction of plasmid DNA 
1ml of culture medium was spun at 14,000rpm. LB was aspirated off completely. 100µl 
solution 1 (50mM Glucose, 25mM Tris HCL pH8.0, 10mM EDTA) was added and vortexed to 
resuspend the pellet. 200µl of solution 2 (0.2M NaOH, 1% SDS) was added and incubated on 
ice for 5minutes to lyse the bacteria. Removed from ice, solution 3 (60ml KoAC, 11.5ml glacial 
acetic acid, 28.5ml H2O) was added to stop lysis. The tubes were then inverted numerous 
times and centrifuged for 2minutes at 14,000rpm. The aqueous phase was transferred to a 
new eppendorf and the rest discarded. 1ml of glacial ethanol was added to precipitate the 
DNA. This was centrifuged for 7 minutes at 14,000rpm, the ethanol was poured off from the 
resulting pellet. The pellet was washed with 70% ethanol and further spun for 15seconds at 
14,00rpm. The ethanol is aspirated off completely and the DNA pellet resuspended in 100ul 
dH2O at 55°C for 10 minutes. DNA was then stored at 4°C.  
 
6.3.4.7 Sequencing protocol 
Sequencing was carried out using a Big Dye 3.1 cycle sequencing kit (#4336917, Applied 
Biosystems, UK), 1µl of DNA was added to 0.5µl Big Dye reaction mix (Applied Biosystems, 
UK), 2µl Big Dye buffer (Applied Biosystems, UK) and 6.5µl of primer (at 0.25µM 
concentration). The primer sequences used are; M13 Forward (-20) 5'GTAAAACGACGGCCAG-
3', and M13 Reverse 5'-CAGGAAACAGCTATGAC-3'. The mix was run (cyclic conditions, Table 
6.6) on a BioRad DNAEngine® Peltier Thermal Cycler (BioRad, UK).  
The plasmid DNA was cleaned using Genetix genCLEAN 96 well Dye terminator removal plate 
plates (Genetix) prior to sequencing. genCLEAN plates were brought to room temperature. 
They were spun at 910g for 5 minutes to remove water from wells. 100µl dH2O is spun 
through the plates at 910g for 5 minutes to wash the gel. 20µl of Plasmid DNA was added to 
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the well and centrifuged at 910g for 5 minutes and collected in a sequencing plate. The 
cleaned DNA is then run through an Applied Biosystems HITACHI 3730 DNA analyser (Applied 
Biosystems, UK) and sequences determined. 
 
 6.3.4.8 Gene identification 
Sequences were viewed using DNASTAR® Lasergene 8 (DNASTAR®, UK). The primer sets used 
and vector sequence were located. Sequence data only from the insert was run through NCBI 
BLAST® to determine gene origin.  
 
6.3.5 In situ hybridisation 
6.3.5.1 Probe manufacture 
6.3.5.1.1 Primers /PCR 
Optimal annealing temperature for the primers was established using a gradient block in the 
thermal cycler.  
Cyp26a1 primers used were; forward, 5' TGTGTGTGTCTAGAACAAGCAGCGCAAGAAGGTGA 3' 
and reverse, 5' TGTGTGTGCTCGAGATTGTAGGAGGTCCATTTAGAAGC 3'. The product length 
was 1052bp. 
The gene product was amplified using the cyclic conditions listed in Table 6.7 with a BioRad 
DNAEngine® Peltier Thermal Cycler (BioRad, UK). 
cDNA was run on a 0.9% agarose gel, the PCR product band was isolated from the gel and 




TOPO vector kit was used as previously described in chapter 6.3.4.5. Bacteria were grown on 
agar/amp plates and colonies picked and grown up as previously described. 
 
6.3.5.1.3 Sequencing  
Sequencing was carried out as per section 6.3.4.7.  
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The sequence results were viewed using DNASTAR® Lasergene 8 (DNASTAR®, UK) and the 
orientation of the insert established.  
 
6.3.5.1.4 Extraction of plasmid DNA 
Qiagen Plasmid Midi Kit (#12143, Qiagen, UK) was used. Two columns were run to extract 
more plasmid DNA. Samples were run as per manufacturer’s instructions.  
0.2ml of culture medium was incubated overnight in 250ml LB plus 100µg/µl ampicillin, at 
37°C with vigorous shaking. Cells were harvested by centrifuging at 6000g for 15 minutes at 
4°C. The pellet was resuspended in 4ml Buffer P1 (50mM Tris-Cl pH8.0, 10mM EDTA, 
100µg/ml RNase A), then lysed at room temperature with 4ml Buffer P2 [200mM NaOH, 1% 
SDS (w/v)] for 5 minutes. Next 4ml of chilled Buffer 3 (3.0M potassium acetate pH5.0) was 
added to the lysate and mixed thoroughly. The lysate was then immediately poured into a 
QIAfilter cartridge and incubated for 10 minutes at room temperature. During this incubation 
a QIAGEN-tip 100 was equilibrated with 4ml of Buffer QBT [750mM NaCl, 50mM MOPS 
pH7.0, 15% isopropanol (v/v), 0.15% Triton X-100 (v/v)]. The lysate was then passes through 
the QIAfilter into the equilibrated QIAGEN-tip 100. Once the lysate has entered the resin 
through gravity, wash the QIAGEN-tip twice with 10ml Buffer QC (1mM NaCl, 50mM MOPS 
pH7.0, 15% isopropanol (v/v). The DNA was eluted from the column using 5ml Buffer QF 
(1.25M NaCl, 50mM Tris-Cl pH8.5, 15% isopropanol (v/v)). The DNA was then precipitated 
out of solution with 3.5ml of room temperature isopropanol and centrifuged at 15,000g for 
30 minutes at 4°C, and the supernatant poured off. The pellet was washed with 2ml of 70% 
ethanol and centrifuged for a further 10 minutes at 15,000g. The supernatant is poured off 
and the pellet air dried at room temperature.  The pellet was then resuspended in 100µl of 
TE (10mM Tris-Cl pH8.0, 1mM EDTA).  
 
6.3.5.1.5 RNA probe protocol 
The plasmid was first linearised. Digested using Xho1 (New England Biolabs, UK) for 2 hours 
in Buffer 2 plus BSA (x100) (New England Biolabs, UK). 
The plasmid DNA underwent a cleanup step. To the 100µl of plasmid DNA in TE; 1µl 
proteinaseK, 3µl 6% (w/v) SDS, was incubated for 30 minutes at 55°C. 100µl of TE pH8 was 
added and 200µl phenol are added and the tube shaken. Next 200µl chloroform was added 
and the tube centrifuged for 5 minutes at 13,200rpm. The top phase was removed and kept. 
A further 200µl chloroform was added to the removed top phase and spun for a further 5 
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minutes at 13,200rpm. The top phase was again removed and kept. To this 30µl 3M sodium 
acetate and 500µl of 100% ethanol are added. Kept at -80°C for at least 1 hour. Spun for 5 
minutes at 13,200rpm and discarded the supernatant. Washed with 70% ethanol.  Spun for a 
further 5 minutes. The pellet was air dried and the DNA dissolved in 50µl dH2O.  
Next 5µl of the template DNA was added to 2µl 10X DIG mix, 2µl DTT and 2µl of Sp6 (Roche, 
UK) and 6µl dH2O. This was incubated at 37°C for 2 hours. 3µl of EDTA was added to stop the 
reaction and the probe was diluted in 80µl dH2O and stored at -80°C.  
 
6.3.5.2 In situ hybridisation protocol 
Retinas stored in glacial methanol were put through graded methanol concentrations to 
DEPC treated dH2O. Washed with PBT (DEPC treated) for 10 minutes. They were then 
partially digested using 1/100 ProteinaseK (Roche, UK) in 6.6% (w/v) SDS. Digestion was then 
stopped by fixation for 4 minutes with a 4% (w/v) paraformaldehyde and 1% (v/v) 
glutaraldehyde solution in PBS. Retinas were the washed in PBT-DEPC for 10 minutes. 
Retinae were then covered in Hybridisation buffer (5ml Hybridisation buffer salts [2M NaCl, 
100mM Tris HCl, 50mM NaH2PO4, 50mM Na2HPO4], 25ml formamide, 5g dextran sulphate, 
0.2mg/ml tRNA, 1ml denhardts solution, 16ml dH2O) and placed at 65°C for 10 minutes. 
Hybridisation buffer plus 1/1000 probe was pre-warmed to 65°C for 5 minutes and the retina 
added, this was then incubated at 65°C overnight. 
Wash buffer (50% (v/v) formamide, 1xSSC, 0.1% (v/v) Tween20) is preheated to 65°C, the 
probe was removed and washed 3 times for 20 minutes at 65°C. Then at room temperature 
the retina was washed 2 times, 20 minutes each, in 1xMABT (58g Maleic acid, 44g NaCl, 
38.5g NaOH, 5ml Tween20 in 5L dH2O). The retina were then incubated in block (8g blocking 
reagent [Roche, UK], 20% sheep serum, 1.25X MABT/dH2O) for 20 minutes. Next into 
secondary antibody, anti Digoxigenin-AP (11093274910, Fab fragment, Roche), 1/1500 in 
block overnight at room temperature. Retinas were washed in 1xMABT repeatedly 
throughout the day (overnight for better background results). They were then washed in 
staining buffer (5.84g NaCl, 12.11g Tris Base in 1l dH2O, pH9.0) for 10 minutes, prior to being 
incubated in staining solution to develop the stain. Staining solution (6.5ml staining buffer, 
24.5µl BCIP, 37.8µl NBT, 700µl 1M MgCl, 14µl Tween20 and toped up to 14ml total volume 
with 10% (w/v) PVA) was added and left on overnight at room temperature and removed 
once the stain has developed. Staining is stopped by washing with staining buffer repeatedly 
and leaving overnight at room temperature to reduce background. Retina could then be 
mounted on slides in 100% glycerol and coverslipped. Imaged using an Olympus dissection 
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stereo microscope (SZX16) with an Olympus fluorescent lamp (U-RFL-T), fitted with a 
Hamamatsu camera (C4742-95) and Simple PCI software v6.6.  
 
6.3.6 Protein lysate analysis 
6.3.6.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
The mini-gel system Protean II (BioRad) was utilised for SDS-PAGE and set up as per 
manufacturer’s instructions. A 10% separating gel was used which consisted of; 3.34ml 
Acrylamide: bis-acrylamide (37.5:1) , 2.5ml 1.5M Tris pH8.8, 4ml dH2O, 100µl 10% SDS, 80µl 
10% APS and 4µl TEMED. The stacking gel used (5%) consisted of; 0.75ml acrylamide: bis-
acrylamide, 0.63ml 1M Tris pH6.8, 3.4ml dH2O, 50µl 10% SDS, 75µl 10% APS and 10µl TEMED. 
The gels were left to polymerise before use. 20μl of boiled lysate (lysed in 2X sample buffer 
with DTT) were loaded per well, with a low (97, 66, 45, 30, 20.1 and14.4 kDa, GE Healthcare) 
molecular weight marker loaded into an adjacent well. The gel tank chamber was topped up 
with running buffer (25μM Tris, 0.1% SDS, 192mM glycine) and the gel was run at constant 
amperage of 15mA for the stacking gel and 30mA for the separating gel.  
 
6.3.6.2 Western Blotting 
Following SDS-PAGE the proteins were transferred onto Whatman protran nitrocellulose 
membrane using a BioRad semi dry transfer cell. Gels were then equilibriated in transfer 
buffer (25mM Tris, 192mM glycine, 20% methanol) for 10 min. The gel was loaded into the 
semi dry transfer cell with 5 sheets of filter paper and the nitrocellulose membrane (all 
soaked in transfer buffer) below, and a further 5 sheets of soaked filter paper above. Protein 
transfer took 30 min at a constant 12V. Next the membrane was stained with 0.1% (w/v) 
ponceau red (in 5% acetic acid) to verify successful protein transfer and identify the position 
of the molecular markers. 
 
6.3.6.3 Immunodecoration 
The nitrocellulose membrane was incubated in block (1% (w/v) Bovine Serum Albumin 
(BSA)/0.2% TritonX-100/0.1% Tween-20 in TBS) for 2 hours at room temperature. The 
primary antibody was diluted 1:5000 in block and the membrane incubated for 2 hours at 
room temperature. The membrane was then washed twice, each 10 min, in block. They were 
then incubated in secondary (HRP conjugated) antibody (diluted in 1% (w/v) BSA/ 0.2% 
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TritonX-100/0.1% Tween-20 in PBS). The membranes were then washed in 0.2% TritonX-
100/0.1% Tween-20 in TBS twice, each 10 min and a final wash in TBS.  
Enhanced chemiliminescence (ECL) was then used to detect the HRP conjugated secondary 
antibody. The membrane was placed in 10ml ECL mix/membrane (5ml of each lumi-light 
western blot substrate solution, Roche) for 5 min. Excess solution was removed and the 
membrane placed in clingfilm and exposed to film. 
 
6.4 Results: 
6.4.1 Markers of the mature macula can be found in foetal retina 
The proteomic data lead to the identification of new markers of the adult macula. We 
investigated whether the expression of any of these proteins could be used to identify the 
presumptive macula in development.  
GFAP, LDHB, αB crystallin and αA crystallin, shown in chapters 4 and 5, mark two sub-
populations of Müller cells at the adult macula. GFAP, LDHB and αB crystallin showed no 
expression in foetal retina, at any time point between CS19 and F2. However, αA crystallin 
which specifically marked foveal Müller cells, was expressed. Flat mount retina preparations 
showed that αA crystallin was expressed in a single circular ‘spot’ temporal to the optic nerve 
(arrow head in Fig. 6.3). There was also a ring of αA crystallin expression circling the optic 
nerve head. The inferior nasal edge of the optic nerve head always had a triangular pattern 
of expression of αA crystallin (arrow in Fig. 6.3). CS19 showed expression at the optic disc but 
no expression in temporal retina. Some dispersed single spherical cells expressed αA 
crystallin at CS19 (Fig. 6.4 A), however upon further investigation with retinal cross sections, 
these cells were within the vitreous and co-label with Iba1 (data not shown), showing that 
they were contaminating microglial cells from the vitreous. The αA crystallin ‘spot’ in 
temporal retina was first expressed at CS20 (50 days) (Fig. 6.4 B).  
The ‘spot’ of αA crystallin expression was present through development to F2 (later stage 
points not currently accessible for analysis). The ‘spot’ remained consistent in size in relation 
to the optic disc, showing that expression does not spread throughout the retina and 
remained localised (Fig. 6.4 B-F). Expression of αA crystallin was restricted to the 
fovea/central macula of the adult retina, suggesting that there is direct correlation between 
the cell population at the developing macula and the Müller cell of the adult macula. This 
means, we have discovered a marker for an area in the embryonic retina that clearly relates 
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(spatially and biochemically) to the centre of the adult macula. For the sake of simplicity and 
the purpose of this thesis we will refer to the αA crystallin positive area as “presumptive 
macula”.   
In summary we have found a novel marker of the presumptive macula in development. The 
expression of this marker, at the start of the 7th week of gestation, is prior to any other 
known marker to date. It is expressed prior to the differentiation of ganglion cells, the first 
cell type to differentiate in the human retina. 
 
6.4.2 A subset of progenitor cells express αA crystallin at the 
presumptive macula 
Specific localisation of αA crystallin to a single spot in temporal retina was confirmed in cross 
sections (Fig. 6.5 A-F), no αA crystallin was found in peripheral retina (Fig. 6.5 C), and a small 
population of cells was found adjacent to the optic nerve (Fig. 6.5 F). Expression of αA 
crystallin was also confirmed in lens tissue (Fig. 6.5 D), αA crystallin is known to be highly 
expressed in the lens as previously stated, and therefore antibody reactivity in the lens acts 
as a positive control for the antibodies used. SDS-PAGE followed by western blotting was also 
carried out to confirm the specificity of the antibodies used; a band corresponding to the 
molecular weight of αA crystallin, ~19.9kDa, was present (Supplementary Fig. 2).  
Cross sections of retina revealed that the αA crystallin positive cells span the entire depth of 
the retina (Fig. 6.6 A-L). This morphology was similar to that of neural epithelial progenitor 
cells. αA crystallin co-stained with neural progenitor markers vimentin (Fig. 6.7 A-H) and 
nestin (not shown) in developing retinas from CS20 to F2. Vimentin and nestin positive neural 
epithelial progenitor cells of the peripheral retina did not express αA crystallin. This means 
that there was a subpopulation of the neural epithelial progenitor cells at the presumptive 
macula that express αA crystallin.  
To test whether the αA crystallin expression might have been a response to higher levels of 
proliferation in the presumptive macula compared to the peripheral retina, an anti-Ki67 
antibody was used to determine the numbers of proliferating cells. However, it would appear 
that there was no difference in the number of Ki67 nuclei found between central (Fig. 6.8 A) 
and peripheral retina (Fig. 6.8 B), or at the optic nerve (Fig. 6.8 C), but further quantitative 




6.4.3 Müller cell differentiation at the presumptive macula 
We found αA crystallin in the adult retina is expressed in Müller cells (chapter 5). However, 
CS20 in the human retina is prior to cell specific differentiation, and through lineage tracing it 
has been shown that Müller cells are among the last cells in the retina to differentiate,421 so 
the question arises, what cell type expressed αA crystallin in the presumptive macula?  
We have used immunohistochemistry with antibodies against known Müller cell markers to 
establish what cell type expressed αA crystallin.  
In foetal retina, parallel sections showed that αA crystallin was expressed in the same region 
as a localised expression of CRALBP, an established mature Müller cell marker (Fig. 6.9 A and 
B). Other parallel sections were however negative GS and GFAP (known Müller cell markers, 
data not shown). CRALBP was expressed in the same restricted retinal area as αA crystallin, 
through until foetal stage F2. It has previously been reported by Walcott and Provis423 that 
CRALBP expression in neural epithelial progenitor cells are present in central retina at 16WG 
and then spreads radially with development, however we have now shown that this 
expression actually starts much earlier. CD44, shown to be a marker of progenitor cells 
destined to become Müller cells77 and a marker of mature Müller cells,77 was also expressed 
in the presumptive macula (arrow head in Fig. 6.9 C). Both CRALBP and CD44 were expressed 
in cells with morphology similar to that of αA crystallin, the neural epithelial progenitor cells 
(Fig. 6.9 D and E).   
Vimentin expression was significantly higher at the presumptive macula compared to 
peripheral progenitor cells (Fig. 6.8). Vimentin labels both neural epithelial progenitor cells 
and adult mature Müller cells, whether vimentin is upregulated during Müller cell maturation 
is unknown, but this could be an explanation for the regional differences seen. 
All neural epithelial progenitor cells in the outer neuroblastic layer of the developing retina 
express SOX9. Upon differentiation expression is suppressed,488 except in Müller cells where 
SOX9 expression has been found in adult mice.488 The cells at the presumptive macula in an 
F2 retina expressed SOX9 in a single layer of nuclei in the outer neuroblastic layer 
(arrowhead in Fig. 6.9 F), surrounded by cells negative for SOX9. All cells of the outer 
neuroblastic layer in the periphery were positive for SOX9 (arrowhead in Fig. 6.9 G).  
Our data supports the theory that Müller cells start to mature first at the developing macula, 
prior to ganglion cell and photoreceptors as previously thought. The progenitor cells with a 
determined Müller cell fate persisted in expressing nestin, indicating that they are not fully 
matured Müller cells and maintain their ‘stemness’.  
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6.4.4 Retinoic acid signalling plays a role in macula position 
determination 
αA crystallin is not a known morphogen or transcription factor. It is unlikely to play a direct 
role in the determination of the presumptive macula. However using the expression of αA 
crystallin as a marker of presumptive macula made it possible to compare sample regions, 
and determine more fundamental factors involved in the specification of this region.  
Fresh tissue was dissected from temporal retina where we have previously identified the 
presumptive macula, and peripheral retina from between the presumptive macula and optic 
nerve was isolated from embryos. qPCR using primers specific for αA crystallin, CRYAA (using 
ACTB as a housekeeping gene to baseline against) was used to confirm accurate dissection of 
the two regions, from a CS20 embryo (the time point at which αA crystallin protein was first 
expressed). mRNA from the two regions of the same retina was used for a differential gene 
display comparison using the GenefishingTM PCR (chapter 6.3.4). The differential gene display 
PCR revealed 32 PCR products that differed in expression (arrow heads in 6.10 A-D). 
Sequencing of these PCR products identified 23 sequences, of which 14 genes were 
identified; 12 upregulated within the presumptive macula and 2 downregulated (Table 6.8). 
One of the genes identified stood out from the rest; cellular retinoic acid binding protein 1, 
CRABP1, known to mediate transport of retinoic acid derivatives during retinoic acid 
signalling. The differential expression of this protein between presumptive macula and 
peripheral retina was confirmed using qPCR on tissue from 5 embryonic/foetal retinae of 
stages; CS20, CS21, CS22, CS23 and F1 (including the CS20 retina used for differential gene 
display). For each sample, qPCR for CRYAA was used to confirm correct dissection (Fig. 6.11 A 
and B).  
Retinoic acid gradients are known to be formed through degradation sinks where 
degradation enzymes limit the amount of retinoic acid. The expression levels of degradation 
enzymes can be spatially regulated at a transcriptional level. CYP26A1, CYP26B1 and CYP26C1 
are known retinoic acid degradation enzymes and have been shown to play a key role in 
retinoic acid gradient formation. CYP26B1 was not found in the developing human retina 
with qPCR (data not shown); however CYP26A1 and CYP26C1 were both found to be 
significantly differentially expressed between the presumptive macula and the peripheral 
retina (Fig. 6.11 C and D). Expression of both CYP26 enzymes was significantly increased in 
the presumptive macula (Fig. 6.11 C and D), with an average fold change of 8.7↑ for 
CYP26A1 (P = 0.002) and 20.3↑ (P = 0.00004) for CYP26C1. Whole mount In situ 
hybridisation revealed that CYP26A1 expression at a single ‘spot’ in temporal retina at F1 
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(Fig. 6.11 E), this ‘spot’ correlated with the CRYAA expression pattern (Fig. 6.11 F). A parralel 
negative control (Fig. 6.11 G) was carried out for the in situ hybridisation, where the mRNA 
probe was not included. This demonstrated that the 'spot' seen was not background staining.  
A sink of retinoic acid must therefore exist at the presumptive macula, suggesting that a lack 
of retinoic acid might play a role in the determination of macula retina in the human retina.  
 
6.5 Discussion: 
The αA crystallin expression at the presumptive macula was confirmed using two antibodies 
from different suppliers, and both antibodies identified exactly the same expression pattern. 
This antibody specificity, along with the lens tissue acting as an internal positive control for 
each eye studied confirmed that the antibody staining represents protein distribution. 
Further to that western blots show the same banding pattern with both αA crystallin 
antibodies in adult human retina and foetal retina; a band was present at ~19.9kDa, the 
expected molecular weight of αA crystallin. An additional band was also present in the adult 
tissue western blot, at ~21kDa, which could correspond to αB crystallin (Supplementary Fig. 
2). The manufacturers of the two antibodies state that there is a possibility of binding with 
αB crystallin. As a separate antibody directed against αB crystallin was also tested in both 
adult and foetal tissue, we know αB crystallin is expressed in adult retina and not in foetal, 
this could explain the presence of the 21kDa band only in the adult tissue western blot. The 
αA crystallin antibodies did not however colocalise with the αB crystallin expression in the 
adult macula, this might be due to the antibody being more specific for 
immunohistochemistry; during SDS-PAGE protein conformations are changed, this could 
allow the binding sites of αB crystallin to which the αA crystallin antibodies recognise, to 
become exposed. The higher molecular weight bands in all blots might be due to binding of 
other small heat shock proteins through the conserved heat shock domain. Further evidence 
of antibody specificity is that αA crystallin was seen increased in the macula of the adult eye 
with comparative proteomics (Table 4.4), and qPCR confirmed increased levels of CRYAA 
mRNA in foetal presumptive macula (Fig. 6.11 A), both correlating with the 
immunohistochemistry data.  
The tissue used was from aborted embryos, collected by the commonly used vacuum-
aspiration abortion method. This method could induce a stress response in the harvested 
tissue, and as αA crystallin has been shown to be upregulated under stress it is possible that 
the crystallin expression represents focused stress on the retina due to the method. 
However, the consistent expression pattern seen between, and within gestational ages (αA 
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crystallin expression was confirmed with at least three embryos per gestational age), 
indicates clearly that this is not a random stress response. Other markers also correlated with 
the αA crystallin expression in the foetal tissue and these markers which are not known 
stress response proteins, making it unlikely again that expression patterns here are purely a 
postmortem stress response.  
We therefore believe that we have discovered a new marker for the developing macula, one 
which for the first time does not rely upon general cell differentiation initiating in central 
retina, and one that is specific for a population of cells found purely in central retina and 
which can be traced to expression patterns in adult tissue. Furthermore this marker labels 
the presumptive macula prior to ganglion cell differentiation. Considering optic fissure 
closure only occurs at CS18 (in GW6), our definition of a specific macula protein at the 
presumptive macula at CS20 is remarkably early (Fig. 6.12).  
It was surprising that we found Müller cell markers in epithelial progenitor cells starting at 
7WG. Previous lineage tracing identifies Müller cells as the last cell type to differentiate 
within the developing retina.421 We found neural epithelial progenitor cells express mature 
Müller cell markers whilst still maintaining their pluripotant state in the human retina. It has 
been argued by other authors that Müller cells and neural epithelial progenitor cells are 
overlapping cell populations,423 and that the progenitor cells do not necessarily differentiate 
into Müller cells, but merely mature into them. There is evidence for that scenario at the 
macula of the human eye; the neural epithelial progenitor cell morphology is similar to that 
of Müller cells, spanning the retinal depth with end feet forming the retina limits. It has also 
been shown that mature adult Müller cells have the capability of giving rise to neuronal 
progenitors. The macula progenitor cells express vimentin at higher levels than the 
peripheral progenitor cells which could be an implication of a switch to Müller cell fate, 
accompanied by the expression of αA crystallin, CD44 and CRALBP and the persistence of 
SOX9. This suggests that a Müller cell fate switch occurs in the macula early in development.  
Co-localisation of the retinoic acid degradation enzymes CYP26A1 and C1 and αA crystallin in 
the retina has been identified. This presumed retinoic acid free region correlates with the 
area centralis and visual streak in other mammals and birds. However, the functional role for 
this lack of retinoic acid, or for retinoic acid signalling in peripheral retina is poorly 
understood. Two distinct phases of retinoic acid signalling have been identified in murine and 
chick model systems; an early phase necessary for optic cup formation (mouse E9.5-10.5), 
and a later phase essential in development of the anterior structures (mouse E10.5-13.5). A 
lack of the retinaldehyde dehydrogenase enzymes that generate retinoic acid, RALDH3 and 
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RALDH1, leads to complete overgrowth of the mesenchyme during cornea and eye lid 
formation due to subsequent loss of retinoic acid in the optic cup.467, 470, 489 However a 
disruption in retinoic acid gradients across the retina during development has topologic 
effects on cell types. VAX2, along with TBX5, is essential in patterning the retinoic acid 
metabolising enzymes of the retina.490 An overexpression of VAX2 influences the topographic 
expression of rod photoreceptors in chick,491 and has been found to be required for 
asymmetric expression of cone marker genes in the vertebrate retina (mouse and medaka 
fish studied).492 The precise molecular mechanisms of cone-specific gene expression still 
remains elusive but is heavily studied.493-500 Retinoic acid has been shown to play an 
important role in cone photoreceptor determination. It has been shown that the retinoid X 
receptor, RXRγ, and the thyroid hormone receptor, THRB, can act together and repress 
expression of the S-opsin gene in dorsal retina of the mouse.496, 498 Retinoic acid receptor-
related orphan receptorβ (RORβ) has also been shown to act as a transcriptional activator of 
S-opsin, along with the cone-rod homeobox transcription factor, CRX.499 RORα also acts as a 
transcriptional activator of the S-opsin, M-opsin and cone arrestin in mouse retina, with 
reductions in expression levels in knock-out mice.  
Retinoic acid has also been shown to promote the formation and survival of rods from 
cultured retinal progenitor cells of developing rate retina501-503 and embryonic stem cells.504 
Studies in zebrafish have shown an increase in rod density and correlating decrease in cone 
density after endogenous retinoic acid exposure,505 Stevens and colleagues have also shown 
that this change in photoreceptor mosaic is not due to selective cone death; they did 
however notice increased cell death within the inner nuclear layer, a possible downstream 
response from cone loss and inter neuron number/ratios with rods versus cones.505 This data 
supports the theory that retinoic acid is crucial in rod/cone cell fate decisions during 
development. This animal model data shows a direct link between retinoic acid signalling in 
the retina and photoreceptor fate decisions and thus rod/cone patterning. 
 How this relates to human and primate retina patterning is not known, but correlation 
between photoreceptor patterning and retinoic acid distribution in mouse retina and chick 
retina (i.e. a decrease in rod density correlating with the retinoic acid free central zone, and 
cone concentrations) mimics that seen in humans. 
Müller cell fate determination in neural epithelial progenitor cells prior to photoreceptor 
gene expression, in a region that correlates to a retinoic acid free zone in the retina, could 
also imply that a macular Müller cell population within the human retina influences cone 




Figure 6.1. CYP26 enzyme expression in mouse and chick retina.  
A and B: Postnatal day 0.5 retina from transgenic mice. X-gal reaction for retinoic acid 
reporter transgene indicates regions of retinoic acid (blue), while the purple bands indicate 
regions of CYP26C1 (A) and CYP26A1 (B) visualised with in situ hybridisation. A corresponding 
region of CYP26A1 is expressed in chick retina (purple strip in C), again using in situ 




Figure 6.2. Timeline of human macula development.  
Main morphological landmarks in macula development (A), and marker expression time 
points for photoreceptors and ganglion cells (B). Blue text indicates morphological 




Table 6.1: TRI REAGENTTM RNA extraction reagents 
 
Reagent Supplier [Stock] 
TRI ReagentTM Sigma, UK N/A 
Chloroform Sigma, UK 100% 
2-Isopropanol Sigma, UK 100% 
Glycogen Ambion, UK 100% 
Ethanol Hayman, UK 75% (v/v) / DEPC dH2O 
RNAsecure Ambion, UK N/A 
 
Table 6.1. TRI REAGENTTM RNA extraction reagents 
 
 
Table 6.2: qPCR primers 





















Table 6.3: Quantitative Real-Time PCR cycling conditions 
Temperature Time Purpose 
Stage 1: single cycle 
95°C 10 minutes Activates enzyme 
Stage 2: repeated 40 cycles 
95°C 15 seconds Denatures double stands 
60°C 1 minute Annealing and Elongation 
Data collection 
Stage 3: (dissociation curve) single cycle 
95°C 15 seconds Denature 
60°C 15 seconds Annealing 
Slow ramp to 95°C Records temperature(s) at which denaturing occurs 
95°C 15 seconds Full denaturing of double stands 
Data collection 
  





























dt-ACP2 (10µM) 5’-CTGTGAATGCTGCGACTACGATGGGGGTTTTTTTTTTTTTTT-3’ 
  




Table 6.5: GenefishingTM PCR cycling conditions 
Temperature Time Purpose 
Stage 1: single cycle, PCR for second strand cDNA synthesis 
Pre-heat thermal cycler to 94°C 
94°C 5 minutes Denature  
50°C 3 minutes Initial annealing temperature, only 10mer core 
sequence of arbitrary ACP will bind to first cDNA 
strand with 8-10 pair matches 
72°C 1 minute Elongation, second strand cDNA synthesised in 
one cycle 
Stage 2: repeated 40 cycle, PCR for amplifying the second-strand cDNA 
94°C 40 seconds Denatures double stands 
65°C 40 seconds Allows annealing of universal sequences of ACP 
while being stringent enough to prevent core 
sequence binding. Allows dT-ACP2 binding.  
ACP and dT-ACP2 cannot anneal to first strand at 
65°C 
72°C 40 seconds Elongation, only targeted PCR products amplified 
Stage 3: single cycle 
72°C 5 minutes Final elongation 
  




Table 6.6: Sequencing reaction cyclic conditions 
Temperature Time Purpose 
Stage1: single cycle 
96°C 1 minute Denature any double strands 
Stage 2: repeated 25 cycles 
96°C 10 seconds Denature 
50°C 5 seconds Annealing 
60°C 4 minutes Elongation 
Finished, store at 4°C 
 




Table 6.7: Cyclic conditions for CYP26A1 In situ hybridisation probe 
Temperature Time Purpose 
Stage 1: single cycle 
94°C 5 minutes Denature double strands/primer dimers 
Stage 2: repeated 40 cycles 
95°C 30 seconds Denature double strands 
59.9°C 30 seconds Annealing 
72°C 60 seconds Elongation 
Stage 3: single cycle 
72°C 10 minutes Final elongation step 
4°C as necessary Storage 
 





Figure 6.3. αA crystallin expression in temporal retina during development  
αA crystallin expression in human embryonic retina at CS22. Anti-αA crystallin antibodies 
reveal a ‘spot’ of expression in temporal retina (arrowhead). Expression is also located at the 
optic nerve rim, more pronounced to the inferionasal side (arrow). No expression is visible in 





Figure 6.4. Time course of αA crystallin expression in human embryonic retina.  
Anti-αA crystallin antibody stained embryonic and foetal retinas (A-F). Expression is found at 
the optic nerve rim in a CS19 retina but a spot is absent in temporal retina. Expression in 
temporal retina starts as CS20 (7WG) (B) and is expressed through development, CS21 (C), 
CS22 (D), CS23 (E) and F1 (F). No expression is found in peripheral retina at any time point. 





Figure 6.5. αA crystallin expression in foetal retina cross sections. 
αA crystallin expression is limited to the presumptive macula and a small region at the optic 
nerve.  Cross sections through the optic nerve (ON) and presumptive macula of CS23 eye 
globe (A). Restricted spatial expression of αA crystallin (green) in central retina (A), 
expression through all layers of the retina (B), peripheral retina shows no expression (C). The 
eye globe of an F2 foetus shows the same restricted pattern (D), expression through all layers 
of the retina (E) and no expression in the periphery. Expression at the optic nerve edge spans 
the depth of the retina also (F). αA crystallin positive lens tissue confirms antibody specificity 






Figure 6.6. αA crystallin positive cells at the presumptive macula have epithelial progenitor 
cell morphology. 
Confocal microscopy images of αA crystallin positive cells at the presumptive macula of an 
embryo CS22 (A-F) and foetus F2 (G-L); A-C, G-I are merged stacks, D-F, J-L are single slice 
images. The transient layer of chievitz is just forming at CS22 (A and D), cells of the inner 
neuroblastic layer are beginning to become disorganised and spherical (asterisks in A and D), 
whilst the outer neuroblastic layer is organising into columnar lines of nuclei with an 
elongated morphology (arrow heads in A and D). αA crystallin positive (green) cells can be 
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seen to span the entire retinal depth (arrows in B and E). Cell processes broaden and meet at 
the prospective inner and outer limiting membranes. By F2 the inner and outer neuroblastic 
layers (INBL and ONBL respectively) are fully differentiated, separated by the layer of chievitz 
(G). αA crystallin positive cell morphology remains constant through gestation, the radial 
cells persist in spanning the entire depth of the retina (arrows in H and K). Scale bars are 





Figure 6.7. Neural epithelial progenitor cells at the presumptive macula are αA crystallin 
positive in an F2 retina.  
Lens tissue acts as a control for αA crystallin antibody specificity (A). The αA crystallin 
positive presumptive macula (large arrow A) and αA crystallin positive cells at the edge of the 
optic nerve (small arrow A) are present within the section. An antibody directed against 
vimentin (red) highlights neural epithelial progenitor cells throughout the retina (A and B), 
vimentin staining is stronger around the presumptive macula (B) compared to peripheral 
retina. Confocal microscopy imaging (C-H) reveals that αA crystallin (C and F) co-localises 
with vimentin (D and G), all αA crystallin positive cells stain for vimentin at the presumptive 
macula (E and H). Arrow heads highlight specific cells in a single confocal slice confirming co-
localisation (F-H). ON; optic nerve, RPE; retinal pigment epithelium, asterisk in A indicates αA 




Figure 6.8. Proliferation in the retina.  
αA crystallin expression (arrow heads, green) at the macula (A) but missing from peripheral 
(B) and is expressed in a small region at the edge of the optic nerve (C). Anti-Ki67 staining 
highlights proliferating cells (red). There was no difference in the numbers of Ki67 positive 







Figure 6.9. Muller cell marker expression at the presumptive macula. 
Immunohistochemistry revealed that αA crystallin (arrowhead in A) co-localised with 
expression of CRALBP (arrow head in B) and CD44 (arrowhead in C) at the presumptive 
macula of an F1 retina. Both CRALBP (D) and CD44 (E) positive cells had neural epithelial 
progenitor cell morphology, spanning the retinal depth (arrows in D and E). A limited 
population of the nuclei in the outer neuroblastic layer expressed SOX9 at the presumptive 
macula (arrowhead in F), while all nuclei of the outer neuroblastic layer in the periphery 




Figure 6.10 Differential gene display  
Differential gene display PCR bands (A-D). Arrow heads indicate bands selected for 




 Table 6.8: Sequenced genes from differential gene expression profiling. 
Up regulated in the presumptive macula 
 
1. CCCTC-binding factor (zinc finger protein) (CTCF), transcript variant 2 
2. cDNA: FLJ22826 fis, clone KAIA4022 
3. Cellular retinoic acid binding protein 1 (CRABP1) 
4. Chromosome 10 clone RP11-183E9 
5. Chromosome 17, clone RP11-87N3 
6. DNA sequence from clone RP11-15N12 on chromosome 6  
7. DNA sequence from clone RP11-429A24 on chromosome 10  
8. DNA sequence from clone RP1-3J17 on chromosome 6q14.3-16.2  
9. Genomic DNA, chromosome 11 clone:CMB9-65A1 
10. Isolate I9 mitochondrion 
11. Multiple endocrine neoplasia 1, (MEN1) 
12. Peroxidasin homolog (Drosophila) (PXDN) 
13. Polymerase (RNA) III (DNA directed) polypeptide H (22.9kD) (POLR3H) 
14. RAN, member RAS oncogene family (RAN) 
15. Ribosomal protein S8 (RPS8) 
16. Serine/arginine repetitive matrix 2 (SRRM2) 
17. Transmembrane protein 185A (TMEM185A), transcript variant 2 
18. Ubiquitin domain containing 2 (UBTD2) 
19. Ubiquitin specific peptidase 11 (USP11) 
20. Weakly Serine/threonine protein kinase Kp78  
 
Down regulated in the presumptive macula 
 
1. Chromosome 5 clone CTD-2073O6 
2. Diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) 
(DBI), transcript variant 1 
3. Nuclear transport factor 2 pseudogene 2 (NUTF2P2)  
 







Figure 6.11. CYP26 enzymes are concentrated at the presumptive macula.  
qPCR confirmed αA crystallin (CRYAA) expression in dissected retinal samples (A). 
Confirmation of differential gene display, using qPCR and tissue from 5 foetal eyes, CS20, 
CS21, CS22, CS23 and F1, showed CRABP1 was significantly increased in the presumptive 
macula (B). Other enzymes involved in retinoic acid signalling, CYP26A1 and CYP26C1, were 
also significantly increased in the presumptive macula (C and D). In situ hybridisation against 
CYP26A1 revealed a spot in temporal retina of an F1 foetus (arrowhead in E), similar in size 
and location to that of αA crystallin immunohistochemistry in another F1 foetus (arrowhead 






Figure 6.12. Timeline of human macula development, updated.  
αA crystallin expression plotted on the timeline of development at 7 weeks gestation (CS20). 
Blue text indicates morphological landmarks, Black text refers to marker expression and cell 
differentiation. wks; weeks.   
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7. Final discussion and Outlook 
Discussion 
This thesis has shown for the first time that there is a subpopulation of Müller cells at the 
macula of the human retina (based on biochemical expression patterns). This sub population 
of Müller cells (GFAP+, LDHB+, αB crystallin+) correlates in size and location with the retinal 
region affected clinically in MacTel type 2 (the ‘MacTel area’). Furthermore, we found in a 
MacTel type 2 postmortem sample, a loss of Müller cells specifically at the macula. This 
Müller cell loss in MacTel type 2 correlated with macular pigment loss seen in gross 
dissection, and this again correlated with the clinically affected ‘MacTel area’, which is 
demarcated by the macular pigment loss (chapters 2 and 4). Together, these findings give 
rise to a conceptionally novel role of Müller glia in retinal disease. In the case of MacTel type 
2, we propose the existence of a specific sub population of Müller cells in the macula that is 
specifically affected by the disease, possibly due to specific metabolic properties or specific 
susceptibilities to certain insults.   
This thesis has also demonstrated that the previously reported micro vascular phenotype in 
the peripheral retina in MacTel type 2 is not disease specific (chapter 3).  Instead we have 
found that with increasing age human retinae accumulate vacuoles within the basement 
membrane of the capillaries; vacuoles normally associated with disease in animal models. 
This poses the question as to whether this feature has any detrimental effect on vision or 
retinal function. It is possible that these vacuoles might be a contributing factor in retinal 
pathology with increasing age.  More importantly, this work has further confirmed that the 
vascular pathology MacTel type 2 is limited to the macula, further strengthening the theory 
of a macula specific Müller cell disease concept.  
A macula specific sub population of Müller cells not only has implications with regards to 
MacTel type 2, but could also have implications for the specificity or susceptibility of other 
macular diseases. Although a detailed study into the dimensions of the region spared from 
crystal deposit in canthaxanthin retinopathy has not been undertaken, from observations of 
published images the region spared is very similar in size and shape to the ‘MacTel area’. This 
sub population of Müller cells might also play a role in the role in other retinal diseases that 
affect the macula.  As mentioned above, it is possible that the metabolism of Müller cells in 
the macula is different from the peripheral retina. Our proteomic analysis has identified 
components from several metabolic pathways (chapter 4) and would support such a view.  
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Furthermore, in this thesis we have identified novel biochemical markers of the macula and 
fovea (chapters 4 and 5). This will be very useful in further research aimed at uncovering 
specific disease susceptibilities of the macula. 
Lastly, in this thesis we have also advanced our understating about the early embryonic 
development of the macula in humans and we have taken a first step at elucidating the 
molecular signalling mechanisms that control macula development, a process which until 
now has posed elusive.  
  
Outlook 
There are three primary questions posed from this thesis that need to be addressed; further 
characterisation of the MacTel type 2 histology, characterisation of the sub population of 
Muller cells in the ‘MacTel area’ and characterisation and mechanisms involved behind 
retinoic acid and macula development. 
1) Further characterization and confirmation of the disease phenotype of MacTel type 2. 
The donation of another sample with MacTel type 2 is needed for confirmation of the 
results in chapter 2. A donor program was established 5 years ago by Marcus Fruttiger, 
recruiting patients from the clinical groups involved in the MacTel project from all over 
the world. This program has been successful and recently a pair of eyes from a second 
clinically confirmed MacTel type 2 patient have been donated. Preliminary unpublished 
results from one of these eyes confirmed the loss of parafoveal Müller cells. Preliminary 
data also showed a degeneration of the photoreceptors in temporal parafovea, which we 
aim to correlate with clinical data that was recorded prior to death. Further analysis of 
this tissue will allow an even greater depth of understanding about the disease and 
potentially direct us towards the cause.  
 
2) Further characterisation of the sub population of Muller cells within the ‘MacTel area’ 
needs to be undertaken and more markers other than GFAP, LDHB and alpha B crystallin 
need to be established. This can be done by two approaches; firstly, the proteomic data 
reported in this thesis could still hold more information to address this. Alternatively our 
collaborators Prof. Mark Gillies and Dr. Alice Len (Save Sight Institute, University of 
Sydney, Australia), undertook a proteomic screen comparing MacTel type 2 macula versus 
periphery and control data, including analysis of the vitreous (Len et al. manuscript under 
review). They have found that the Muller cell markers were also downregulated in the 
MacTel type 2 retina, confirming our findings; furthermore an increase in these proteins 
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was found in the vitreous, implying protein release from Muller cells in the vitreous upon 
cell death. A number of other unexpected proteins were identified as up regulated in the 
vitreous of the MacTel type 2 patient, these have an expression pattern similar to those of 
Vimentin and CRALBP. As such they can be regarded as potential Muller cell proteins and 
further investigation into their distribution in the retina needs to be taken. The second 
approach could be to carry out a comparative genomic screen of the two regions 
investigated here with proteomics. This can either be conducted using qPCR or full 
genomic profiling of the regions using array techniques.  
 
3) Now that an early marker of the presumptive macula (CRYAA) has been established, 
further differentially expressed genes can be identified. Manual dissection of presumptive 
macula, which relies on a certain amount of guess work, can now be confirmed as 
accurate using a qPCR against CRYAA. So far this has given a very strong lead into 
understanding macula development (retinoic acid signalling), however a complete 
mechanism has yet to be established. The GenefishingTM kit used was based on a 20 
primer set, another 5 sets are available commercially. Obviously this method does not 
provide a complete picture of gene expression such as gene array technology, but as 
clearly demonstrated in this thesis, the method is a powerful and efficient way to identify 
differentially expressed genes from extremely small amounts of tissue, which is essential 
as only small amounts of RNA can be retrieved from the foetal eyes. Comparative gene 
profiling could also be undertaken, but to have enough material prior mRNA amplification 
steps would have to be undertaken, which can introduce bias. Again probing of the 
sample sets could be undertaken against components of the classic morphogenic 
pathways, such as WNT, NOTCH and SHH. In situ hybridization and immunohistochemistry 
could then be used to confirm distribution patterns. Temporal relationships between 
differentially expressed genes would also need to be established to be able to deduce 
possible functional relationships.  
Characterisation of the CRYAA+ cells also needs to be undertaken, the data presented in 
this thesis shows that adult Müller cells express CRYAA in the central macula, and that 
embryonic/foetal CRYAA+ cells express three mature Müller cell markers. CD44 has been 
proposed to distinguish neuronal progenitor cells from immature Muller cells.77 Therefore 
other Müller cell and progenitor cell markers (such as GLAST, NDP, GLUL) could help to 
further characterise the CRYAA+ cells.   
Working on a primate specific feature, with focus on human tissue, there are limited 
experimental options available to address function directly. Gene knock-out and 
transgenic technology, which have been instrumental in mouse developmental biology, 
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cannot be applied easily. One potential way to determine transcriptional relationships is 
to expose retinal explants to potential morphogens and use qPCR as a read out of gene 
expression changes.  
 
In further understanding the pathobiology of MacTel type 2, and the specialisation of the 
Müller cells in the ‘MacTel area’ it will hopefully be possible to inform in the future a 
therapeutic approach to treat MacTel type 2, and other macular diseases. In better 
understanding the development of the macula and the cells involved in its specialisation, it 
might also be possible to direct a regenerative stem cell approach, whereby specialised 
photoreceptors or Müller cells can be generated and transplanted into the macula, hopefully 





8. Supplementary data 
 
Supplementary Figure 1. αA crystallin expression in lens tissue.  
αA crystallin immunoreactivity (green) of the lens of a C57BL6 mouse acts as a positive 
control for the antibody (A), compared to the autoflourescence of the negative control (no 
primary antibody) for mouse lens tissue (B). αA crystallin expression in the lens from a duck 
(C) and negative control (D), and also from the  lens tissue from a chick (E) compared to the 
negative control (F) confirm specificty in avian tissue. Data from the Santa Cruz antibody is 
displayed above, however both αA crystallin antibodies colocalised with each other. Scale bar 
is equal to 100µm.  
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Morphological land marks 
CS 1  0.1-0.15 (diameter) 1 day Fertilisation, Unicellular 
CS 2  0.1-0.2 (diameter) 1.5-3 days More than 1 cell but no blastocystic cavity.  
CS 3  0.1-0.2 (diameter) 4 days Free blastocyst 
CS 4  0.1-0.2 (diameter) 5-6 days Attaching blastocyst 
CS 5  0.1-0.2 (diameter) 7-12 days Implanted but previllious 
CS 6  0.2 mm (diameter) 13 days Chorionic villi: primitive streak may appear 
CS 7  0.4 mm (length) 16 days Notochordal process 
CS 8  1.0-1.5 (length) 18 days Presomitic, primitive pit; notochordal canal; neural folds may appear. 
CS 9 1-3 somites 1.5-2.5 (length) 20 days Somites appear. Head fold present 
CS 10 4-12 
somites 
1.5-3.0 (length) 22 days Fusion of neural folds is imminent or in progress. Otic sulcus may have appeared. 
Pharyngeal arch 1 begins to be visible. 
CS 11 13-21 
somites 
2.5-4.5 (length) 24 days 
 
Rostral neoropore is in the process of closing. Otic invagination is shallow or still widely 
open. Pharyngeal arches 1 and 2 are evident. 
CS 12 21-29 
somites 
3-5 (length) 26 days 
 
Three pharyngeal arches are visible; the dorsal curvature of the body is becoming filled out 
into a smooth convexity; Caudal neuropore is closing or closed: the otic vesicles are almost 
closed but not detached; the upper limb buds are appearing, centred around a 
condensation opposite somites 8-18. After stage 12 the number of pairs of somites 
becomes increasingly difficult to determine and so is no longer used in staging. 
CS 13 30+ somites 4-6 (length) 28 days 
(4 weeks) 
All four limb buds are usually visible; otic vesicle is closed; the lens disc is generally not yet 
indented 
CS 14  5-7 (length) 32 days 
(4 weeks 
plus) 
Invagination of the lens disc but with an open lens pit; a well defined endolymphatic 
appendage; elongated and tapering upper limb buds. In some specimens the marginal 
vessel can be recognised in the upper limb bud. 
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CS 15  7-9 (length) 33 days  
(4 weeks 
plus) 
Lens vesicles are closed; nasal pits are appearing; hand plates are forming. Embryos appear 
wider than the previous stage due to growth of spinal ganglia, muscular plates and 
mesenchyme tissue in the trunk. 




The nasal pits are coming to face ventrally and to disappear from the profile view; retinal 
pigment is becoming visible externally; pharyngeal arch 2 is more massive and more 
conspicuous whereas arch 3 is receding from the surface; auricular hillocks are beginning to 
appear. Somites can be seen distinctly in the caudal part of the trunk. The marginal vein is 
distinct in the lower limb bud. 





The head is relatively larger than previously; the main axis of the trunk has become 
straighter and a slight indication of a lumbar curvature may be found; the nasal pit is 
further medial and is directed ventrally so that the nostril is not visible in profile views and 
nasofrontal grooves are distinct; the full complement of auricular hillocks is present on the 
mandibular and hyoid arches; the hand plate exhibits definite digital rays and the foot has 
acquired a rounded digital plate; surface elevations of individual somites are becoming 
limited mostly to the lumbosacral region.  
CS 18  13-17 (length) 44 days 
(6 weeks 
plus) 
The body is more of a unified cuboidal mass and both cervical and lumbar flexures are 
indicated; the limbs are longer, the digital plate of the hand is definitely notched, the elbow 
region is usually discernible. The hand plate develops crenations at the rim caused by the 
projecting tips of the individual digits. Toe rays can be identified in some specimens; eyelid 
folds are present in the more advanced embryos; a distinct tip of the nose can be seen in 
profile; auricular hillocks are being transformed into specific parts of the external ear. 
CS 19  17-20 (length) 47-48 days 
(6 weeks 
plus) 
The trunk has begun to elongate and straighten slightly; with the result that the head no 
longer forms a right angle with the line of the back of the embryo. The limbs extend nearly 
directly forward. The toe rays are more prominent but interdigital notches have not yet 
appeared in the rim of the foot plate. 
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CS 20  21-23 50-51 days 
(7 weeks 
plus) 
Details of internal structures may now be obscured from surface view because of the 
thickening mesoderm. Thus the cerebellum is no longer distinct as seen from the surface. 
The upper limbs have increased in length and become slightly bent at the elbow. The hands 
with their short stubby fingers are still far apart but they are curving slightly over the 
cardiac region and approach the lateral margins of the nose. A delicate fringe-like vascular 
plexus now appears in the superficial tissues of the head. In the temporofrontal region a 
growth centre arches over the eye and in the occipital region a second growth centre 
occurs above the ear. The edge of the plexus is approximately halfway between the eye-ear 
level and the vertex of the head 




The superficial vascular plexus of the head has spread upward to form a line at somewhat 
more than half the distance from the eye-ear level to the vertex.  
The fingers are longer and extend further beyond the ventral body wall than they did in the 
previous stage. The distal phalangeal portions appear slightly swollen and show the 
beginning of tactile pads. The hands are slightly flexed at the wrists and nearly come 
together over the cardiac eminence. The feet are also approaching each other and the toes 
of the two sides sometimes touch. 




The eyelids which have been thickening gradually are now rapidly encroaching upon the 
eyes. The formation of the auricle has progressed noticeably the tragus and antitragus 
especially are assuming a more definite form. The superficial vascular plexus of the head 
extends upwards and three-quarters of the way above the eye-ear level. The hands extend 
further out in front of the body of the embryo and the fingers of one hand may overlap 
those of the other.  
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CS 23  Full range 23-30 





The head has made rapid progress in its bending towards the erect position. The head is 
distinctly rounded out, and the cervical region and trunk are of a more mature shape. The 
eyelids may show some fusion laterally and medially but the eyes may be largely open. The 
limbs have increased markedly in length and show more-advanced differentiation of their 
subdivisions. The forearm ascends to or above the level of the shoulder. The superficial 
vascular plexus is rapidly approaching the vertex of the head leaving only a small non 
vascular area that will soon become bridged by anastomosing branches. The external 
genitalia are well developed but do not suffice for the detection of sex. Only in foetuses of 
about 50mm is it safe to make an assessment of sex. Head more rounded and shows human 
characteristics. External genitalia still have sexless appearance. Distinct bulge still present in 
umbilical cord caused by herniation of intestines. Tail has disappeared. “Praying feet” may 
be visible. Foot length less than 5mm, Crown rump length less than 40mm 













Foetal age  
Morphological land marks 
F1 Above 5 to 6 8 41-50 >56.5 
weeks 
 
F2 Above 6 to 8 11 51-60 9 weeks Head is almost half of the foetus. As the head extends and the chin is raised from the thorax 
the neck develops. The eyelids have fused. The fingernails appear.  
F3 Above 8 to 9 13 61-70 10 weeks Midgut herniation returns to the enlarged abdomen. 
F4 Above 9 to 12 17 70-85 
 
11weeks  
F5 Above 12 to 
16 
24 86-98 12 weeks Sex distinguishable externally. Well defined neck. The ear has moved from the neck on to 
the head. The eyes have moved to the front of the face. Toe nails develop 
 





Supplementary Figure 2. αA crystallin western blots. 
 Western blots can be used to check antibody specificity, by confirming that the product has 
the expected molecular weight. αA crystallin  has a molecular weight of ~19.9KDa. Foetal 
human whole retina tissue was probed using both αA crystallin antibodies, Santa Cruz (A) and 
Abcam (B). Both antibodies gave the same pattern on the gel and a band was present at the 
expected weight for αA crystallin. Adult human macula tissue was also probed using both αA 
crystallin antibodies (Santa Cruz, C and Abcam, D). The same banding pattern as with foetal 
tissue was seen, with the addition of a band at around 21kDa.     
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